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ABSTRACT 
INVESTIGATION OF THE MECHANISMS GOVERNING CARRIER DOMAIN 
TRANSLOCATION IN S. AUREUS PYRUVATE CARBOXYLASE 
 
 
Joshua H. Hakala, B.S., B.A. 
 
Marquette University, 2019 
 
A central debate in protein biochemistry focuses on the mechanism by which 
ligands contribute to conformational changes in proteins. Two primary hypotheses 
describe this process: the induced-fit hypothesis and the conformational ensembles 
hypothesis. In contrast to the induced-fit hypothesis, the conformational ensembles 
hypothesis states that the protein pre-exists in multiple conformational states, with ligand 
binding shifting the equilibrium towards a preferred conformation. The contribution of 
ligand binding to large-scale conformational changes is particularly relevant to multi-
domain “swinging-arm” enzymes, for which pyruvate carboxylase (PC) serves as a well 
characterized paradigm system. PC catalyzes the ATP-dependent carboxylation of 
pyruvate to oxaloacetate. The biotin cofactor on the biotin carboxyl carrier protein 
(BCCP) domain is carboxylated via a MgATP-dependent reaction in the biotin 
carboxylase (BC) domain. The BCCP domain then travels to the carboxyltransferase 
(CT) domain where the carboxyl group is transferred from the biotin cofactor to pyruvate, 
generating oxaloacetate. There have been conflicting proposals for how ligand binding 
governs carrier domain translocation in PC but, to date, there have been no attempts to 
directly observe the positioning of the carrier domain independent of catalytic turnover. 
To directly observe the equilibrium positioning of the BCCP carrier domain, site-specific 
cross-linking was used to trap the BCCP domain in two separate orientations during 
translocation. This approach enabled a detailed analysis of how BCCP domain 
positioning responds to substrates and allosteric effectors. These studies show that carrier 
domain positioning is governed by conformational selection, with the carrier domain 
accessing intermolecular positions irrespective of the presence or identity of the ligand(s). 
Further, interactions between biotin and several conserved active site residues in both the 
BC and CT domains serve to shift the carrier domain positioning equilibrium. These 
studies offer the first compelling evidence that carrier domain positional equilibrium in 
PC is governed by conformational selection and offer new insights into the molecular 
level interactions contributing to these conformational changes.  
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1 
I. INTRODUCTION  
Chemical and physical interactions are necessary for the maintenance of life. The 
regulation of these interactions is critical to cellular maintenance, proper development, 
the prevention of disease, and successful reproduction. For example, the TCA cycle that 
is central to cellular metabolism must maintain a proper equilibrium of intermediates to 
ensure an appropriate metabolic flux into the numerous biosynthetic pathways that 
branch out from the main cycle. When the concentration of TCA cycle intermediates are 
low, they must be replenished to maintain metabolic flux and prevent deleterious 
outcomes. Pyruvate carboxylase (PC; E.C. 6.4.1.1), which converts pyruvate to 
oxaloacetate, is present in nearly all life forms, where it plays a critical role in 
maintaining proper flux through the TCA cycle. Aberrant PC activity is a hallmark of 
diseases such as Type-II diabetes and cancer (Han and Liu, 2010; Phannisil, et al., 2015).  
 PC has been intensely studied since its initial discovery and purification in 
the 1960s. Subsequent kinetic studies determined that the pyruvate carboxylation reaction 
occurs in two separate steps catalyzed by the same enzyme (Utter and Keech, 1960; Utter 
and Keech, 1963; Keech and Utter, 1963; Scrutton, Keech, and Utter, 1965). By 1981, it 
had been established that PC consisted of two separate active sites, like other biotin-
dependent carboxylases, with a biotin cofactor tethered to a carrier domain responsible 
for transferring CO2 from the first subsite to the second (Goodall, et al., 1981). Many 
early kinetic studies were interpreted to suggest that carrier domain translocation was 
induced by the binding of substrate to the second active-site (Easterbrook-Smith, et al., 
1976; Goodall, et al., 1981; Attwood and Wallace, 1986).  These early studies revealed 
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that acyl-CoA derivatives activated pyruvation carboxylation, specifically acetyl-CoA 
(Scrutton, Keech, and Utter, 1965). The first X-ray crystal structure of PC, from 
Rhizobium etli, clearly showed the existance of two spatially distinct active sites (St. 
Maurice, et al., 2007). The carrier domain with tethered biotin was also captured in a 
conformation between the intramolecular first active site and intermolecular second 
active site, suggesting an intermolecular translocation pathway for catalysis. When 
describing interactions between the carrier domain and another domain throughout this 
dissertation, the term “intramolecular” will be used when the carrier domain is interacting 
with a domain on its own polypeptide chain. The term “intermolecular” will be used 
when the carrier domain is interacting with a domain across the face of the PC tetramer 
on a separate polypeptide chain.  
Studies over the past decade have continued to interpret results in light of an 
induced conformational change mechanism for carrier domain translocation, despite the 
lack of any direct experimental observations of carrier domain positioning.  In this model, 
the carrier domain is proposed to remain in the vicinity of the first active site until a 
substrate binds in the second active site. Binding of a substrate in the second active site 
induces a conformational change that causes carrier domain translocation to the second 
active site.  
This dissertation describes a series of biophysical studies designed to elucidate the 
effect of ligands on carrier domain positioning and to understand the mechanism that 
governs carrier domain positioning in PC. This enables the proposal of a new model for 
carrier domain translocation in PC and offers a detailed description of how ligands and 
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active site residues alter carrier domain positioning in this complex, multi-domain 
enzyme. 
1.  Fundamental Principles and Mechanisms of Ligand Binding to Proteins  
At the core of many biological processes is a binding interaction between two or 
more units. Whether the target is a receptor, a strand of DNA, or an enzyme, at least two 
units must bind together in order for a signal to be transmitted, transcription to begin, or a 
reaction to be catalyzed. When considering this phenomenon in enzymes, a fundamental 
challenge has been to understand the mechanism that couples ligand binding with the 
conformational changes that result in catalysis. In 1894, Emil Fischer was the first to 
attempt a description of this phenomenon using the “lock-and-key” model, which views 
the protein as a rigid structure that must precisely fit the shape of the ligand. A second 
model, published by Daniel Koshland in 1958, became a lasting, canonical description of 
ligand binding in proteins. This model, commonly called the “induced conformational 
change” model, considers that the protein exists in a single conformation, similar to the 
“lock-and-key” model, but allows that a conformational change can occur as a result of 
ligand binding.  Finally, in the last few decades, a model has been evolving that takes into 
account observed conformational heterogeneity in protein populations as well as the 
energy landscape theory of proteins. This model, called “conformational selection”, 
views proteins as conformationally flexible entities and takes into account 
thermodynamic laws when considering conformational behavior. This section will trace 
the evolution of models that have been developed to explain the relationship between 
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ligand binding and conformational change in proteins and will apply these models to 
enzyme systems.  
1.1  Evolution of the Ligand Binding Models 
  Emil Fischer’s “lock and key” model was the first attempt to explain ligand 
binding to proteins (Fischer, 1894). In this model, the enzyme is viewed as a rigid 
construct that contains a binding pocket of a specific size and shape. To accommodate 
ligand binding, this binding pocket, the “lock”, must precisely match the shape of the 
ligand, “the key”. While this model was successful in explaining why an enzyme has 
specificity for a certain substrate, a failing of this model is that it does not consider 
conformational changes that occur throughout the enzyme and that give rise to regulatory 
properties. This model also does not explain how the unstable transition state is stabilized 
by the enzyme during catalysis. 
In 1958, Daniel Koshland proposed his theory of ligand binding, commonly 
referred to as the “induced conformational change” model. In this model, the protein is 
considered to be flexible, in contrast to the rigidity that is assigned by Fischer’s model. 
Binding of the ligand to the enzyme is allowed, even if the binding site does not perfectly 
fit the shape of the ligand. Upon binding, the ligand interacts with nearby residues, 
resulting in conformational changes that further strengthen the binding interaction. Some 
years later, this initial model was further expanded in a classic paper by Koshland, 
Némethy, and Filmer to describe cooperativity in hemoglobin, and became known as the 
KNF model (Koshland, et al., 1966). Hemoglobin consists of two heterodimers (ab) that 
together form a homodimer (a2b2), with one binding site for molecular oxygen in each 
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subunit, as observed in the first crystal structure of hemoglobin obtained by Perutz 
(Perutz, et al. 1960).  Molecular oxygen binding to hemoglobin obeys a sigmoidal 
binding behavior. The shape of the curve indicates positive cooperativity within 
hemoglobin, such that when one oxygen molecule binds to one subunit of hemoglobin, a 
conformational change occurs, facilitating the subsequent binding of molecular oxygen to 
the remaining, non-oxygen-bound subunits.     
Hemoglobin subunits exist in two dominant conformations, the “T” state, which 
has low oxygen affinity, and the “R” state, which has high oxygen affinity. When oxygen 
binds to the T state, a conformational change occurs that shifts the hemoglobin 
conformation from the T state to the R state. This relationship led to the concept of 
oxygen-binding cooperativity, with the affinity for oxygen of hemoglobin increasing as 
oxygen binds. The KNF model predicts that in the absence of oxygen, all subunits exist 
in the T state. Upon oxygen binding, the oxygen-bound subunit adopts the R state and 
induces adjacent subunits to also adopt the higher affinity R-state. Ultimately, all 
subunits of hemoglobin will adopt the R state in the presence of oxygen, proceeding via a 
sequential transition of the individual subunits (Figure I-1).  
A competing model was proposed to explain cooperativity in hemoglobin by 
Monod, Wyman, and Changeux, referred to as the “MWC” model (Monod, Wyman, 
Changeux, 1965). This model relies on three assumptions that set it apart from the KNF 
model: (1) Hemoglobin can exist in one of only two states, T or R; (2) the state of the 
protein (T or R) is governed by the overall quaternary structure of the protein; (3) all of 
the subunits switch between states simultaneously, such that the tetramer exists either 
entirely in the T state or entirely in the R state. Regardless of the presence/absence of 
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ligands, the hemoglobin population would exist in an equilibrium with some percentage 
existing in the T state and some percentage existing in the R state (Figure I-1).  
A major difference between these two models becomes clear when considering 
the conformational flexibility of the protein. According to the KNF model, the protein 
subunits uniformly exist in the T state in the absence of ligands. According to this model, 
hemoglobin cannot access the R state in the absence of oxygen. In the KNF model, 
conformational changes take place only as a consequence of ligand binding. Conversely, 
in the MWC model, the protein always exists in an equilibrium between the T and R 
states, so that each state is populated to some degree. In the MWC model, conformational 
changes precede ligand binding, shifting the population equilibrium between T and R 
states (Figure I-1).  
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Figure I-1. Comparison between KNF model and MWC model 
The low-oxygen affinity T state is represented by squares while the high-oxygen affinity R state is 
represented by triangles. Red fill represents the oxygen-bound state. The MWC model is contained in the 
blue rectangle with all subunits of hemoglobin changing conformation together and existing as a population 
in an equilibrium between the T and R states. The KNF model displays the sequential conformational 
change steps as oxygen binding induces a conformational change to the R state.  
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As the mechanisms underlying the thermodynamics of protein folding were 
coming into focus, the energy landscape theory of protein folding began to take shape. 
The energy landscape theory is often represented by a “protein folding funnel”. 
According to this model, each conformation that a protein adopts has an associated free 
energy, with a lower free energy being more stable than a conformation with a higher free 
energy. As a protein folds, its free energy generally flows down the energy funnel, 
ultimately reaching a free energy minimum that represents the final, stable conformation 
of the protein. Along the path from the high-energy unfolded state to the low-energy 
folded state, there can be many local energy wells that stabilize the protein for a period of 
time. These wells can reside at energy levels far above the energetic minimum and may 
be deep enough to become “kinetic traps”, where time and/or energy input is required for 
the protein to emerge and continue down the folding pathway. This protein folding 
landscape has also been applied to the conformational changes that take place during 
enzyme catalyzed turnover.  
Recent models of protein conformational change have combined principles of the 
MWC model and the energy landscape theory into what is known as the “conformational 
selection” model. According to this model, a population of enzymes will exist in an 
ensemble of conformations, including (but not limited to) the “free” state and the “ligand-
bound” state, according to a thermodynamic distribution that is driven by thermal 
fluctuations; those conformations with a lower free energy will be more populated 
(Kumar, et al., 2000, Boehr, et al., 2009). In this model, a ligand preferentially binds to a 
pre-existing conformation of an enzyme that has the highest affinity for the ligand, much 
like the lock and key model. However, ligand-binding generally results in a lowering of 
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the free energy for the ligand-bound state, leading to a shift in the enzyme population 
towards this conformation.  
Since the initial studies on hemoglobin, the KNF / induced conformational change 
model has been applied to a range of systems, including enzymes (Michel, 2016; Corbett, 
P.T., et al., 2005). This model starkly contrasts with the conformational selection model 
in not considering flexible oscillations in enzymatic conformation prior to the ligand-
binding event. More recently, many enzyme systems have been described using the 
conformational selection model. For example, the MWC/conformational selection model 
better accounts for conformational changes in aspartate transcarbamylase (Changeaux, et 
al., 1968; Changeaux and Rubin, 1968; Velyvis, et al., 2007), nicotinic acetylcholine 
receptors (Colquhoun and Sakmann, 1985; Jackson, 1984; Bertrand, et al., 1992), and G-
protein coupled receptors (Lefkowitz, et al., 1993; Choe, et al., 2011; Xu, et al., 2011), 
while the induced conformational change model best explains conformational change in 
hexokinase (Bennett and Steitz, 1978) and kinesin (Kull and Endow, 2013).  
1.2  Applying Ligand-Binding Models in Enzymes  
The role of an enzyme in living systems is to accelerate the rate of a chemical 
reaction. This rate enhancement is primarily achieved through the stabilization of the 
high-energy transition state for the chemical reaction. In addition, an enzyme active site 
must bind the substrate(s) such that the substrate is optimally oriented for catalysis. 
Active site residues often play a dual-role: they must bind the substrate in the ground 
state, but they must also preferentially stabilize the high energy transition state as the 
substrate is converted into product. There are three major steps in any enzyme-catalyzed 
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reaction: the binding of substrate(s), the chemical conversion of substrate(s) into 
product(s), and the release of product(s). The binding affinity of an enzyme (E) with a 
substrate is represented by the dissociation constant, Kd but this is often difficult to 
measure kinetically. In most treatments, all of the microscopic rate constants that 
represent the formation and breakdown of the enzyme-substrate complex (ES) are 
collected into what is called the Michaelis constant, Km. Finally, the maximum turnover 
rate, which is calculated by dividing the maximum velocity by the total enzyme 
concentration, is represented by kcat. 
The lock and key model can be described by the simple expression E + L ⇌ EL, 
in which the conformation of the enzyme (E) does not change throughout the binding 
process. In the induced conformational change model, a conformational change occurs as 
a result of interactions between the ligand and active site, such that the expression can be 
written E + L  ⇌ EL ⇌ E*L, in which E* represents a different conformation of the 
enzyme that has a high affinity for the ligand. Finally, in the conformational selection 
model, a population of an enzyme would contain an ensemble of conformations with the 
ligand preferentially binding to the conformation with highest affinity for the ligand. This 
can be written E + L ⇌ E* + L ⇌ E*L (Vogt, et al., 2014). Therefore, the conformational 
state E* exists in the absence of ligands in the conformational selection model, while 
existing only in the presence of ligands in the induced conformational change model. An 
observation of multiple enzyme conformational states in the absence of ligands serves to 
experimentally support the conformational selection model in an enzymatic system.  
When considering the thermodynamics of enzyme catalyzed reactions, the 
energetic difference between the enzyme-substrate (ES) complex at the ground-state 
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energy level and the high-energy transition state ([ES]‡) is represented by Gibbs free 
energy of activation (DG‡) (Figure I-2A). Catalysis is generally accompanied by an 
overall reduction in DG‡ for a reaction. These concepts can be applied to protein folding 
as well, with a distribution of conformations existing in solution, each with an associated 
Gibbs free energy. Generally, the lower-energy conformations will be more heavily 
populated than a higher-energy conformation. The free energy of a conformation can 
shift upon ligand binding, generally to a lower energy state which leads to an increase in 
the population of that state (Figure I-2B) (Boehr, et al., 2009). 
This section has presented the development of ligand-binding theories and their 
relationship to conformational changes in proteins and enzymes. The conformational 
selection model embraces the thermodynamic principles and concepts of protein 
conformational fluidity introduced here. Rather than considering substrates and products, 
the free energies of interacting domains can be considered, with kinetic barriers 
separating the transition from one interaction to another. The thermodynamic and kinetic 
barriers associated with conformational changes accompanying ligand binding events can 
reveal fundamental information regarding the free energy landscape of an enzyme.  
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Figure I-2 Thermodynamic representation of enzymatic reactions and conformational changes. 
Gibbs free energy is plotted on the y-axis while reaction progress is plotted on the x-axis. A. The free enzyme 
in the presence of substrates state (E+S), high-energy transition state (ES‡), and free enzyme in the presence 
of product state (E+P) are shown. The dashed lines indicate the changes in Gibbs free energy between the 
states with the blue line representing the enzyme catalyzed reaction and the black line the uncatalyzed 
reaction. B. The Gibbs free energy associated with two empty active sites is shown by solid horizontal black 
lines. Ligand binding results in a change in free energy (red). The dashed lines represent the kinetic barrier 
for the conformational change from Conformation 1 to Conformation 2. The thermodynamic change depicted 
by the decreased Gibbs free energy of the ligand bound state of Conformation 1 results in a shift in the 
conformational equilibrium, represented by the large red arrow.  
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2.  PYRUVATE CARBOXYLASE 
Carrier domain enzymes present a unique system in which to study the effect of 
ligand binding on enzyme conformation. In many enzymes, the carrier domain must 
translocate a relatively large distance during catalysis. However, the mechanism 
governing this translocation to ensure efficient transfer of intermediates between active 
sites is an area of active study (Perham, 2000; Lowry, et al., 2016; Khosla, et al., 2014; 
Zeczycki, et al., Menefee and Zeczycki, 2014). PC is a multi-domain enzyme that can 
serve as a model to study the relationship between ligand binding and conformational 
changes. It is an enzyme with a relatively simple construction, containing just two active 
sites and a carrier domain that bridges the individual half reactions. PC forms a tetramer 
of ~500 kDa, which is smaller and more easily studied than many other carrier domain 
systems that are often composed of larger oligomeric structures that can be more than 1 
MDa in mass. PC has also been well characterized kinetically and structurally, making it 
an ideal system for these studies. 
PC catalyzes the carboxylation of pyruvate to oxaloacetate, which serves as an 
anaplerotic input to the TCA cycle. The first half-reaction, which occurs in the biotin 
carboxylase (BC) domain, carboxylates the biotin cofactor that is tethered to the carrier 
domain, using bicarbonate as the carboxyl donor concomitant with the cleavage of ATP. 
The carrier domain translocates to the second active site in the carboxyltransferase (CT) 
domain, where the second half-reaction occurs. In this domain, the carboxyl group is 
transferred from biotin to pyruvate, forming oxaloacetate. The translocation of biotin, 
which covers ~70 Å, is responsible for coupling these reactions. The substrate and 
product of this reaction, pyruvate and oxaloacetate, are both important molecules in 
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metabolism. Pyruvate is the final product of glycolysis and can be funneled into several 
different metabolic pathways while oxaloacetate serves as one of the major inputs into 
the TCA cycle, which is a central pathway for oxidative metabolism. The metabolic role 
of PC will be briefly introduced, along with the structure and function of the individual 
domains of PC.  
2.1  The Role of Pyruvate Carboxylase in Metabolism and Disease 
Pyruvate serves as a central metabolite in what may be the most crucial 
crossroads in all of metabolism.  It is best known as the final product of glycolysis, but it 
is derived from many catabolic pathways including amino acid catabolism, and lactic 
acid oxidation. Pyruvate can have several fates, including being shuttled into the 
mitochondria (in organisms containing this organelle) for entry into the TCA cycle as 
acetyl-CoA under aerobic conditions, fermentation into lactate or ethanol under anaerobic 
conditions, or transamination to the amino acid alanine (Gray, et al., 2014). When one or 
more biosynthetic pathways are upregulated to draw intermediates away from the TCA 
cycle, levels of TCA cycle intermediates decrease, which deleteriously impacts the flux 
in and out of the cycle. The primary role of pyruvate carboxylase is to replenish the TCA 
cycle intermediate oxaloacetate through the biotin-dependent carboxylation of pyruvate, 
thereby balancing the withdrawal of intermediates from the TCA cycle.  
TCA cycle intermediates are drawn out through several biosynthetic pathways 
including lipogenesis, amino acid generation, nucleotide synthesis, and porphyrin 
biosynthesis. Citrate can be transported out of the mitochondria for conversion back to 
acetyl-CoA which can be used for fatty acid synthesis or the formation of the lipid 
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cholesterol. Succinyl-CoA is a key component in the synthesis of porphyrins, which 
themselves are used for the construction of hemes and other metal-binding structures. 
Several amino acids, including glutamate and glutamine, are derived from the TCA cycle 
intermediate a-ketoglutarate. Not only is glutamine incorporated into proteins, it also 
serves as a key precursor for the synthesis of both purine and pyrimidine nucleotides and 
acts as the major nitrogen carrier in vertebrates. While pyruvate is the major metabolite 
used in gluconeogenesis, glutamine, alanine, lactate, and glycerol can also be converted 
for use in gluconeogenesis (Gerich, et al., 2001). PC catalyzes the first step of 
gluconeogenesis with the conversion of pyruvate to oxaloacetate, which is then shuttled 
out of the mitochondria as malate.  
Given the crucial role of PC in central metabolism, a disruption in PC expression 
and/or activity has been linked to a number of disease states. Pyruvate carboxylase 
deficiency, for example, is an autosomal, recessive disorder that ranges from benign to 
severe (Marin-Valencia, et al., 2010). In mice, a correlation between PC activity, 
pancreatic islet cell size and mass, as well as the presence of hyperglycemia has been 
observed, highlighting the role of PC in metabolic health (Han and Liu, 2010). PC 
expression is upregulated in human breast cancer tissue, where an increase in PC 
expression has been associated with tumor size and proliferation (Phannisil, et al., 2015). 
The higher metabolic demand on PC in many cancers is explained by the need for 
increased anaplerotic input to compensate for a higher flux through the biosynthetic 
pathways needed to support cellular growth and division in cancer cells (Phannisil, et al., 
2015).  
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PC is broadly distributed among bacteria, plants, invertebrates and vertebrates 
(Wallace, et al., 1998). At least one microbial species, Listeria monocytogenes is 
particularly dependent on the anaplerotic role of pyruvate carboxylase. L. monocytogenes 
does not encode 2-oxoglutarate dehydrogenase, leaving L. monocytogenes with an 
incomplete, branched TCA cycle. Consequently, L. monocytogenes is highly dependent 
upon PC (encoded by pycA in L. monocytogenes) to replenish oxaloacetate, which is the 
only route to malate and fumarate in this incomplete TCA cycle. It has been observed that 
in pycA mutants, L. monocytogenes has decreased virulence in mice and cannot replicate 
in mammalian hosts (Schär, et al., 2010).  
2.2  Structure of Pyruvate Carboxylase 
In most PC enzymes, all functional domains are encoded on a single polypeptide 
chain (Figure I-3). The biotin carboxylase (BC) domain, site of the first half-reaction, is 
located at the N-terminus of the polypeptide and is linked to the carboxyltransferase (CT) 
domain by a helical region that forms the core of the allosteric domain. The CT domain 
threads back into a half beta barrel that completes the allosteric domain, which then 
terminates in the biotin carboxyl carrier protein (BCCP) domain.  
2.2.1  Tetrameric Structure 
PC forms tetramers at high concentrations, which dissociate to dimers and 
monomers at concentrations below 4 EU/mL (~0.13 mg/mL) (Khew-Goodall, et al., 
1991; Attwood and Geeves, 2002). This process of dilution inactivation can be rescued, 
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to varying degrees, by the addition of the allosteric activator, acetyl-CoA, as well as by 
ATP and/or Mg2+, both of which bind in the BC domain (Attwood, et al., 1993; Attwood 
and Geeves, 2002). The PC homotetramer is stabilized by contacts at each corner of the 
tetramer, where homodimerization interfaces stabilize identical domains to form two 
perpendicular faces of the tetramer, as observed in the first X-ray crystal structures of PC 
from Rhizobium etli (RePC) and Staphylococcus aureus (SaPC) (Figure I-4) (St. Maurice, 
et al., 2007; Xiang and Tong, 2008). These first structures revealed that the distance 
between active sites is ~70 Å, too far apart for biotin to reach both active sites without 
involving significant carrier domain translocation. A pathway of carrier domain 
translocation was hinted at in the RePC structure with the carrier domain positioned 
between the intramolecular BC domain and intermolecular CT domain. After the 
structure was obtained, it was then experimentally confirmed that the carrier domain 
travels across the face of the tetramer to the CT domain on a separate polypeptide chain 
(St. Maurice, et al., 2007). This was further supported by the first SaPC structure in 
which the carrier domains were observed to be interacting with the CT domain of the 
opposing polypeptide chain on the same face of the tetramer (Xiang and Tong, 2008).  
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Figure I-3 Rhizobium etli pyruvate carboxylase monomeric structure. 
Shown is the monomeric structure of Rhizobium etli PC. The biotin carboxylase (BC) domain is blue, the 
allosteric domain is green, the carboxyltransferase domain (CT) is yellow, and the biotin carboxyl carrier 
protein (BCCP) domain is green. The resolved nucleotide portion of ethyl-CoA is shown bound in the 
allosteric domain and a non-hydrolyzable ATP analog is shown bound in the BC domain.  
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Figure I-4 Pyruvate carboxylase tetrameric structures from R. etli and S. aureus.  
Shown is the tetrameric structures of Rhizobium etli PC (PDB ID: 2QF7) A difference between the 
asymmetric (RePC) and symmetric (SaPC) conformations are visible with the interaction of allosteric 
domains between faces in the symmetric conformation. (A) and Staphylococcus aureus (PDB ID: 3BG5) 
(B). The top face is colored green while the bottom face is blue.  
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2.2.2  Biotin Carboxylase (BC) Domain Structure  
The biotin carboxylase (BC) domain is common across all biotin-dependent 
carboxylase enzymes. The active site in the BC domain binds Mg-ATP, with the aid of an 
additional magnesium ion, and bicarbonate, which donates the CO2 for carboxylation of 
biotin. The structure of the BC domain is comprised of three subdomains: A, B, and C 
(Waldrop, et al., 1994; Broussard, et al., 2015; Tong, 2017). The A and C subdomains 
contribute the bulk of the BC domain, while the B-subdomain acts as a highly flexible lid 
that closes down on the active site in the presence of substrates (Thoden, et al., 2000). 
The B subdomain interacts with substrates through a glycine-rich P-loop that positions 
itself over the phosphate groups of ADP/ATP. In the presence of the nucleotide and 
Mg2+, the B-subdomain combines with the C-subdomain to form the complete binding 
interface for the carrier domain (Thoden et al., 2000; Lietzan et al., 2011; Kondo, et al., 
2004; Chou, et al., 2009; Chou, et al., 2011; Menefee and Zeczycki, 2014). Interestingly, 
only two specific interactions between non-conserved residues have been identified 
between the BC and BCCP domains (Lietzan, et al., 2011), suggesting that the interface 
itself between the B-subdomain lid and C-subdomain makes the most important 
contribution to carrier domain docking.  
2.2.3  Carboxyltransferase (CT) Domain Structure  
The carboxyltransferase (CT) domain of PC is less broadly distributed among the 
biotin-dependent enzymes, where different domains have evolved to accommodate the 
carboxylation of different substrates. The CT domain is composed of two subdomains: an 
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a8b8 TIM-barrel core capped by a C-terminal funnel-like subdomain composed of nine 
a-helices that leads to the CT domain active site located at mouth of the TIM-barrel. At 
the near-edge of the TIM barrel, a dicationic metal ion, Zn2+ or Mn2+, is bound that aids 
in the coordination and binding of pyruvate (St. Maurice, et al., 2007; Xiang and Tong, 
2008; Yu, et al., 2009). The TIM barrel is a conserved structure present in members of 
the DRE-TIM superfamily which contains a wide range of enzymes that require the 
breaking or formation of C-C bonds (Frantom, et al., 2014).  
The presence of pyruvate has a dramatic impact on the conformation of a flexible 
loop (Arg621-Asn630) within the CT domain active site (PDB ID: 4JX5) (Lietzan, et al., 
2013A) (Figure I-5). In the presence of pyruvate, Arg621 (RePC numbering) forms a salt 
bridge with the carboxyl moiety of pyruvate (Figure I-5B). Whereas, in the absence of 
pyruvate, Arg621 is disordered (Figure I-5A). This Arg621-pyruvate interaction 
corresponds with movement of the loop into a closed conformation, which rotates Tyr628 
from an outward facing conformation to one where it is oriented into the active site and 
within hydrogen-bonding distance of Asp590 (Figure I-5B) (PDB ID: 4JX4) (Lietzan, et 
al., 2013A). The positioning of Asp590 is further stabilized by an interaction with the 
side chain of nearby Arg594. This chain of interactions directly contributes to active site 
conformational rearrangements upon pyruvate binding.  
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Figure I-5 RePC CT domain active site structure rearrangement in the presence of pyruvate. 
A. RePC X-ray crystal structure in the absence (A) (PDB ID: 4JX4) and presence (B) (PDB ID: 4JX5) of 
pyruvate. Y628 rotates into the active site in the presence of pyruvate, providing a binding platform for biotin.  
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The repositioning of Tyr628 upon pyruvate binding stabilizes biotin binding in 
the CT domain active site through a sulfur-pi interaction between the thiophene ring of 
biotin and the aromatic ring of Tyr628 (Lietzan, et al., 2013A). Such interactions are 
predicted to contribute 1-2 kcal/mol of stabilization energy (Reid, et al., 1985; 
Maveyraud, et al., 1996; Zauhar, et al; 2000). The importance of these residues (Tyr628, 
Arg594, Asp590) to catalysis were confirmed by the near-complete loss of catalytic 
activity in Y628A and D590A RePC mutants (Lietzan, et al., 2013A). The structure of the 
pyruvate binding pocket also supports the observation that a-keto acid analogues can 
induce carboxybiotin decarboxylation (Attwood and Wallace, 1986). Several small a-
keto acids analogs bind in an identical manner to pyruvate in the active site (Lietzan and 
St. Maurice, 2013), stabilizing the Tyr628 biotin-binding platform and favoring the 
placement of carboxybiotin in the active site. Conversely, analogs lacking either the a-
keto group or carboxyl group do not induce carboxybiotin decarboxylation (Attwood and 
Wallace, 1986). 
2.2.4  Carrier Domain Structure  
The crystal structure for the carrier domain from E. coli acetyl-CoA carboxylase, 
which is homologous to the PC carrier domain, was first determined in 1995 (Athappily 
and Hendrickson, 1995). The BCCP domain is composed of two stacked b-sheets which 
are each composed of four antiparallel b-strands. Located roughly midway through this 
domain, and projecting out from a b-hairpin turn, is the conserved biotinylated lysine. 
This lysine is one of four conserved residues (MKME) that make up a common 
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biotinylation motif across all biotin-dependent enzymes (Samols, et al., 1998; Duval, et 
al., 1994). The carrier domain is positioned at the C-terminus of PC and is connected to 
the allosteric domain by a relatively long, flexible arm.  
2.2.5  Allosteric Domain Structure and Function 
The first X-ray crystal structure of RePC, co-crystallized with ethyl-CoA, 
revealed the existence of the allosteric domain, which is positioned between the BC and 
CT domains and at the base of the carrier domain (PDB ID: 2QF7) (Figure I-3) (St. 
Maurice, et al., 2007). The allosteric domain has a simple composition in PC, consisting 
of a central a-helix covered by four antiparallel b-strands partially wrapping around it. 
The a-helix and b-strands are non-contiguous, with the helix originating from the C-
terminal end of the BC domain and the four antiparallel b-strands located C-terminal to 
the CT domain. In the symmetric tetrameric conformation captured in the SaPC structure, 
the allosteric domains of the top face of the tetramer formed a dimerization interface with 
the allosteric domains on the bottom face of the tetramer. Thus, this domain has also been 
named the PC tetramerization domain (Xiang and Tong, 2008). This domain has no 
strong sequence conservation in other biotin-dependent enzymes, though a very similar 
structural motif has been observed in several other biotin-dependent enzymes. The BT 
domain of acyl-CoA carboxylases is one example of a similarly structured domain that 
resembles the PC allosteric domain. However, rather than containing four b-strands like 
the PC allosteric domain, the BT domain has eight b-strands that wrap around the central 
a-helix (Tong, 2017) 
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Since the discovery and initial characterizations of PC, it was known that acyl-
CoA derivatives activated PC (Scrutton, et al., 1965). Acetyl-CoA is commonly the most 
effective activator of PC and has been the most extensively studied, along with allosteric 
inhibitors such as L-aspartate. The first crystal structure of RePC showed ethyl-CoA (a 
nonhydrolyzable analogue of acetyl-CoA) bound in the allosteric domain (Figure I-3). 
Acetyl-CoA is stabilized in the binding site by hydrogen bonding with two conserved 
arginine residues, Arg427 and Arg472 in RePC (St. Maurice, et al., 2007). Mutations to 
these residues have an impact beyond simply affecting acetyl-CoA binding. For example, 
the Km for ATP is increased by mutations to these residues. (Adina-Zada, et al., 2012). 
Many site-specific mutations have been made in this domain to elucidate the mechanism 
of allosteric activation by acetyl-CoA.  
Activation by Acetyl-CoA. Soon after PC was initially purified, it was discovered 
that acetyl-CoA acted as an activator (Scrutton, et al., 1965). Acetyl-CoA is generated 
cellularly by the pyruvate dehydrogenase complex for entry into the TCA cycle or by 
fatty acid oxidation. As acetyl-CoA enters into the TCA cycle, it condenses with 
oxaloacetate, forming citrate. This is a logical feedback mechanism, in which a higher 
concentration of acetyl-CoA, perhaps derived from an increased flux through glycolysis, 
requires an increased concentration of oxaloacetate with which to condense.  
Several kinetic studies have determined that the BC domain is the locus of action 
for acetyl-CoA. Acetyl-CoA was observed to increase the magnitude of the dissociation 
rate constant for fluorescent analogues of both ATP and ADP (Geeves, et al., 1995). One 
initial study suggested that acetyl-CoA accelerates the formation of the carboxyphosphate 
intermediate and ATP cleavage. ATP cleavage was also better coupled to carboxybiotin 
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formation in the presence of acetyl-CoA, as well (Legge, Branson, Attwood, 1996). This 
was supported by a more recent study in which chimeric PC enzymes constructed from 
two isoforms of yeast PC (PYC1 and PYC2) were investigated for their regulatory 
properties. Despite having different degrees and characteristics of activation by acetyl-
CoA, it was determined that the BC domain was the locus of acetyl-CoA activation 
(Jitrapakdee, et al., 2007). 
Several recent studies have suggested that the role of acetyl-CoA is not simply 
confined to the BC domain. A 2011 study by Zeczycki, et al. showed that, under ideal 
conditions, acetyl-CoA enhanced the coupling between the BC domain and CT domain 
reactions, reducing non-productive ATP cleavage (Zecycki, et al., 2011). Succeeding this 
study was a thermodynamic and kinetic study conducted in SaPC to investigate the 
activation of acetyl-CoA. Acetyl-CoA was proposed to not only constrain the movements 
of the carrier domain, but also to kinetically and thermodynamically couple MgATP and 
pyruvate. The authors suggested that acetyl-CoA may even regulate the quaternary 
conformation and domain motions of PC (Westerhold, et al., 2018). This is consistent 
with suggestions by Sirithanakorn, et al. that acetyl-CoA may stabilize the symmetric 
conformation in PC, which involves a conformational change in the quaternary structure 
and corresponds to a repositioning of the carrier domain (Sirithanakorn, et al., 2016). 
However, direct observations of the effects of acetyl-CoA on carrier domain positioning 
or conformational dynamics of PC in response to acetyl-CoA are currently lacking.  
Inhibition by L-aspartate. As a product of the TCA cycle, L-aspartate displays 
classic feedback inhibition of PC. Studies of L-aspartate inhibition have generally been 
performed in conjunction with acetyl-CoA in which L-aspartate has been observed to 
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reduce the degree of activation by acetyl-CoA. However, studies of PC cloned from three 
different species revealed that acetyl-CoA and L-aspartate binding are mutually 
exclusive, suggesting that they share a common binding site (Cazzulo and Stoppani, 
1968; Osmani, et al., 1981; Sirithanakorn, et al., 2014). Supporting this, Osmani, et al. 
suggested the binding site to be outside of the BC active site, as its inhibition with respect 
to MgATP is non-competitive in Aspergillus nidulans PC whereas an observation of 
competitive inhibition would have suggested a shared binding site between MgATP and 
L-aspartate (Osmani, et al., 1981). Despite being mutually exclusive, the two effectors 
appear to have distinct binding sites: mutation of the acetyl-CoA binding site does not 
affect L-aspartate inhibition in RePC (Adina-Zada, et al., 2012). No crystal structure has 
yet revealed the L-aspartate binding site, preventing a complete understanding of how L-
aspartate competes with acetyl-CoA and inhibits BC domain activity.  
The locus of action of L-aspartate is the BC domain and not the CT domain 
(Sirithanakorn, et al., 2014). L-aspartate does not affect the coupling between BC and CT 
domain reactions whereas acetyl-CoA greatly affects half-reaction coupling 
(Sirithanakorn, et al., 2014; Zeczycki, et al., 2011B). Finally, L-aspartate was observed to 
similarly affect all carrier domain translocation pathways in RePC while acetyl-CoA 
preferentially activated the translocation pathway between the intramolecular BC domain 
and intermolecular CT domain (Liu, et al., 2018). The mechanism by which L-aspartate 
inhibits PC catalytic activity remains unresolved and direct observations of the effect of 
L-aspartate on carrier domain translocation have not been made.  
  
 
 
28 
2.3  Catalysis in Pyruvate Carboxylase 
The carboxylation of pyruvate requires two active sites working in concert. The 
cleavage of ATP in the presence of bicarbonate leads to the carboxylation of the carrier 
domain-tethered biotin. The carrier domain must then translocate to the CT domain 
where it transfers the carboxyl group from biotin to pyruvate, forming oxaloacetate 
(Figure I-6). Each domain must stabilize biotin in the active site while preventing the 
abortive decarboxylation of carboxybiotin. Abortive decarboxylation can occur if 
pyruvate isn’t present to accept the carboxyl group in the CT domain or if carboxybiotin 
returns to the BC domain active site and decarboxylates in the reverse reaction. The 
catalytic reactions and the BC domain mechanism for controlling biotin access will be 
introduced here. The mechanism of stabilizing biotin in the CT domain active site was 
discussed above.   
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Figure I-6 Illustration of SaPC carrier domain translocation. 
The SaPC tetramer is shown with BC domains in blue, CT domains in yellow, and a BCCP domain in pink. 
Biotin is represented as a grey sphere tethered by a flexible black linker. The CT domain active site Mn2+ is 
represented by a light grey sphere. Carrier domain translocation is shown from the BC domain of its own 
polypeptide chain to the CT domain of the opposing polypeptide chain. Other carrier domains have been 
omitted for clarity. Illustration by Anya Lei Koza with creative and scientific input by Joshua H. Hakala.  
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2.3.1  BC Domain Function 
The first step in the RePC BC domain reaction occurs when Mg2+ and MgATP 
bind in the BC domain active site, which may occur in either an ordered binding process 
or through a rapid random equilibrium (Attwood and Graneri, 1992). To aid in proper 
orientation of the nucleotide, Lys245 interacts with the 𝛾-phosphate	of ATP with the 
positively charge Lys stabilizing the negatively charge phosphate group of ATP 
(Zeczycki, et al., 2011A). In turn, the positioning of Lys245 is stabilized by the formation 
of a hydrogen bond between the side chain of Glu218 and the amino group of Lys245 
(Zeczycki, et al., 2011A). After bicarbonate binds, the first chemical step is the 
deprotonation of bicarbonate. Glu305 acts as a general base in the deprotonation of 
bicarbonate, which is promoted by hydrogen-bonding to Glu218 (Zeczycki, et al. 
2011A). This highlights the dual-purpose of Glu218, which was further supported when 
the E218A mutation in RePC resulted in a complete loss of catalytic activity (Zeczycki, et 
al., 2011A). The 𝛾-phosphate	of ATP undergoes a nucleophilic attack by the “activated” 
bicarbonate. This is proposed to form a carboxyphosphate intermediate, along with ADP 
(Ogita and Knowles, 1988). This highly unstable carboxyphosphate intermediate breaks 
down to CO2 and inorganic phosphate (PO43-). However, at this stage, the N1 position of 
biotin would still be protonated and unable to react with CO2. The phosphate liberated 
from ATP cleavage has been proposed to deprotonate the N1 position of biotin, priming it 
for the final electrophilic attack by CO2 (Menefee and Zeczycki, 2014).  The proposed 
mechanism for the BC domain reaction is summarized in Figure I-7. 
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Figure I-7 BC Domain Mechanism 
Shown is the proposed mechanism of the BC domain. Adapted from Zeczycki, et al., 2011A. 
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To aid in the positioning of the inorganic phosphate in close proximity to biotin, 
Arg301 has been proposed to behave as a general base catalyst in promoting the proton 
transfer from the N1 position of biotin to the phosphate. The deprotonation of the N1 of 
biotin results in the formation of a biotin enolate, which is stabilized by Arg353 
(Zeczycki, et al., 2011A). This mechanism was further supported by the dramatically 
reduced ability of the R353M RePC mutant to catalyze the formation of carboxybiotin 
(Zeczycki, et al., 2011A). When the biotin enolate breaks down, a nucleophilic attack is 
initiated on the electrophilic carbon of CO2, resulting in the final carboxybiotin product.  
A mechanism to control carboxybiotin access to the BC domain active site has 
also been proposed. A T882A RePC X-ray crystal structure co-crystallized with ADP and 
phosphonoacetate shows the carrier domain docked with the BC domain (PDB ID: 
3TW6) (Lietzan, et al., 2011). In this structure, biotin does not project into the active site. 
Instead, biotin is removed and pointing away from the active site. In this structure, 
Glu248 and Arg353 interact through a salt bridge, forming a “gate” that appears to block 
the entry of biotin to the active site. This Glu248-Arg353 interaction has been proposed 
to prevent the abortive decarboxylation of biotin. This proposal was supported by the 
observation that, when these residues were mutated, it led to increased rates of ADP 
phosphorylation, increased rates for the reverse BC domain reaction, and decreased 
coupling efficiency between the BC and CT domain reactions (Lietzan, et al., 2011; 
Lietzan et al., 2013B; Zeczycki, et al., 2013).         
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2.3.2  CT Domain Function 
The CT domain is responsible for properly orienting and binding carboxybiotin in 
the active site, stabilizing the formation of the biotin enolate during the decarboxylation 
of biotin, binding pyruvate, and stabilizing the formation of the enol-pyruvate 
intermediate as pyruvate carboxylation is underway. To accomplish this, there are two 
separate regions in the vicinity of the active site. The N-terminal subdomain provides all 
residues necessary for pyruvate binding and enolization while the C-terminal subdomain 
provides the residues that bind carboxybiotin and stabilize the biotin enolate.  
In RePC, after carboxybiotin is bound in the active site, biotin decarboxylates, 
leading to the formation of a biotin enolate intermediate (Figure I-8). The developing 
negative charge on the ureido oxygen is stabilized by Gln844, Ser885, and the 
polypeptide backbone amide of Lys866 (Zeczycki, et al., 2009). In the next step, Thr882 
donates a proton to the N1 position of biotin which then, in a concerted manner, abstracts 
a proton from the methyl group of pyruvate (Sheng and Liu, 2014). This action leads to 
the generation of the pyruvate-enol intermediate, which is stabilized by the positively-
charged active site Zn2+. Finally, the enol-pyruvate breaks down to promote a 
nucleophilic attack on the carbon of CO2, completing the carboxylation of pyruvate 
(Zeczycki, et al., 2009).  
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Figure I-8 CT Domain Mechanism 
Shown is the proposed CT domain mechanism. Adapted from Zeczycki, et al., 2009.  
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2.4  Conformational Changes in PC Associated with Catalysis 
Many kinetic studies on PC have attempted to provide insights into how carrier 
domain positioning contributes to catalytic turnover. Based on increased rates of 
carboxybiotin decarboxylation in the presence of CT domain ligands, it was suggested 
that CT domain ligands induce the translocation of the carrier domain from the BC 
domain to the CT domain (Easterbrook-Smith, et al. 1976; Goodall, et al., 1981; Attwood 
and Wallace, 1986). This led to a model in which the carrier domain was proposed to 
occupy two different positional states in or near the BC domain in the absence of CT 
domain ligands, with a third state representing carboxybiotin translocation to the CT 
domain for rapid decarboxylation (Easterbrook-Smith, et al., 1976; Goodall, et al., 1981; 
Attwood and Wallace, 1986). These initial models assumed that the carrier domain did 
not translocate to the CT domain or occupy any other conformations near the CT domain 
in the absence of a CT domain ligand. More recent structural and kinetic studies have 
revealed a high inherent flexibility to the carrier domain (Adina-Zada, et al., 2019, Liu, et 
al., 2018), suggesting that this assumption may not hold to be true.  
In 2011, Zeczycki, et al. observed that, in the presence of saturating pyruvate and 
acetyl-CoA, the ratio of phosphate release to oxaloacetate formation was 1:1 in RePC. 
Recall that in the BC domain, ATP cleavage occurs concomitantly with biotin 
carboxylation, which produces ADP and inorganic phosphate, which is released after the 
reaction is complete. Oxaloacetate is the product of the CT domain reaction. Therefore, 
the observation that the ratio of phosphate release to oxaloacetate formation was near 
unity indicates an efficient coupling of these two reactions. In the absence of acetyl-CoA, 
the half-reactions become highly uncoupled, with much more Pi released than 
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oxaloacetate formed (Zeczycki, et al., 2011B). Thus, acetyl-CoA plays a crucial role in 
establishing catalytic efficiency in PC, but the mechanism for this enhancement was still 
unknown. Recently, a kinetic study using a system of hybrid tetramers of SaPC with 
inactivated BC or CT domains was used to suggest that pyruvate and acetyl-CoA 
facilitate long-range communication throughout the tetramer and induce carrier domain 
translocation (Westerhold, et al., 2016). Westerhold, et al. also discovered that acetyl-
CoA thermodynamically couples MgATP and pyruvate, while this coupling is abolished 
in the absence of acetyl-CoA, further suggesting a role for acetyl-CoA in long-range 
communication between active sites. In addition, acetyl-CoA decreased the activation 
entropy in SaPC, suggesting that acetyl-CoA constrained the motions of the carrier 
domain (Westerhold, et al., 2017). Finally, a study of carrier domain translocation 
pathways demonstrated that, in RePC, acetyl-CoA activates the catalytic pathway for 
carrier domain translocation from the intramolecular BC domain to the intermolecular CT 
domain whereas the allosteric inhibitor, L-aspartate, did not influence any one 
translocation pathway over any other (Liu, et al., 2018).  
Several structural studies have been performed which have helped to understand 
the role of acetyl-CoA on PC structure. Initial electron microscopy studies revealed that 
the tetrahedral shape of PC adopts a tighter conformation in the presence of acetyl-CoA 
or pyruvate (Attwood, et al., 1986). RePC was captured in an asymmetric conformation 
with the BC and CT domains on opposing polypeptide chains on one face of the tetramer 
65 Å apart and 80 Å apart on the opposite face. The carrier domain in this conformation 
of PC was located in the vicinity of the BC domain in the presence and absence of acetyl-
CoA (St. Maurice, et al., 2007). Conversely, the symmetric conformation was captured in 
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SaPC with the opposing active sites approximately 75 Å apart. In the symmetric PC 
conformation, the carrier domain was positioned in the vicinity of the CT domain in the 
absence and presence of acetyl-CoA (Xiang and Tong, 2008; Yu, et al., 2009). When 
combined, these structures highlight the difficulty in assigning any specific conformation 
to the presence of acetyl-CoA. In 2010, a cryo-EM study of SaPC observed several 
different conformational states of PC in the absence of active turnover. These 
conformational states supported suggestions that the carrier domain interacts with the BC 
domain on the same polypeptide chain (intramolecular) and the CT domain of the 
opposing polypeptide chain (intermolecular) (Lasso, et al., 2010).  Finally, a cryo-EM 
study was performed in which SaPC samples undergoing catalysis were frozen and 
analyzed for conformational variability (Lasso, et al. 2014). It was discovered that there 
were populations of SaPC that adopted the symmetric conformation and populations that 
adopted the asymmetric conformation, demonstrating that PC can adopt both 
conformations during catalysis. These two conformations appeared to capture PC in the 
process of catalyzing the two separate half-reactions, with PC oscillating between these 
two states during the catalytic cycle. Each state, symmetric or asymmetric, correlated 
with specific carrier domain positions. Interestingly, asymmetric PC displays only two 
acetyl-CoA binding sites whereas symmetric PC contains four binding sites, suggesting 
that acetyl-CoA may regulate the adoption of these conformational states (Lasso, et al., 
2014). 
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3. CARRIER DOMAIN ENZYMES AND CONFORMATIONAL CHANGE 
STUDIES 
Pyruvate carboxylase belongs to a large class of multi-domain enzymes that 
utilize a prosthetic group aboard a carrier domain to transport an intermediate between 
active sites. Multifunctional enzymes and multi-enzyme complexes of this class are 
similar in that they catalyze multi-step reactions in spatially distinct active sites and 
require a carrier domain to physically couple their activities. While the prosthetic group 
carrying the intermediates may differ, the core function of efficiently transporting 
intermediates from one active site to another is conserved. The prosthetic groups 
participating in these reactions provide two benefits. First, the intermediate is prevented 
from diffusing away into solvent or being captured by a different system due to the 
covalent bond with the prosthetic group. Second, the flexible nature and length of these 
groups and the carrier domains allow the prosthetic group to reach and access distant 
active sites while maintaining high local concentrations for the reactive intermediates 
(Perham, 2000). The prosthetic groups of the enzymes discussed here and shown in 
Figure I-9 include biotin (biotin-dependent enzymes), phosphopantetheine (polyketide 
synthases), lipoic acid (pyruvate dehydrogenase complex), and the amino acid cysteine 
(which acts as a prosthetic group for the carrier protein in the bacterial sulfur oxidation 
pathway).  
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Figure I-9 Prosthetic Group Structures 
Several prosthetic groups utilized by carrier domain enzymes are shown. A.  Biotin B. Lipoic Acid C. 
Phosphopantetheine D. Cysteine 
 
3.1 Biotin-Dependent Enzymes 
Biotin was first discovered as an agent that reduced the toxicity of raw egg whites 
to humans in 1936. The “toxin” responsible for this toxicity was the protein avidin, which 
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irreversibly binds biotin. This strong interaction has proven useful, as avidin has been 
used in studies of biotin-dependent enzymes for decades as well as in a variety of 
biotechnological applications.  (Waldrop, et al., 2012; Diamandis and Christopoulos, 
1991). As exemplified above, the biotin cofactor is utilized by carrier domain enzymes 
for the transport of carbon dioxide in transcarboxylation reactions. Biotin is composed of 
a ureido ring fused to a tetrahydrothiophene ring with a valerate side chain. The cofactor 
is covalently tethered through a pseudo-peptide linkage to a specific lysine side-chain in 
biotin-dependent enzymes. Biotin participates in three types of enzyme-catalyzed 
reactions. The first reaction, exemplified by PC, is ATP-dependent carboxylation. The 
second reaction type occurs in a class of enzymes that couple sodium transport in 
anaerobes to the decarboxylation of b-keto acids (Dimroth and Hilbi, 1997). The third 
reaction type is catalyzed by a large assembly of polypeptides called transcarboxylase. In 
this unusual reaction, transcarboxylase transfers a carboxyl group to pyruvate from 
methylmalonyl-CoA, forming oxaloacetate and propionyl-CoA (Wood, et al., 1963). 
Pyruvate carboxylase was extensively described in section 1.2. This section will focus on 
a related, well-characterized biotin-dependent carboxylase that catalyzes the ATP-
dependent carboxylation of acetyl-CoA.       
Acetyl-CoA carboxylase (ACC) catalyzes the ATP-dependent carboxylation of 
acetyl-CoA to malonyl-CoA. The product of this reaction is a key precursor in fatty acid 
biosynthesis, as well as in the biosynthesis of some polyketides. Like PC, ACC is 
composed of at least three major domains: the BC domain, CT domain, and BCCP 
domain.  
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Prokaryotic ACCs function as assemblies of individual subunits while eukaryotic 
ACCs include all functional domains on a single polypeptide chain (Cronan Jr., et al., 
2002). Eukaryotic ACCs also contain two additional domains: a large central domain 
(CD) and a BC-CT (BT) interaction domain (Wei and Tong, 2015). The BC domain of 
ACC catalyzes the ATP-dependent carboxylation of the biotin-cofactor and is structurally 
and functionally similar to the BC domain in PC and all other biotin-dependent 
carboxylases. More uniquely, the BC domain of ACC is also subject to regulation and 
conformational dynamics. In eukaryotic ACC, the BC domain is only catalytically active 
as a dimer. Large conformational changes have been observed in the BC domain dimer 
interface in crystal structures comparing the BC domain dimer and monomer (Wei and 
Tong, 2015; Shen, et al., 2004). During catalysis, the BC domains from two different 
polypeptide chains come together to form an active dimer. In the monomeric form, a 
flexible loop occupies part of the BC-BCCP binding interface while, in the dimer, this 
loop is not in a position to obstruct this binding interaction (Wei and Tong, 2015). This 
illustrates one mechanism of controlling biotin access to an active site. However, in either 
the open conformation or the dimerized BC domain conformation, the distance between 
BC and CT domains is greater than 110 Å. This is much larger than the observed 
separation of active sites in other biotin-dependent enzymes and is too large to be bridged 
by carrier domain translocation alone (Hunkeler, et al., 2016).  
The central domain of single-chain ACCs has only recently been structurally 
characterized and have been found to be quite dynamic and an important point of 
regulation (Hunkeler, et al., 2016). This domain does not directly bind substrates or 
catalyze any reactions, but instead plays a large regulatory role in the dynamics of ACC. 
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The CD domain is positioned between the BC and CT domains and serves as the 
attachment point for the BCCP domain. The central domain is regulated by 
phosphorylation of a regulatory loop at the interface between two smaller subdomains. 
Phosphorylation stabilizes the loop and restricts conformational flexibility. While the 
regulatory role of the CD domain has been related to BC domain dimerization, its 
proximity and physical connection to the carrier domain may be important. However, 
there have been no direct attempts to relate the conformational dynamics of the BC, CD, 
and BCCP domains in ACC. Especially absent to date are studies of how carrier domain 
dynamics relate to catalysis in ACC, making this recent study on the effects of 
phosphorylation on conformational dynamics our best understanding of conformational 
dynamics in ACC.  
3.2  Crosslinking Studies of Polyketide Synthase 
Polyketide synthases (PKSs) are massive, multi-modular enzyme complexes that 
catalyze the production of a diverse range of natural products. PKSs operate like an 
assembly line, passing an intermediate product between multi-domain modules to 
catalyze very specific, ordered reactions to generate elaborately decorated natural 
products. Due to the complex nature of the final product, these reactions must maintain 
exquisite directionality. There are many open questions regarding the structure and 
organization of the modules, the mechanism ensuring proper reaction directionality, and 
the mechanism behind conformational changes in these enzymes. Given the size of these 
complexes, many of the standard biochemical and biophysical approaches are 
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inaccessible in these systems. Currently, no X-ray crystal structure of a complete PKS 
module has been determined.  
6-deoxyerythronolide B synthase (DEBS) is a PKS that operates as an a2b2g2 
homodimer and has been extensively studied in recent years. X-ray crystal structures of 
individual domains and lower-resolution techniques such as cryo-EM and small angle X-
ray scattering (SAXS) has contributed to a better understanding of this system in recent 
years (Robbins, et al., 2016). A DEBS module, which is a homodimer, is composed of at 
least a ketosynthase domain (KS), an acyltransferase (AT) domain, and an acyl-carrier 
protein (ACP). Some modules also contain a ketoreductase domain (KR) and/or a TE 
domain, which cyclizes the 14-membered product. An ACP domain can interact with 
either AT domain in the homodimer. Interestingly, the ACP domain only participates in 
chain elongation with the intermolecular KS domain but prefers the intramolecular KS 
domain during chain translocation (Robbins, et al., 2016). Previous work has 
demonstrated that protein-protein interactions play an important role in transporting 
intermediates between modules, but there is no direct evidence to explain the reason for 
the preferred ACP domain associations during catalysis.   
While no studies have reported directly on ACP domain positioning, one recent 
study has shed light on a mechanism related to ACP domain translocation. This study 
was designed to reveal how the assembly line-style process of catalysis is synchronized 
to keep the directionality of reactions proceeding in the proper direction. Protein 
interactions between various DEBS domains were captured by crosslinking in the 
presence/absence of substrates. This study ultimately revealed a mechanism that prevents 
more than one polyketide chain from being bound to an active site of the same module. 
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This mechanism, dubbed the “turnstile mechanism”, prevents KS domain acylation of the 
next polyketide chain until the previous chain elongation product has moved downstream 
by virtue of the ACP domain transferring it to a downstream module. To summarize, the 
KS domain active site is closed until the growing polyketide chain that has just finished 
interacting with the KS domain is transported to the next module, ensuring proper 
directionality of the multi-step reaction and correct product formation. However, the 
molecular underpinnings of this mechanism have not been established and the role of 
conformational changes in this system is not yet known (Lowry, et al., 2016). 
3.3  Sulfur Oxidation Enzyme Interactions Explored by Disulfide Bond Formation 
The microbial oxidation of sulfide to sulfate for energy generation in bacteria can 
follow two pathways: the sulfide:quinone oxidoreductase pathway or the Sox pathway. 
The Sox pathway utilizes a heterodimeric carrier protein SoxYZ that uses a Cys residue 
to carry various sulfur-containing species for catalysis by multiple enzyme partners. 
Since SoxYZ does not co-purify with any Sox enzymes, it has been suggested that these 
interactions between SoxYZ and the active-site containing partners are weak and 
transient (Rother, et al., 2001). Prior to a 2015 study by Grabarczyk, et al., there have 
been no specific interactions between the carrier protein and other Sox enzymes 
discussed in the literature. However, a highly conserved loop on the surface of SoxYZ, 
termed the “Z-loop”, was proposed to play a role in interactions between SoxYZ and its 
partners (Sauvé, et al., 2007).  
The 2015 study by Grabarczyk, et al. investigated the interactions between 
SoxYZ and SoxB, a Sox pathway enzyme, using crystallography, biophysical techniques, 
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and molecular modelling (Grabarczyk, et al, 2015). One of these techniques involved 
mutating an active site residue to a cysteine that would form a disulfide bond with the 
carrier protein cysteine, trapping the interacting pair together for further analysis. SoxYZ 
interacts with SoxB at several places on the surfaces of each protein. When the SoxY 
carrier arm is inserted into the tunnel leading to the active-site of the SoxB enzyme, 
hydrogen-bonding interactions occur in the active-site tunnel and at the base of the carrier 
arm. In this scenario, a surface loop on SoxB is positioned to rest in a pocket on the SoxZ 
surface through stabilizing hydrophobic and electrostatic interactions. While a description 
of these interactions contributed to a greater understanding of the molecular interface 
between SoxB and SoxZ, they did not provide an explanation for how the dissociation of 
the carrier arm facilitates interactions with other Sox enzymes. Structural and kinetic data 
suggest that Arg416 in the SoxB active site undergoes an induced conformational change 
in the presence of the sulfonate-containing substrate. In the absence of substrate, Arg416 
forms an ion pair with a mobile loop near the active site. This mobile loop sterically 
clashes with SoxY insertion into the active site, disfavoring binding in the absence of 
substrate. When SoxY-substrate binds, the mobile loop is displaced, freeing Arg416 to 
interact with the sulfonate-group on the carrier domain, further disfavoring interaction 
with the mobile loop. After catalysis, the sulfonate-group is lost, favoring the return of 
the Arg416-mobile loop interaction. This disfavors SoxY binding, freeing the carrier 
domain to dissociate and interact with other Sox enzymes. This protein-protein 
interaction resembles the Tyr621-biotin interaction proposed in the CT domain of PC as a 
way to stabilize the carrier domain in a catalytically-relevant conformation.  
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3.4  A FRET Investigation of a Nonribosomal Peptide Synthetase 
Nonribosomal peptide synthetases (NRPSs) produce peptide-based natural 
products such as the antibiotic vancomycin or the immunosuppressant cyclosporin A. 
The genes for these enzymes are typically arranged in an operon in bacteria and as a gene 
cluster in eukaryotes. NRPSs operate as a series of modules, much like polyketide 
synthases, with each module containing multiple domains to catalyze various chemical 
steps and the addition of amino acids to the growing peptide. The aminoacyl or peptidyl 
intermediate is transferred between domains or modules using a central peptidyl-carrier-
protein (PCP) domain. The PCP domain has a 4’-phosphopanthetheine with a terminal 
sulfhydryl group which covalently binds the aminoacyl or intermediate for transport. 
Crystal structures have shown that only one catalytic site is within range of the prosthetic 
group, indicating that the PCP domain must translocate. However, prior to 2017, no 
observations of PCP domain translocation had been made, nor was it clear how carrier 
domain positioning is governed.  
In 2017, conformational changes within gramicidin synthetase I from 
Aneurinibacillus migulanus were investigated using FRET (Alfermann, et al., 2017). The 
construct of gramicidin synthetase I investigated was composed of two domains, the 
catalytic A domain and the PCP carrier domain. The A domain is a member of the acyl-
CoA synthetase, NRPS adenylation domain, luciferase enzyme (ANL) superfamily 
(Marahiel, et al., 1997; Gulick, A.M., 2009). This domain catalyzes the activation of an 
amino acid with ATP, forming aminoacyl adenylate (amino acid-AMP) and 
pyrophosphate (PPi), and covalently attaches it to the terminal cysteine of the PCP 
domain. In a full gramicidin synthetase I enzyme, the PCP domain would then interact 
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with an upstream or downstream module for peptide bond formation or chemical 
alterations of the intermediate peptide. The A domain is composed of two subdomains: 
the N-terminal AN and C-terminal AC, connected by a short linker (Conti, et al., 1997). In 
the absence of substrate, these domains do not strongly interact and adopt an open 
conformation. In the presence of substrate, a closed conformation is adopted with active 
sites forming at the interface between the domains.  
In the FRET study, EGFP was fused to the C-terminal portion of the PCP domain 
while a cysteine was introduced in the A domain which was labeled with an appropriate 
fluorophore to generate a FRET signal when interacting with EGFP. It was observed that 
gramicidin synthetase I adopts multiple conformations in solution with the 
conformational equilibrium shifted by ligand binding. Large concentrations of PPi, one of 
the products of the reaction catalyzed by the A domain, inhibited forward progress in 
catalysis by favoring the adoption of a specific conformation, disfavoring conformations 
required for further catalytic steps. Separately, the PCP-bound thioester intermediate was 
proposed to have high affinity for a downstream catalytic domain, ensuring proper 
direction of peptide synthesis (Linne and Marahiel, 2000; Mootz and Marahiel, 1997; 
Belshaw, et al., 1999). Taken together, these mechanisms offer insight into how these 
complex enzymatic systems may control carrier domain translocation and reaction 
progress.  
3.5  Trapping the Acyl Carrier Protein of a Fatty Acid Synthase 
 Fatty acid synthesis generally refers to the production of long-chain fatty acids 
using acetyl-CoA and NADPH. This process is catalyzed by a series of enzymes that 
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perform chain elongation and chemical modifications to achieve specific end products. 
An acyl carrier protein is used to transport the growing fatty acid between enzyme active 
sites throughout the reaction cycle. This carrier protein utilizes phosphopantetheine as the 
prosthetic group that covalently bonds to the fatty acid chain. These enzymes are of 
interest for their potential to be used in biofuel synthesis, as well as antibiotic 
development (Finzel, et al., 2015). As in other carrier domain enzyme systems, there are 
many open questions regarding the mechanism that controls fatty acid length and how the 
acyl carrier protein (ACP) selectively binds to the “correct” downstream enzyme (Finzel, 
et al., 2015).   
A recent study re-engineered ACPs with covalently bound substrate analogues of 
different lengths, for investigation with FabA, an enzyme in the microbial fatty acid 
synthesis pathway that performs a dehydratase reaction with a specific preference for 
fatty acid chains 8-12 carbons long. To investigate how this enzyme selects for a 
substrate of a specific length and interacts with the carrier protein, a crosslinking system 
was developed to trap ACP-substrate complexes bound to FabA (Finzel, et al., 2015). 
This study revealed three relevant regions.  A positively charged area on the surface of 
FabA, which was proposed to form the ACP binding interface, was confirmed to play a 
crucial role in binding ACP. Two phenylalanines at the opening of a tunnel leading to the 
active site contributed favorable hydrophobic interactions with fatty acid chains of longer 
lengths. Finally, the morphology of the active site pocket was determined to impact the 
length of the fatty acid chain that selected for catalysis. Constriction of the pocket 
through mutagenesis of residues lining the pocket led to less interaction with longer fatty 
acid chains (Finzel, et al., 2015). Taken as a whole, these findings are similar to PC in 
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that protein-protein interactions are proposed to stabilize the carrier domain-active site 
complex (BC and CT domain of PC) while active site residues may restrict access of the 
prosthetic group to the active site (BC domain arginine and glutamate of PC).  
3.6  Pyruvate Dehydrogenase Complex Lipoyl Domain Interactions Investigated by 
Crosslinking 
The pyruvate dehydrogenase complex (PDC) catalyzes the production of acetyl-
CoA and NADH from the decarboxylation of pyruvate. This is a central enzyme in 
metabolism, controlling the carbon flux from glycolysis into the TCA cycle and 
maintaining glucose homeostasis. The PDC is a massive, unwieldy complex that is 
composed of duplicates of three catalytic enzymes, referred to as E1, E2, and E3. There 
are generally multiple E1 and E3 units bound to each E2 unit.  The E2 enzyme, 
dihydrolipoyl transacetylase, utilizes lipoic acid as the prosthetic group of the carrier 
domain that transfers an acetyl group to CoA, forming acetyl-CoA (Patel, et al., 2014).  
A study in 2006 in which the bovine dodecahedral E2 core domain was 
crystallized in the absence/presence of acyl-CoA revealed a gating mechanism to control 
substrate access to the active site. These structures revealed that CoA binding favors a 
conformational change that opens up the opposite side of the active site channel, allowing 
a second substrate to bind (Kato, et al., 2006). Recently, the first high-resolution structure 
of the E2 core (H. sapiens E2) was obtained using cryoEM (Jiang, 2018). This structure 
revealed a similar gating structure to that observed in bovine E2, suggesting that these 
two E2 cores behave similarly.  
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A recent study combined crosslinking of the carrier domain to catalytic domains 
with mass spectrometry to analyze the interaction frequency in the absence/presence of 
CoA (Prajapati, et al., 2019). This study revealed that the presence of CoA increased 
carrier domain interaction with the E2 domain and the downstream E3 active site. The 
authors interpreted this to suggest that substrate binding affected the sampling of catalytic 
conformations. However, given the lack of high-resolution structures of the lipoyl carrier 
domain interacting with the E1, E2, and E3 catalytic domains, much remains to be 
discovered about how its translocation is controlled, such as exactly how the 
conformational change promoted by CoA binding affects interactions with the carrier 
domain, how the organization of interactions between the carrier domain and many 
surrounding active sites is controlled, and how substrate binding in the E1 and E3 
domains might affect lipoyl domain binding (Yu, et al., 2008) (Prajapati, et al., 2019). 
4.  OVERVIEW 
PC is an important enzyme of central metabolism, providing a critical anaplerotic 
input for a variety of biosynthetic reactions. PC also serves as an important paradigm in 
which to study mechanisms of allosteric regulation and the relationship between ligand-
binding and large-scale domain movements. There have been numerous studies over the 
past ~50 years focused on kinetically characterizing the enzyme function, understanding 
the effect of acetyl-CoA on the enzyme structure and function, and describing the overall 
PC catalytic cycle in great detail. The results of all of these studies, at some level, are 
dependent on carrier domain translocation. The carrier domain bridges the individual 
reactions in each of the two active sites during catalysis, translocating a relatively large 
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distance in the process. While many studies have interpreted carrier domain behavior 
indirectly from kinetic or structural data, the mechanism governing the translocation of 
the carrier domain is perhaps the least understood phenomenon in PC. In this section, I 
will highlight the major questions related to carrier domain translocation in PC and 
outline how this dissertation will contribute to clarifying the relationship between ligand 
binding and carrier domain positioning in PC.      
In early kinetics studies of pyruvate carboxylase, CT domain ligands were shown 
to enhance the decarboxylation of carboxybiotin, presumably in the CT domain 
(Easterbrook-Smith, et al., 1976; Goodall, et al., 1981; Attwood and Wallace, 1986). 
These results were, understandably, interpreted to suggest that CT domain ligands 
induced carrier domain translocation to the CT domain and that, in the absence of these 
ligands, the carrier domain remained in the vicinity of the BC domain. Under ideal 
conditions, acetyl-CoA was observed to efficiently couple the BC domain half-reaction 
with the CT domain half-reaction, suggesting that acetyl-CoA plays a key role in 
mediating carrier domain translocation (Zeczycki, et al., 2011B). More recently, a 
kinetics-based study in SaPC has suggested that pyruvate and acetyl-CoA facilitate long-
range communication that serve to induce carrier domain translocation (Westerhold, et 
al., 2016).  Acetyl-CoA has also been shown to reduce the activation entropy in SaPC, 
suggesting that the conformational flexibility of the carrier domain is constrained by 
acetyl-CoA (Westerhold, et al., 2017) However, none of these studies have directly 
demonstrated that carrier domain translocation is induced by ligand binding, nor have 
they offered a mechanism for the role that acetyl-CoA plays in affecting carrier domain 
translocation. Meanwhile, various structural studies have proposed an alternative to the 
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induced conformational change mechanism in PC, where local conformational changes 
are sufficient to alter the domain positioning (Lietzan, et al., 2011; Lietzan, et al., 
2013A).    
This dissertation describes a detailed effort to investigate the mechanism 
governing carrier domain translocation. I have focused on directly observing the 
positioning of the carrier domain through the use of crosslinking traps, in order to capture 
the carrier domain in two distinct intermolecular conformations. The effects of substrates 
and effectors on carrier domain positioning are also investigated to more thoroughly 
investigate the mechanism governing carrier domain positioning and to better understand 
the molecular interactions responsible for shifting the positional equilibrium. Decades of 
prior studies have interpreted carrier domain translocation using the induced 
conformational change model, which was developed prior to the modern description of 
thermodynamics in protein folding and conformational change. Prior to the studies 
outlined in this dissertation, there had been no attempts to directly observe carrier domain 
positioning in PC. Crystal structures suggest an alternative to the induced conformational 
change model for controlling carrier domain positioning by revealing potential 
interactions between active site residues and biotin which may favor/disfavor biotin 
access to these active sites (Lietzan, et al., 2011; Lietzan, et al., 2013A). However, these 
static structures do not capture the dynamic interplay between ligand binding and shifts in 
the carrier domain positional equilibrium. While there is clear evidence to support that 
CT domain ligands stimulate carboxybiotin decarboxylation, the induced conformational 
change model is not required to explain these observations. Similarly, while acetyl-CoA 
has been observed to accelerate the rate of reactions catalyzed in the BC domain, the 
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relationship between this allosteric activator and carrier domain positioning has not been 
explored. This dissertation will outline research that is focused on directly determining 
the mechanism behind carrier domain translocation and the role of ligands in shifting 
carrier domain positioning.       
This study was performed entirely with PC cloned from Staphylococcus aureus 
PC (SaPC). This was considered an ideal choice since several X-ray crystal structures 
exist with the carrier domain positioned in two different intermolecular interactions: one 
with biotin positioned in the CT domain active site and the other structure with biotin 
positioned in the exo-binding site (Xiang and Tong, 2008). SaPC is also responsive to 
acetyl-CoA activation (Yu, et al., 2009) has been studied kinetically (Yu, et al., 2009) and 
has recently been used to study the kinetic and thermodynamic effects of acetyl-CoA on 
SaPC activation (Westerhold, et al., 2016; Westerhold, et al., 2017).   
Based on the studies described in this dissertation, I propose that carrier domain 
positioning in PC is governed by the conformational selection model. Regardless of the 
presence or absence of ligand(s), the carrier domain repositions itself into various 
intermolecular conformations. This is in direct opposition to the induced conformational 
change model. Ligands shift the equilibrium positioning of the carrier domain, with 
biotin playing the primary role in the sensitivity of the carrier domain to these ligands. 
Residues that have been proposed to interact with biotin and which serve to 
favor/disfavor positioning of biotin in either the CT or BC domain active sites are 
observed to shift carrier domain positioning and alter the kinetic barriers to carrier 
domain translocation. Acetyl-CoA favors carrier domain positioning away from the BC 
domain by reducing a kinetic barrier to translocation in the presence of substrates and by 
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thermodynamically favoring this intermolecular repositioning. BC domain substrates 
have a kinetic and thermodynamic effect on carrier domain translocation, shifting carrier 
domain positioning towards the BC domain, while pyruvate has the opposite effect, 
thermodynamically and kinetically favoring translocation of the carrier domain to adopt 
an intermolecular position. These combined studies revolutionize our understanding of 
carrier domain translocation in PC by offering the first direct observations of carrier 
domain translocation and positioning, offering alternative explanations to several 
previous interpretations of carrier domain behavior. This work highlights the great 
potential for PC to serve as a paradigm system in which to study the relationship between 
ligand binding, catalytic turnover and large-scale domain rearrangements in complex 
enzyme systems. 
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II. MATERIALS AND METHODS 
Acetyl-CoA was purchased from Crystal Chem, Inc. (Elk Grove Village, IL) and 
CoALA Biosciences (Austin, TX). Sodium phosphate (mono- and di-basic), potassium 
phosphate (mono- and di-basic), ammonium chloride, Tris buffer, L-arabinose, D-
glucose, glycine, bis-tris propane, DL-dithiothreitol (DTT), sodium dodecyl sulfate 
(SDS), ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), 
chloramphenicol, glycerol, and granulated Luria broth were purchased from Research 
Products International Corp. (Mount Prospect, IL). Kanamycin sulfate was purchased 
from VWR (Dublin, Ireland) and Gold Biotechnologies (Olivette, MO). D-biotin was 
purchased from VWR (Dublin, Ireland). Epoxysuccinyl-L-leucylamido(4-guanido) 
butane (E-64) was purchased from Research Products International Corp. (Mount 
Prospect, IL) or Gold Biotechnologies (Olivette, MO). Pepstatin A and dimethyl 
sulfoxide was purchased from Fisher Scientific (Waltham, MA). Sodium chloride, malic 
dehydrogenase, and lactate dehydrogenase were purchased from Sigma Aldrich (St. 
Louis, MO). 30% acrylamide/bis solution, tetramethylethylenediamine (TEMED), 
Coomassie Brilliant Blue G-250 and R-250 were purchased from Bio-Rad (Hercules, 
CA). 4´ Laemmli SDS loading buffer and triethanolamine hydrochloride were purchased 
from Alfa Aesar (Haverhill, MA). Glacial acetic acid was purchased from 
MilliporeSigma (Burlington, MA). Methanol was purchased from Avantor (Radnor, PA). 
Staphylococcus aureus (SaPC) PC was previously cloned into a modified pET-27b vector 
and was generously supplied by Dr. Liang Tong, Columbia University (12). The masses 
of reagents used were measured by  Mettler Toledo XS2002S or Mettler Toledo XS105 
balances (Columbus, OH).  
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SaPC Mutagenesis, Expression, and Purification. All SaPC genes were expressed 
and purified in an identical manner. Mutations in SaPC were generated according to the 
Agilent Quikchange II Site-Directed Mutagenesis protocol. Primers were obtained from 
Integrated DNA Technologies. All constructs used in this study were confirmed by DNA 
sequencing of the gene in its entirety by Functional Biosciences, Inc. (Madison, WI). The 
primers used for mutagenesis are shown in Appendix A, Figure VIII-1 and were 
synthesized by Integrated DNA Technologies (Coralville, IA). Each PCR reaction tube 
for mutagenesis had a total reaction volume of 28 μL with consisted of 2.5 μL of 10´ 
ammonium buffer, 0.5 μL each of a 10 μM stock of the forward and reverse primer, 5 μL 
DNA template (50-100 ng/μL plasmid DNA), 0.5 μL dNTP (from 10 mM stock), 0.5 μL 
Premium Bullseye PR DNA polymerase obtained from Midwest Scientific (Valley Park, 
MO), and 19 μL of sterile, distilled and deionized water. The PCR reaction for 
mutagenesis was performed in several steps. Step 1: 95 °C for 3 minutes, Step 2: 95 °C 
for 50 sec., Step 3: 3-5 °C below lowest TM of primers for 50 sec., Step 4: 72 °C for 14 
min., and Step 5: 72 °C for 7 min. Steps 2-4 were repeated 18 times before Step 5 was 
initiated. After mutagenesis, 1 μL of Dpn1, obtained from New England Biolabs 
(Ipswich, MA), was reacted with the PCR reaction product for 3 hours at 37 °C to digest 
the original DNA template before transformation.  Electro-competent E. coli Top10 cells 
were used for transformation by electroporation. 50-100 ng of plasmid was added to the 
50 μL of Top10 cells on ice. This mixture was transferred to a frozen electroporation 
cuvette with a 1 mm electroporation gap and electroporated at 1600V in an Eppendorf 
Electroporator 2510. 1 mL of Luria broth was added immediately after transformation, 
transferred to a sterile tube, and the cells were allowed to recover at 37 °C for 45 mins. – 
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1 hour before plating on a Luria Broth agar plate with 25 µg/mL kanamycin. DNA was 
purified from the Top10 cells using the Promega Wizard Plus SV Miniprep Kit following 
the included spin purification protocol obtained from Promega (Fitchburg, WI).  
Glycerol stocks were created by mixing 700 mL of overnight culture, incubated at 
37 °C, with 300 µL of 50 % (v/v) sterile glycerol and stored at -80°C.  
All PC clones were co-transformed and co-expressed with the pCY216 vector 
encoding Escherichia coli biotin protein ligase A (BirA) to ensure complete biotinylation 
of PC. Transformed E. coli BL21 (DE3) cells were cultured in M9 minimal media with 
25 µg/mL kanamycin and 30 µg/mL chloramphenicol at 37 °C to an optical density 
(OD600) of 0.8 - 1.0, after which protein expression was induced by the addition of 
isopropyl 1-thio-β-D-galactopyranoside (IPTG) and L-arabinose to a final concentration 
of 0.5 mM and 25 mM, respectively. The culture was also supplemented with D-(+)-
biotin at a final concentration of 3 mg/L. Induced cells were incubated at 16 °C for 16 - 
24 hours before harvesting by centrifugation at 6000 rpm for 15 min. at 4 °C.  
All SaPC enzymes were purified using sequential Ni2+-affinity and anion 
exchange chromatography. Harvested cell paste (20 – 30 g) was re-suspended in 200 mL 
lysis buffer (20 mM Tris-HCl pH 7.8; 200 mM NaCl; 0.5 mM EGTA; 5 mM imidazole; 6 
mM β-mercaptoethanol; 1 mM PMSF; 1 μM pepstatin A; and 5 μM E-64). Cells were 
lysed by sonication for 10 minutes at a temperature, monitored by a thermoprobe in the 
lysate, between 4-10 °C and pelleted by centrifugation at 20,000 rpm for 30 mins at 4 °C. 
A Branson Model 450 Digital Sonifier with a model 102-c converter and a ½” diameter 
Tapped Bio Horn was used for the sonication. The supernatant was loaded on a 5 mL 
Ni2+-nitrilotriacetic acid profinity resin column (Bio-Rad, Hercules, CA). The column 
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was washed with 12´ column volume of wash buffer (20 mM Tris-HCl pH 7.8; 200 mM 
NaCl; 0.5 mM EGTA; 20 mM imidazole; 6 mM β-mercaptoethanol) and the protein was 
eluted with a gradient from 20 mM to 250 mM imidazole using wash buffer and elution 
buffer (20 mM Tris-HCl pH 7.8; 200 mM NaCl; 0.5 mM EGTA; 250 mM imidazole; 6 
mM β-mercaptoethanol). Purified protein was pooled and dialyzed against a buffer 
compatible with anion-exchange chromatography (20 mM triethanolamine, pH 8.0; 50 
mM NaCl; 1 mM EGTA; and 2 mM dithiothreitol (DTT)) at 4 °C overnight. The 
dialyzed protein was loaded onto a 10 mL Q-Sepharose Fast Flow resin column (GE 
Healthcare), washed with 10x column volumes of dialysis buffer and eluted from the 
column in dialysis buffer with a gradient from 50 mM to 1 M NaCl. SaPC typically elutes 
between 400 - 800 mM NaCl. The purified protein was pooled and dialyzed against 
storage buffer (20 mM Bis-Tris Propane, pH 7.2; 15 mM NaCl; 10 mM MgCl2, and 1 
mM TCEP) for three successive changes of 4 hours or more. The protein was 
concentrated to a final concentration of 4 mg/mL − 10 mg/mL and was drop frozen in 
liquid nitrogen prior to storage at -80 °C. Concentration was achieved by using Amicon 
Ultra-15 100K centrifugal filters from MilliporeSigma. Centrifugation was conducted at 
4,000 rpm and  All protein concentrations were determined using the predicted extinction 
coefficient corresponding to absorbance at 280 nm. 
Mutagenesis Rationale. The Q891/N1102 and D907/Q1118 pairs were chosen for 
mutagenesis to cysteines for crosslinking due to their proximity (< 8 Å) for crosslinking 
based on the 3BG5 SaPC crystal structure, as well as their general lack of conservation 
(Xiang and Tong, 2008). Y621, E243, and T876 were mutated all mutated to alanine to 
ensure consistency with previous studies of these mutations in literature (Lietzan, et al., 
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2013A, Lietzan, et al., 2011, Zeczycki, et al., 2009). V1062 was determined from the 
3BG5 crystal structure of SaPC to represent an amino acid near the base of the carrier 
domain suitable for truncation of the carrier domain. TAG was chosen for the stop codon 
introduced as it required the least number of nucleotides to be mutagenized of the three 
available stop codons (TAG, TAA, TGA). W808 was mutated to a phenylalanine as this 
amino acid represented the most structurally and biochemically conservative choice. 
K1112 was mutated to a glutamine as this is also a structurally conservative choice and 
this mutation had been successfully performed in the lab in PC from other species.  
Enzymatic Activity Assay. A Shimadzu UV-1800 UV Spectrophotometer with an 
attached Shimadzu CPS Controller was used for all enzyme activity assays. The UV 
Probe ver. 2.62 (Shimadzu Corp., Kyoto, Japan) software was used to monitor all activity 
assays and calculate rates of absorbance change. The ranges for the rate measurements 
were selected to cover linear portions of absorbance change during the reactions with the 
same ranges applied to all replicates. Readings were taken for the times as described 
below with a cycle time of 22 sec. with a Windows XP-based computer or 30 sec. after a 
new Windows 10-based computer was installed.  
Pyruvate carboxylation activity was measured spectrophotometrically at 340 nm 
by following the conversion of oxaloacetate to malate using the coupled enzyme, malate 
dehydrogenase (MDH). Reactions were performed in a buffer containing 0.1 M Tris-HCl 
(pH 7.8), and 7 mM MgCl2. All substrates and coupling reagents were prepared as a 10x 
stock solution in this buffer that provided final reaction concentrations of 25 mM 
NaHCO3, 2.5 mM ATP, 0.25 mM acetyl-CoA, 12 mM sodium pyruvate, 0.12 mM 
NADH, and 10 U/mL MDH. All measurements were performed in triplicate and the 
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errors are reported as the standard deviation. The final PC concentration in the assay 
ranged from 2.5 - 10 μg/mL per reaction. Reactions were followed until completion or 10 
mins. had elapsed. Data from crosslinking inactivation assays were fit to Equation 1 
using a least-squares regression in GraphPad Prism (version 8.1.1 for Windows, 
GraphPad Software, San Diego, California, USA). The value for kobs was determined by 
fitting the data to Equation 1, where a represents the initial value at t = 0, b describes the 
limiting residual value, t is the time in seconds, and kobs is the observed rate constant.  
 y = 	 (a − b) ∗ e-./01∙3 + b      (Equation 1) 
 
The PC-catalyzed rate of oxamate-induced oxaloacetate decarboxylation activity 
was measured spectrophotometrically at 340 nm by following the conversion of pyruvate 
to lactate using the coupled enzyme, lactate dehydrogenase (LDH)5, 6, 12, 13. Reactions 
were performed at 25 °C in a buffer containing 0.1 M Tris-HCl (pH 7.8), and 7 mM 
MgCl2. All substrates and coupling reagents were prepared as a 10´ stock solution that 
provided final concentrations of 0.12 mM NADH, 0.5 mM oxamate, 0.2 mM 
oxaloacetate, 0.25 mM acetyl-CoA, and lactate dehydrogenase (10 units). Reactions were 
initiated by the addition of SaPC (60-200 μg/mL). Reactions were followed until 
completion or 20 mins. had elapsed. 
ADP phosphorylation by carbamoyl phosphate activity was measured by 
following the production of ATP photometrically at 340nm using a hexokinase/glucose-
6-phosphate dehydrogenase coupled assay5, 6, 12, 14. Specific activities were measured at 
25 °C in 1-mL reaction volume containing 0.1 mM Tris, 7 mM MgCl2, 3.5 mM ADP, 
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0.25 mM acetyl-CoA, 20 mM carbamoyl phosphate, 0.4 mM glucose, 0.36 mM NADP, 
glucose-6-phosphate dehydrogenase (5 units) and hexokinase (1 unit). Reactions were 
initiated by the addition of SaPC (150-200 μg/mL). Reactions were followed until 
completion or 20 mins. had elapsed.  
SaPC Crosslinking. BMOE was prepared in 100% DMSO at 20´ the desired 
reaction concentration. SaPC was reacted at a final concentration of 1 mg/mL (premixed 
with substrates for a minimum of 10 minutes when applicable) in a buffer containing 0.1 
M Tris-HCl (pH 7.8), 7 mM MgCl2 with the desired concentration of BMOE (and 
identical concentration of substrate when applicable) at room temperature. After a 
defined incubation period, dithiothreitol was used to quench the reaction at a final 
concentration of 13 mM for 15 minutes at room temperature. Samples were then either 
assessed for activity using the MDH assay described above or mixed with 4´ Laemmli 
Buffer in reducing conditions and heated to 100 °C for 3 minutes for SDS-PAGE analysis 
using an 8% polyacrylamide gel. Protein molecular weights were estimated using the 
Spectra Multicolor High Range Protein Ladder (Thermo Scientific, Waltham, MA). SDS-
PAGE gels were run at 100V until the dye-front ran off the bottom of the gel. Coloration 
was achieved with Coomassie Brilliant Blue G-250 (Bio-Rad, Hercules, CA). 
SDS-PAGE Gel Preparation. 150 mL of resolving buffer contained 27.23g Tris 
base dissolved in distilled, deionized water and adjusted to pH 8.8 with 6N HCl. 100mL 
stacking buffer contained 6g Tris base dissolved in distilled, deionized water and adjusted 
to pH 6.8 with 6N HCl. 1 L of 10x electrode running buffer for SDS-PAGE contained 
30.3 g Tris base, 144 g glycine, and 10 g SDS dissolved in distilled, deionized water. The 
8% acrylamide resolving gel was composed of 13.8 mL distilled, deionized water, 8 mL 
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30% acrylamide, 7.2 mL resolving buffer, and 293 μL of 10% SDS. These components 
were stirred together before the simultaneous addition of 154 μL of 10% ammonium 
persulfate and 16 μL TEMED. The mixture was stirred briefly before pouring for gel 
formation. This was allowed a minimum of 45 minutes for polymerization to occur. 5% 
stacking gel was poured on top of this to form the stacking portion of the final SDS-
PAGE gel. This stacking gel was composed of 2.9 mL distilled, deionized water, 850 μL 
30% acrylamide, 1.25 mL stacking buffer, 50 μL of 10% SDS. These components were 
mixed before the simultaneous addition of 25 μL of 10% ammonium persulfate and 5 μL 
TEMED. This mixture was stirred before it was poured on top of the resolving portion 
and the appropriate comb was inserted for well formation. This was allowed to remain 
undisturbed for 45 minutes for polymerization to occur. To achieve reducing conditions 
in the loading buffer, β-mercaptoethanol was added to the 4´ Laemmli buffer to achieve 
a 5% β-mercaptoethanol / 95% 4´ Laemmli buffer (v/v) final mixture.  
Coomassie protein stain was composed of 225 mL distilled, deionized water, 225 
mL methanol, 50 mL glacial acetic acid, and 0.25 g Coomassie Brilliant Blue G-250. 
This was stirred until the Coomassie stain was completely dissolved. Protein gel destain 
solution was composed of 700 mL distilled, deionized water, 200 mL methanol, and 100 
mL glacial acetic acid. Staining was performed with an overnight incubation of the gel 
with protein stain while destaining was performed for at least 1 hour to achieve minimal 
background staining.  
Densitometric Analysis. Densitometric analyses were performed using the 
LabWorks software developed by UVP, Inc. (Upland, CA). The coloration intensity of 
each band was determined from images of the SDS-PAGE gels. The “Area Density 
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Analysis Tool” function in Labworks was utilized for determination of the density of 
each band. A rectangle was drawn around each band with a size to include the full band 
but exclude nearby bands or excess background. The software includes background 
subtraction to minimize the effect of varying sizes of these rectangular areas. This was 
verified by drawing varying sizes of rectangles around a band and ensuring that the areal 
density remained unchanged.  The normalized density of the monomer band was 
determined by dividing the monomer band density by the total of the band density for 
both the monomer and dimer bands. This software does not have any automatic feature to 
detect overloads in the bands when determining areal density other than to color the 
saturated portions of a band in red when obtaining the image. All images where obtained 
using exposure times to prevent this kind of saturation.  
Stopped-Flow Spectroscopy. Stopped-flow spectroscopy was performed using an 
Applied Photophysics SX20 instrument at room temperature obtained from Applied 
Photophysics, Ltd. (Leatherhead, England). Intrinsic tryptophan fluorescence was 
observed at an excitation wavelength of 295 nm using a 350 nm emission filter. SaPC 
(0.35 mg/mL) was premixed with substrates for a minimum of 10 minutes when 
applicable and loaded in one drive syringe and mixed 1:1 with the substrate/BMOE 
mixture in the second drive syringe. The final concentration of substrates or ligands used 
was 2.5 mM ATP, 5 mM ADP, 5 mM phosphonoacetate (PPA), 0.25 mM acetyl-CoA, 12 
mM pyruvate, and 10 mM L-aspartate. All solutions were prepared in a buffer containing 
0.1 M Tris-HCl (pH 7.8), 7 mM MgCl2. Applied Photophysics Pro-Data SX software was 
used to operate the instrument, interpret, and average the data. All data are the average of 
4-5 replicates. Reported rates are the average value of three independent acquisitions of 
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these replicates. The data from each sample was normalized to start at a value of 1 to 
account for variability in initial fluorescence intensity. Normalization was performed to 
plot the fractional change in intensity: the measured intensity at every time point was 
divided by the initial measured intensity at t = 0. Data were fit to Equation 2, where a 
represents the amplitude, kobs represents the observed rate, t represents time in seconds, c 
represents the slope of the linear second phase, and d represents the initial value at t = 0. 
 y = 	a ∗ (1 − e./01∙3) + ct + 	d     (Equation 2) 
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III. CONFORMATIONAL SELECTION GOVERNS CARRIER DOMAIN 
POSITIONING IN STAPHYLOCOCCUS AUREUS PYRUVATE CARBOXYLASE 
1. Introduction 
Two classical models are typically used to describe conformational changes 
accompanying ligand binding in biological macromolecules: the induced-fit hypothesis 
states that ligand binding induces a conformational change in the protein (Koshland, 
1959; Koshland, et al., 1966), while the conformational selection hypothesis states that 
the protein pre-exists in multiple conformational states, with ligand binding shifting the 
population towards the ligand-bound conformation (Monod, et al., 1965; Boehr, et al., 
2009). While these models have been tested and elaborated upon in many systems, the 
large-scale carrier domain motions associated with swinging domain enzymes provide a 
particularly intriguing and challenging system in which to study the influence of ligands 
on protein conformational change (Perham, 2000).  
 The mechanism by which reaction intermediates are transferred in a coordinated, 
unidirectional manner remains largely undefined in swinging domain enzymes. For 
example, assembly line polyketide synthases are built on an array of multiple modules 
and domains, requiring exquisite coordination as intermediates are transferred between 
active sites on distinct modules and domains. It has been proposed that vectorial synthesis 
in multimodular enzymes is dependent on conformational changes among the catalytic 
and carrier domains (Khosla, et al., 2014), but it remains unclear whether these 
conformations interchange freely at equilibrium or whether conformational changes are 
induced by ligand binding and catalytic turnover events. This is a particularly difficult 
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question to investigate in large and unwieldy systems such as polyketide synthases and 
their multi-domain counterparts, for which conventional structural and functional 
approaches do not easily apply. Instead, smaller and more tractable swinging domain 
enzyme systems can serve as structurally and biophysically accessible paradigms to study 
the relationship between ligand binding and large-scale protein conformational changes. 
One such enzyme, pyruvate carboxylase (PC), is a homotetrameric, swinging domain 
enzyme that has been well characterized structurally and kinetically (Lietzan, et al., 2014; 
Tong, 2013; Jitrapakdee, et al., 2008; Menefee and Zeczycki, 2014). During catalysis, the 
carrier domain of PC undergoes a conformational change spanning more than 70 Å, 
providing an ideal system to study the influence of ligand binding on large-scale 
conformational changes in swinging domain enzymes.  
PC catalyzes the ATP-dependent carboxylation of pyruvate to oxaloacetate, with 
bicarbonate serving as the carboxyl group donor. The reaction proceeds through two 
connected half-reactions catalyzed in distinct and remote active sites (Figure II-1A). In 
the first half-reaction, the biotin cofactor on the biotin carboxyl carrier protein (BCCP) 
domain is carboxylated with the concomitant cleavage of MgATP in the biotin 
carboxylase (BC) domain. The second half-reaction occurs in the carboxyltransferase 
(CT) domain, where the carboxyl group is transferred from the biotin cofactor on the 
BCCP domain to pyruvate, generating oxaloacetate. These two half-reactions are coupled 
through the intermolecular translocation of the biotinylated carrier domain, which must 
translocate over 70 Å to transfer the carboxyl group between active sites on the BC 
domain and the CT domain (Figure III-1A) (St. Maurice, et al., 2007; Xiang and Tong, 
2008; Lasso, et al., 2014).    
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Figure III-1 SaPC carrier domain motions and conformations. 
A.  A schematic of the PC tetrameric structure and intermolecular carrier domain translocation. BC 
domains are colored in blue, CT domains in yellow, and the BCCP carrier domain in red. A hypothetical 
intermolecular translocation pathway is traced for a single carrier domain from the BC domain of its own 
subunit to the exo binding site on the CT domain of a neighboring subunit. B. The SaPC X-ray crystal 
structure (PDB ID: 3BG5) showing the BCCP domain of one subunit (red) interacting at the exo binding 
site of the CT domain on the opposing subunit (yellow). The Mn2+ ion, colored as a grey sphere, and 
pyruvate are shown in the CT domain active site. Gln891 on the CT domain and Asn1102 on the BCCP 
domain were both mutated to cysteine to enable maleimide-based crosslinking to trap the BCCP domain in 
an intermolecular conformation. 
Prior efforts to study the influence of ligand binding on carrier domain 
translocation in PC have largely relied on interpretations of kinetic data. For example, 
detailed studies of carboxybiotin decarboxylation in sheep liver PC (Easterbrook-Smith, 
et al., 1976; Goodall, et al., 1981) and chicken liver PC (Attwood and Wallace, 1986) 
were performed in the presence of various CT domain ligands and were interpreted based 
on a ligand-induced conformational change model, where CT domain substrates were 
considered to induce carrier domain translocation to the CT domain. Based on rate 
enhancements observed in the presence of CT domain substrates or free biotin, it was 
concluded that substrates and cofactors mediate communication between subunits by 
inducing conformational changes through the enzyme (Zeczycki, et al, 2009). More 
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recent kinetic analyses were also interpreted in light of an induced conformational change 
model to propose that both pyruvate and the allosteric activator, acetyl-CoA, facilitate 
long-range communications that induce carrier domain translocation (Westerhold, et al., 
2016; Westerhold, et al., 2017). While these interpretations are reasonable, kinetic studies 
cannot directly observe carrier domain positioning and are limited to observations that 
conflate ligand binding, catalytic turnover and carrier domain translocation. In short, 
while many studies on PC have been interpreted using an induced conformational change 
model, they do not attempt to directly assess the conformational change model itself. 
In contrast to the interpretations described above, snapshots of PC from X-ray 
crystallography and cryo-electron microscopy have revealed multiple conformational 
states and carrier domain positions that are independent of the identity or bound state of 
the ligand (St. Maurice, et al., 2007; Lasso, et al., 2014; Yu, et al., 2009). These structural 
studies suggest that the carrier domain may sample multiple positions in a ligand-
independent dynamic equilibrium (Lietzan, et al., 2011; Lietzan, et al., 2013A). 
Ultimately, neither kinetic measurements nor structural studies are suitable to determine 
whether carrier domain positioning exists in a dynamic equilibrium or, instead, is 
governed by ligand-induced conformational changes. To address this question, alternative 
approaches are required that directly follow the positioning of the carrier domain, 
independent of catalytic turnover. 
Here we directly observe positioning of the carrier domain to clarify the 
mechanism of ligand associated conformational changes on the carrier domain in 
Staphylococcus aureus PC (SaPC). Using an intermolecular crosslinking trap, combined 
with a variety of analytical approaches, the positioning of the BCCP carrier domain is 
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directly observed as a function of substrates and allosteric effectors. These data clearly 
demonstrate that carrier domain positioning in PC is governed by conformational 
selection and also suggest that the allosteric activator, acetyl-CoA, favors the carrier 
domain to engage in an intermolecular interaction with the CT domain. This work 
clarifies the mechanism of carrier domain positioning in PC and can be extended to other 
carrier domain enzyme systems that function in vectorial biosynthesis. 
2. Results 
2.1  Crosslinkers trap the intermolecular SaPC carrier domain conformation. 
To directly observe SaPC carrier domain positioning, a system was designed to 
trap the BCCP carrier domain using maleimide-based homobifunctional crosslinkers. 
Specifically, the system was designed to capture the BCCP domain as it accesses an 
intermolecular interaction with the CT domain of an opposing subunit (Figure III-1A). 
The carrier domain has been observed in two intermolecular conformations in the SaPC 
crystal structure. In one conformation, biotin is docked in the CT domain active site 
while, in the second conformation, biotin is docked in the so-called “exo-binding site” 
which is located immediately adjacent to the CT domain active site. The exo-binding site 
conformation of SaPC was chosen as the basis for the crosslinking mutations to minimize 
detrimental effects on catalytic turnover. Two specific residues were targeted for 
mutation to cysteines, based on the X-ray crystal structure of SaPC with BCCP in the 
exo-binding site conformation (Xiang and Tong, 2008) (PDB ID: 3BG5): Gln 891 on the 
CT domain and Asn 1102 on the BCCP domain were both mutated to cysteine to 
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generate the double mutant, Q891C/N1102C SaPC (Figure III-1B). The Q891C/N1102C 
double mutant and the corresponding single mutants retained 30 – 50% of the wild-type 
pyruvate carboxylation activity, indicating that these mutations have only a modest 
impact on catalytic turnover (Table -1).  
 
Table III-1 Pyruvate carboxylation activity for SaPC and mutated constructs of SaPC. 
 
SaPC kcat (min-1) % Compared to WT 
WT 1430 ± 100 - 
Q891C 510 ± 50 36 
N1102C 690 ± 20 48 
Q891C/N1102C 390 ± 30 27 
(n = 3; errors represent standard deviations) 
 
 
To initially characterize this system, Q891C SaPC, N1102C SaPC, and 
Q891C/N1102C SaPC were incubated with bismaleimidoethane (BMOE) for 15 minutes 
and analyzed by SDS-PAGE (Figure III-2A). BMOE was selected as the crosslinker for 
its relatively short spacer arm, but longer crosslinkers were also evaluated and no 
discernable difference was observed compared to BMOE (Figure III-3). Crosslinked 
samples are predicted to run at twice the subunit molecular weight (SaPC monomer = 131 
kDa), resulting in a ~260 kDa crosslinked dimer. No crosslinked dimers were observed in 
the Q891C single mutant across a wide range of BMOE concentrations, while a very 
small degree of crosslinked dimers developed in the N1102C mutant at low 
concentrations of BMOE (10 μM).  A high degree of crosslinked dimers were observed in 
the Q891C/N1102C double mutant at 300 μM and 1 mM. Some higher molecular weight 
species were observed at all BMOE concentrations in both the single mutants and the 
Q891C/N1102C double mutant. Analytical ultracentrifugation of crosslinked wild-type 
SaPC and Q891C/N1102C SaPC confirmed that these high molecular weight species 
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were composed of large, aggregated protein. These species presumably arose from 
nonspecific crosslinking between individual protomers. A small percentage of these high 
molecular weight species were present across all samples incubated with BMOE and, 
therefore, were not considered further in this analysis.   
 
Figure III-2 Q891C, N1102C, and Q891C/N1102C SaPC crosslinked with BMOE. 
A. 8% acrylamide SDS-PAGE gel of SaPC mutants at 1 mg/mL reacted with either 0 μM, 10 μM, 300 μM, 
or 1 mM BMOE for 15 min. Q891C SaPC and N1102C SaPC did not form crosslinked dimers at BMOE 
concentrations greater than 300 μM. Q891C/N1102C SaPC was primarily crosslinked into dimers at 
BMOE concentrations of 300 and 1000 μM. 5 μg of SaPC was loaded in each lane. B. 8% acrylamide SDS-
PAGE gel showing time-dependent crosslinking Q891C/N1102C SaPC with BMOE ± 5 mM 
ADP/phosphonoacetate for various reaction times. Q891C/N1102C SaPC at 1 mg/mL was incubated with 0 
or 300 μM BMOE for the indicated times in the absence/presence of 5 mM ADP and 5 mM 
phosphonoacetate and then quenched with 13 mM DTT for 15 minutes. Lane 1: Q891C/N1102C SaPC 
reacted with 0 μM BMOE. Lane 2-7: Q891C/N1102C SaPC reacted with 300 μM BMOE for 30 s, 1 min, 2 
min, 4 min, 8 min, or 15 min. Lane 8: Molecular Weight Ladder. Lanes 9-14: Q891C/N1102C SaPC 
preincubated with 5 mM ADP and 5 mM phosphonoacetate for 15 minutes, then reacted with 300 μM 
BMOE for 30 s, 1 min, 2 min, 4 min, 8 min, 15 min. Lane 15: wild-type SaPC reacted with 300 μM 
BMOE. 5 μg of SaPC was loaded in each lane.  C. Densitometric analysis of monomer bands in Figure 2B 
as a function of time. Either no substrates were added (p) or 5 mM ADP and 5 mM phosphonoacetate (¢) 
were present during crosslinking. The y-axis represents the normalized monomer density, determined as 
described in the methods section. 
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Figure III-3 Q891C/N1102C SaPC incubated with bismaleimidoethane (BMOE), 1,4-
(bis)maleimidobutane (BMB), and 1,6-(bis)maleimidohexane (BMH). 
Each SaPC mutant was preincubated at 1 mg/mL with the indicated concentration of crosslinker for 120 
seconds. Samples were quenched with 13 mM DTT for 15 minutes. 7 μg of SaPC was loaded in each lane. 
1: 0 μM BMOE; 2: 10 μM BMOE; 3: 300 μM BMOE; 4: 0 μM BMB; 5: 100 μM BMB; 6: 300 μM BMB; 
7: 0 μM BMH; 8: 100 μM BMH; 9: 300 μM BMH.  
 
 
In the absence of ligands, the percentage of crosslinked dimers, as measured by 
SDS-PAGE, rapidly approached equilibrium (Figure III-2B). The rate of approach to 
equilibrium was greatly reduced, however, in the presence of ADP and 
phosphonoacetate, an analogue of the carboxyphosphate intermediate. These ligands 
substantially reduced the rate of crosslinked dimer formation relative to that observed in 
the absence of ligands (Figure III-2B).  A quantitative densitometric analysis was 
performed to determine the change in monomer density as a function of time (Figure III-
2C). These data are described by a single exponential decay and revealed that ADP and 
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phosphonoacetate dramatically reduce the observed rate constant for crosslinked dimer 
formation (Table III-2). While this generally illustrates that BC domain ligands can 
perturb the carrier domain equilibrium, the rapid re-equilibration observed in the absence 
of substrates precluded a more detailed kinetic analysis using this approach. Although 
this data is promising, the bands of the gels in Figure III-2 and others throughout the 
following studies may be overloaded. Further, the Coomassie G-250 dye was used 
throughout for protein coloration while R-250 may be more optimal for use in 
densitometry.  
 
Table III-2 Summary of observed first-order rate constants determined using densitometry, 
inactivation kinetics and intrinsic tryptophan fluorescence.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
* Reported errors represent the standard errors calculated from iterative non-linear curve fitting. The data 
were fit to Equation 1, where each data point was plotted as the average ± standard deviation of 3 
independent determinations. 
** Reported errors represent standard deviations from n=3 independent measurements of kobs. 
# Very high errors result from manual sample handling. These values are provided as estimates only.  
 
 
To complement and confirm the densitometric analysis by SDS-PAGE, 
inactivation kinetics were also assessed as a reporter of carrier domain crosslinking. 
Crosslinks between the BCCP and CT domains will immobilize the carrier domain, 
thereby inactivating the enzyme by preventing subsequent rounds of carboxyl group 
Substrate Densitometric 
kobs (s-1)* 
Inactivation 
kobs (s-1)* 
ITF 
 kobs (s-1)** 
None 0.051 ± 0.003 0.057 ± 0.014 0.073 ± 0.002 
ADP + 
phosphonoacetate 0.009 ± 0.001 0.005 ± 0.001 0.026 ± 0.001 
A. CoA N/A 0.083 ± 0.17# 0.082 ± 0.001 
Pyruvate N/A 0.091 ± 0.24# 0.081 ± 0.001 
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transfer between active sites. To confirm that enzyme inactivation was specific to carrier 
domain crosslinking, initial velocities were evaluated for the Q891C SaPC, N1102C 
SaPC, Q891C/N1102C SaPC, and wild-type SaPC as a function of crosslinker incubation 
time (Figure III-4). The native pyruvate carboxylation activities of these mutants are 
shown in Table III-1. Wild-type SaPC retained its full enzymatic activity over 15 minutes 
of incubation with 300 μM BMOE. The activity of the Q891C mutant increased slightly 
upon incubating with BMOE, perhaps as a consequence of masking the cysteine mutation 
at that position. The N1102C mutation exhibited a slight loss of activity (~8% over 15 
minutes), which coincides with the small amount of dimers observed by SDS-PAGE 
(Figure III-2A). Compared with the wild-type and individual mutants, the 
Q891C/N1102C mutant exhibited a rapid and significant loss of activity upon incubation 
with BMOE, consistent with specific crosslinking between the carrier domain and the CT 
domain. The observed rate constant for inactivation was very similar to the rate of 
crosslinked dimer formation observed by SDS-PAGE (Table III-2). 
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Figure III-4 Inactivation kinetics for wild-type SaPC and 3 mutated constructs of SaPC. 
Wild-type (p), Q891C (q), N1102C (¿), or Q891C/N1102C (¢) SaPC were reacted with 300 μM 
BMOE in 5% DMSO for 30 s, 2 min, 8 min, or 15 min. All reactions were then quenched with 13 mM 
DTT for 15 min. The initial velocity (vi) was determined and divided by the initial velocity determined 
after incubating the same enzyme with 5% DMSO for 15 min (vo). Each sample was measured in triplicate 
using the malate dehydrogenase coupled enzyme assay. The error bars represent the standard deviation 
from three independent measurements. Error bars for Q891C/N1102C are included but are obscured by the 
data markers. 
2.2 Intrinsic tryptophan fluorescence reports on carrier domain conformational states. 
Both densitometry and inactivation kinetics are constrained by their reliance on 
manual sample handling, limiting these measurements to slower re-equilibration events 
such as those slowed by the presence of ADP and PPA. To gain greater time-resolution 
and accuracy, we explored whether changes in intrinsic tryptophan fluorescence (ITF) 
intensity could serve as a reporter on carrier domain positioning. Fortuitously, in SaPC, 
all 5 tryptophan residues are located in the CT domain (Figure III-5). As such, we 
predicted that the Trp fluorescence intensity would increase when the carrier domain is 
  
 
 
76 
positioned near the CT domain, resulting from the altered local environment of the five 
CT domain tryptophan residues. Consistent with this prediction, wild-type SaPC yielded 
distinct ITF signals in the presence of different ligands (Figure III-6A). When SaPC was 
mixed with ATP, a BC domain substrate, a rapid decrease in the ITF signal intensity was 
observed. Conversely, when SaPC was mixed with acetyl-CoA, an increase in the ITF 
signal intensity was observed.   
 
 
Figure III-5 Structure of SaPC (PDB ID: 3BG5) showing the location of the five tryptophan residues. 
A: The BC domains (blue), CT domains (yellow), allosteric / PC tetramerization domains (green), and 
BCCP domain (red) are shown. All five Trp residues (dark yellow) are located in the CT domain. B: A 
close-up view of the CT domain (yellow) with the BCCP domain (red) docked in the exo-binding site. 
Tryptophans (dark blue; Homo sapiens PC numbering) are highlighted, illustrating the proximity of Trp838 
to biotin. 
 
 
  
 
 
77 
Figure III-6 The role of substrates and the biotinylated carrier domain in generating the tryptophan 
fluorescence signal. 
A. Wild-type SaPC intrinsic tryptophan fluorescence (ITF) in the presence of substrate/effector. Wild-type 
SaPC (0.35 mg/mL) was mixed with 2.5 mM ATP (blue), 0.25 mM acetyl-CoA (red), or buffer (black) at 0 
s in a stopped-flow instrument with tryptophan excitation at 295 nm and ITF emission measured at 350 nm. 
B. Q891C/V1062X (ΔBCCP) SaPC ITF in the presence of substrate/effector. Q891C/V1062X SaPC (final 
concentration of 0.175 mg/mL) was mixed with buffer (black) or final concentrations of 2.5 mM ATP 
(blue) or 0.25mM acetyl-CoA (red) at 0 s in a stopped-flow instrument with tryptophan excitation at 295 
nm and ITF emission measured at 350 nm. C. Q891C/N1102C/K1112Q SaPC ITF in the presence of 
substrate/effector. Q891C/N1102C/K1112Q SaPC (final concentration of 0.175 mg/mL) was mixed with 
buffer (black) or final concentrations of 2.5 mM ATP (blue) or 0.25 mM acetyl-CoA (red) at 0 s in a 
stopped-flow instrument with tryptophan excitation at 295 nm and ITF emission measured at 350 nm.  
Dashed lines represent the fit of the data to Equation 2. 
 
We reasoned that the presence of ATP favors one conformational state for the 
BCCP carrier domain that reports as a decrease in ITF signal intensity, while the presence 
of acetyl-CoA favors a different state for the carrier domain that reports as an increase in 
ITF signal intensity. To confirm that carrier domain positioning mediates the ITF signal, 
we produced a SaPC construct with a C-terminal truncation by introducing a STOP 
codon (TAG) at Valine 1062, eliminating the BCCP domain (Q891C/V1062X; ΔBCCP 
SaPC). This construct was assessed for changes in the ITF signal intensity in the presence 
of ligands. When this ΔBCCP SaPC mutant was mixed with either substrate or allosteric 
effector, no change in ITF intensity was observed (Figure III-6B), confirming that 
changes in the ITF intensity are a consequence of interactions with the BCCP domain and 
are not simply a result of conformational changes upon ligand binding. The specific 
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contribution of biotin to the ITF signal was also investigated by mutating the biotinylated 
Lys 1112 to glutamine (Q891C/N1102C/K1112Q), to produce an unbiotinylated SaPC. 
Again, the fluorescence intensity did not change in the presence of substrates (Figure III-
6C), indicating that the biotin cofactor is necessary for generating the ITF signal.  
 Having established that the ITF signal intensity is both BCCP and biotin 
dependent, the behavior of the system was evaluated in the presence of BMOE 
crosslinker (Figure III-7). While wild-type SaPC and the single mutants displayed only 
very small changes in signal intensity when mixed with BMOE (Figure III-7A), the 
crosslinking competent Q891C/N1102C SaPC displayed a large increase in fluorescence 
intensity in the presence of BMOE, as predicted from locking the BCCP domain in 
proximity to the CT domain. To distinguish whether biotin contributes to the ITF signal 
intensity or, rather, to positioning of the BCCP domain itself, crosslinking of the 
unbiotinylated SaPC was evaluated by SDS-PAGE in the presence of BMOE (Figure III-
8). Crosslinking was observed both in the presence and absence of substrates and, while 
the response to substrates dramatically diminished in unbiotinylated SaPC, the 
unbiotinylated carrier domain did not lose the ability to position itself for crosslinking. 
Furthermore, when Q891C/N1102C/K1112Q was reacted with 200 μM BMOE in the 
presence of exogenously added biotin or biocytin, the ITF signal intensity did not 
replicate what was observed with the biotinylated Q891C/N1102C (Figure III-7B), 
indicating that biotin must be properly tethered to the BCCP domain to produce large 
increases in the ITF intensity in the presence of BMOE. Thus, we conclude that the 
intrinsic fluorescence signal changes observed in SaPC directly report on changes in the 
positioning of the carrier domain and its tethered biotin cofactor. 
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Figure III-7 SaPC ITF changes observed in the presence of crosslinker. 
A. Q891C/N1102C mixed with buffer (black), Q891C SaPC reacted with 200 μM BMOE (blue), N1102C 
SaPC reacted with 200 μM BMOE (green), Q891C/N1102C SaPC reacted with 200 μM BMOE (maroon), 
and wild-type SaPC reacted with 200 μM BMOE (orange). All mixing occurred at 0 seconds in a stopped-
flow instrument with excitation at 295 nm and ITF emission measured at 350 nm. B. 
Q891C/N1102C/K1112Q SaPC ITF changes observed when crosslinked in the presence of biotin or 
biocytin. Q891C/N1102C/K1112Q SaPC (0.175 mg/mL final concentration) was incubated with buffer 
(black), 5 mM final concentration of biotin (blue), or 5 mM final concentration of biocytin (green) for 15 
minutes before being mixed with an equal concentration of biotin or biocytin and 200 μM final 
concentration of BMOE at 0 seconds in a stopped-flow instrument with excitation at 295 nm and ITF 
emission measured at 350 nm. Q891C/N1102C/K1112Q SaPC mixed with buffer (black) is also shown for 
reference. Dashed lines represent the fit of the data to Equation 2. 
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Figure III-8 Q891C/N1102C (biotinylated) SaPC and Q891C/N1102C/K1112Q (unbiotinylated) 
crosslinked in the presence and absence of ADP and phosphonoacetate (PPA). 
Each SaPC mutant at 1mg/mL was preincubated with no ligands present or 5 mM ADP and 5 mM 
phosphonoacetate for 10 minutes and then reacted with 300 μM BMOE for 10 s, 30 s, 60 s, and 120 s. 
Samples were quenched with 13mM DTT for 15 minutes. 5 μg of SaPC was loaded in each lane. A. 
Q891C/N1102C; B. Q891C/N1102C/K1112Q; C. Densitometry analysis of relative monomer density as a 
function of time for Q891C/N1102C without ligands (p), Q891C/N1102C with 5 mM ADP and 5 mM 
phosphonoacetate (¢), Q891C/N1102C/K1112Q without ligands (¿), and Q891C/N1102C/K1112Q with 
5 mM ADP and 5 mM phosphonoacetate (q). The experiment was performed in triplicate, with the error 
bars representing the error propagated standard deviation of the measured band densities. 
 
 
Given that biotin is necessary for mediating changes in the ITF signal intensity, 
we sought to determine which Trp residue(s) in the CT domain interact with biotin and 
contribute to the ITF signal change. The crystal structure of SaPC (PDB ID: 3BG5) 
reveals that biotin is positioned near Trp808 in the exo-binding site of SaPC (Figure III-
5B). This residue was mutated to a phenylalanine (W808F) to assess the sensitivity of 
this mutated SaPC to changes in ITF intensity. Unfortunately, the W808F mutation 
rendered the protein aggregation-prone and it could not be purified, precluding a clear 
confirmation of this prediction. 
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2.3  Substrates and effectors alter the carrier domain positioning equilibrium. 
 To assess the contribution of substrates and effectors to carrier domain 
positioning, the crosslinking competent Q891C/N1102C SaPC was incubated with 300 
μM BMOE for 2 minutes in the presence of various substrates and effectors (Figure III-
9). Both pyruvate and acetyl-CoA increased the amount of crosslinked dimer in the 
presence of ADP and phosphonoacetate compared to dimer formation in the presence of 
just ADP and phosphonoacetate.  This suggests that pyruvate and acetyl-CoA both shift 
the carrier domain positioning towards the CT domain on the opposing subunit. 
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Figure III-9 Q891C/N1102C SaPC crosslinked in the presence of various substrates and effectors. 
A. Q891C/N1102C SaPC crosslinked in the presence of various substrates and effectors. Q891C/N1102C 
SaPC at 1 mg/mL was reacted with 300 μM BMOE for 120 s in the presence of a combination of 5 mM 
phosphonoacetate, 0.25 mM acetyl CoA, 12 mM pyruvate and/or 5 mM adenosine 5’-diphosphate (ADP), 
as listed below, then quenched with 13 mM DTT for 15 minutes. A. 5 μg was loaded in each lane. (1) No 
Substrates; (2) Acetyl CoA (AC); (3) Acetyl-CoA, Pyruvate (Pyr); (4) ADP; (5) ADP, Pyruvate; (6) 
Phosphonoacetate; (7) Phosphonoacetate, Pyruvate; (8) ADP, Phosphonoacetate; (9) ADP, 
Phosphonoacetate, Pyruvate; (10) ADP, Phosphonoacetate, Acetyl-CoA; (11) ADP, Phosphonoacetate, 
Pyruvate, Acetyl-CoA; (12) Phosphonoacetate, Acetyl-CoA; (13) Phosphonoacetate, Pyruvate, Acetyl-
CoA. The molecular weights for the ladder on the right are shown in kDa. B. A densitometry analysis was 
performed with the relative monomer density shown for each ligand combination. 
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The rate of inactivation was determined for Q891C/N1102C SaPC reacted with 
BMOE crosslinker in the presence of ADP and phosphonoacetate in combination with 
pyruvate and acetyl-CoA (Figure III-10). It was necessary to include ADP and 
phosphonoacetate in these measurements to reduce the inactivation rates into a 
measurable range. These data were fit to a single exponential decay (Equation 1), where 
the fastest rate of inactivation was observed in the absence of substrates (Figure III-10; 
Table III-3). This indicates that the BCCP domain explores an ensemble of 
conformations in the absence of substrates, trapping the carrier domain in an 
intermolecular conformation in a time-dependent manner. The presence of ADP and 
phosphonoacetate reduced the rate of inactivation ~7-fold, consistent with BC domain 
substrates drawing the carrier domain equilibrium position towards the BC domain. 
Conversely, the addition of acetyl-CoA increased the rate of inactivation, consistent with 
a reduction in the activation energy barrier for the translocation of the carrier domain 
from the BC to the CT domain. The combination of acetyl-CoA and pyruvate produced 
the fastest rates of inactivation in the presence of ADP and phosphonoacetate (Figure III-
10; Table III-3).  
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Figure III-10 Inactivation kinetics for Q891C/N1102C SaPC crosslinked with BMOE in the presence 
of various substrates.  
Inactivation kinetics for Q891C/N1102C SaPC crosslinked with BMOE in the presence of various 
substrates. Q891C/N1102C SaPC was reacted with 300 μM BMOE in 5% DMSO for 10 s, 30 s, 1 min, 2 
min, 4 min, 8 min, or 15 min and then quenched with 13 mM DTT for 15 min. Each sample was then 
assayed in triplicate for catalytic activity using the malate dehydrogenase coupled enzyme assay. The initial 
velocity (vi) was determined and divided by the initial velocity determined after incubating the same 
enzyme with 5% DMSO for 15 min (vo). The error bars represent the standard deviation obtained from each 
sample assayed in triplicate. Rates were measured in the absence of added ligands (purple circles), in the 
presence of 5 mM ADP and 5 mM phosphonoacetate (blue squares), in the presence of 5 mM ADP, 5 mM 
phosphonoacetate, and 12 mM pyruvate (green triangles), in the presence of 5 mM ADP, 5 mM 
phosphonoacetate, and 0.25 mM acetyl-CoA (orange inverted triangles), or in the presence of 5 mM ADP, 
5 mM phosphonoacetate, 12 mM pyruvate, and 0.25 mM acetyl-CoA (red diamonds). 
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Table III-3 Observed rates of inactivation for the different substrate combinations used during 
inactivation kinetics experiments with Q891C/N1102C SaPC.  
 
ADP Phosphonoacetate Pyruvate Acetyl-CoA kobs (s-1)* 
0 0 0 0 0.057 ± .014 
5 mM 5 mM 0 0 0.005 ± .001 
5 mM 5 mM 0 0.25 mM 0.011 ± .001 
5 mM 5 mM 12 mM 0 0.005 ± .001 
5 mM 5 mM 12 mM 0.25 mM 0.017 ± .002 
* Reported errors represent the standard errors calculated from iterative non-linear curve fitting in GraphPad 
Prism. The data were fit to data where each data point was plotted as the average ± standard deviation of 3 
independent determinations.  
 
 
 The effects of substrates on BCCP domain positioning were further evaluated by 
following changes in ITF intensity. The rapid acquisition of ITF data in a stopped-flow 
instrument permitted a direct analysis of the effect of substrates and effectors on BCCP 
domain positioning, without requiring the inclusion of ADP and phosphonoacetate in all 
experiments. Q891C/N1102C SaPC was mixed with various substrates and the change in 
ITF intensity was monitored continuously for 120 seconds. The presence of ADP and 
phosphonoacetate decreased the observed ITF intensity, as shown in the first 120 seconds 
of Figure III-11, consistent with the data presented in Figure III-6A. After the system was 
allowed to reach equilibrium, the crosslinker was subsequently added to observe the 
impact of the ligand on the rate at which the system re-equilibrates to the trapped 
conformation. The data were fit to a single exponential equation (Equation 2). After 
addition of the crosslinker, ITF was followed for an additional 120 seconds. The presence 
of ADP and phosphonoacetate substantially reduced the rate of increase in the ITF 
intensity, relative to the combination of either or both acetyl-CoA and/or pyruvate with 
ADP and phosphonoacetate (Figure III-11). A comparison of the observed rates of carrier 
domain repositioning, measured by each approach, is summarized in Table III-2. This 
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reveals remarkable agreement between the measurements, despite the different methods 
used.  
 
 
Figure III-11 SaPC ITF intensity in the presence of substrates/effector. 
Q891C/N1102C SaPC was first mixed with ligand at t = 0 and the ITF intensity was recorded for 120 
seconds. Q891C/N1102C SaPC, preincubated with the ligand, was then mixed with ligand and 200 μM 
BMOE, to the same final concentrations, and the ITF intensity was recorded for 120 seconds (denoted as 
beginning at 140 seconds).  In all cases Q891C/N1102C SaPC was mixed to a final concentration of 0.175 
mg/mL with buffer (purple), 12 mM final concentration of pyruvate (pink), 0.25 mM final concentration of 
acetyl-CoA (green), or 5 mM final concentrations each of ADP and phosphonoacetate (blue) in a stopped-
flow instrument. Tryptophan was excited at 295 nm and ITF emission was recorded at 350 nm. 
 
 
 Using ITF intensity as a direct measure of carrier domain positioning, we sought 
to investigate the role of two allosteric effectors in carrier domain positioning: acetyl-
CoA and L-aspartate. Acetyl-CoA enhances the coupling efficiency between the two half-
reactions of PC (Zeczycki, et al., 2011B). Westerhold et al. proposed that the enhanced 
coupling efficiency in the presence of acetyl-CoA is mediated by the carrier domain 
(Westerhold, et al., 2017). In the present study, acetyl-CoA increased the ITF intensity, 
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consistent with the carrier domain positioning equilibrating to favor an intermolecular 
interaction with the CT domain (Figure III-11). While acetyl-CoA does not, on its own, 
alter the observed rate of ITF intensity change, the combination of pyruvate and acetyl-
CoA leads to a 360% increase in the observed rate of ITF intensity change in the presence 
of BMOE (t test; p< 0.01) (Table III-4, Figure III-12). Acetyl-CoA also increased the 
observed rate of ITF intensity change when ATP was present in combination with 
BMOE. These data indicate that acetyl-CoA reduces the kinetic barrier for the 
translocation of the carrier domain in the presence of substrates.  
 
 
Figure III-12 Q891C/N1102C SaPC crosslinked in the presence of ligands and monitored for change 
in ITF intensity. 
A final concentration of 0.175 mg/mL Q891C/N1102C SaPC was mixed with either buffer or various 
substrates at final concentrations listed in the Methods section, with 200 μM BMOE present at 0 s in a 
stopped-flow instrument with tryptophan excitation at 295 nm and emission measured at 350 nm. A.  SaPC 
was mixed with either buffer (black), buffer + BMOE (purple), ATP + BMOE (orange), acetyl-CoA and 
BMOE (green), or ATP + acetyl-CoA + BMOE (blue). B. SaPC was mixed with either buffer (black), 
buffer+BMOE (purple), acetyl-CoA + BMOE (green), pyruvate + BMOE (orange), or acetyl-CoA + 
pyruvate +BMOE (blue). Dashed lines represent the fit of the data to Equation 2. 
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Table III-4 The effect of ligands on the observed rates of ITF intensity change.  
substrate 
(+ BMOE) 
 
Q891C/N1102C SaPC kobs (s-1) 
 
kobs / (kobs [No Substrate]) 
None [4.8 ± 1.0] x 10-2 - 
ATP [3.0 ± 0.3] x 10-2 0.63 
Acetyl-CoA + ATP [3.6 ± 0.3] x 10-2 0.75 
Acetyl-CoA [5.0 ± 0.3] x 10-2 1.0 
Pyruvate + Acetyl-
CoA [17.4 ± 2.6] x 10
-2 3.6 
L-Aspartate [3.4 ± 1.0] x 10-2 0.70 
None* [7.3 ± 0.2] x 10-2 - 
Pyruvate* [8.1 ± 0.1] x 10-2 1.1 
* Assay performed independently from above data. (n = 3; errors represent standard deviations) 
 
 
L-aspartate is an allosteric inhibitor of microbial PC enzymes (Osmani, et al, 
1981; Cazzulo and Stoppani, 1968; Jitrapakdee, et al., 2007; Sirithanakorn, et al., 2014). 
L-aspartate inhibition is competitive with respect to acetyl-CoA and its effects are 
independent of the coupling between MgATP cleavage and oxaloacetate formation 
(Sirithanakorn, et al., 2014). Sirithanakorn et al. proposed that L-aspartate may inhibit 
carboxybiotin formation or slow the rate of carrier domain translocation between the 
active sites (Sirithanakorn, et al., 2014). When L-aspartate is mixed with Q891C/N1102C 
SaPC, no ITF intensity change is observed (Figure III-13A), in contrast to what is 
observed with the allosteric activator, acetyl-CoA. However, when Q891C/N1102C 
SaPC is crosslinked in the presence of L-aspartate, the observed rate of ITF intensity 
change is 30% slower (t test; p < 0.05) (Table III-4, Figure III-13B) than the rate in its 
absence. This indicates that while L-aspartate may not alter the ground state energy of the 
enzyme, it has a kinetic effect that reduces the rate of carrier domain repositioning. 
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Figure III-13 Effect of L-aspartate on Q891C/N1102C SaPC carrier domain positioning and 
crosslinking rates. 
Data was collected with a stopped-flow instrument with tryptophan excitation at 295 nm and ITF emission 
measured at 350 nm. A. SaPC was mixed with either buffer (black) or a final concentration of 10 mM L-
aspartate (blue) at 0 sec. B. SaPC was mixed with either buffer (black), buffer + 200 μM BMOE (purple), 
10 mM L -aspartate + 200 μM BMOE (orange), or 0.25 mM acetyl-CoA (green) at 0 sec. Dashed lines 
represent the fit of the data to Equation 2. 
3. Discussion  
 The carrier domain of PC is known to translocate during catalysis between an 
intramolecular interaction with the BC domain and an intermolecular interaction with the 
CT domain on the opposing subunit (Figure 1) (St. Maurice, et al., 2007; Xiang and 
Tong, 2008; Lasso, et al., 2014; Liu, et al., 2018). Here, we directly observe the 
positioning of the PC carrier domain, independent of catalytic turnover, using a range of 
techniques that rely on trapping the carrier domain in an intermolecular conformation, in 
close proximity to the CT domain. Several models of PC catalysis propose that the carrier 
domain is governed by an induced conformational change: the carrier domain remains in 
proximity of the BC domain until a CT domain ligand binds, and is subsequently induced 
to translocate to the CT domain upon the binding of a CT domain ligand (Easterbrook-
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Smith, et al., 1976; Goodall, et al., 1981; Attwood and Wallace, et al., 1986). However, 
several structures of PC reveal the carrier domain participating in an intermolecular 
interaction with the CT domain, even in the absence of ligands. These structures suggest 
that the carrier domain can sample a wide range of conformations, consistent with a 
conformational selection model where substrates and effectors serve to shift the 
equilibrium positioning of the carrier domain from one domain to another during 
catalysis. A conformational selection model is in opposition to previous interpretations, 
but it is well supported by the direct observations of carrier domain positioning presented 
in this study. It is particularly noteworthy that, regardless of the presence or identity of 
the ligands, multiple approaches demonstrate that the carrier domain can be trapped in 
proximity to the CT domain. This can only be the case if, under all conditions, the carrier 
domain regularly samples positions proximal to the CT domain, consistent with a 
conformational selection model. A similar model has recently been proposed to govern 
conformational dynamics in the nonribosomal polypeptide synthase, gramicidin 
synthetase I from Aneurinibacillus migulanus. Positional changes of the carrier domain in 
gramicidin synthetase I correlate with the presence of bound ligands, where the carrier 
domain samples multiple conformations in a dynamic equilibrium (Alfermann, et al., 
2017). The carrier domains of polyketide synthases, such as 6-deoxyerythronolide B 
synthase (DEBS), may also be governed by conformational selection, with the carrier 
domain positional equilibrium shifted by a turnstile mechanism that ensures 
synchronization of the assembly line-style reactions (Lowry, et al., 2016). 
 The observed rates of carrier domain re-equilibration are remarkably consistent 
across multiple methods of observation (Table 1). The general crosslinking approach, 
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therefore, provides multiple ways to independently measure rates of carrier domain 
repositioning, absent of catalytic turnover. It should be noted that the observed rates of 
repositioning are two orders of magnitude lower than the kcat value and are not a suitable 
estimate of carrier domain translocation rates during catalytic turnover. Rather, the 
observed rate constants represent the re-equilibration of the BCCP domain to the exo-
binding site within an ensemble population and include the chemical crosslinking steps 
which are likely to be slow relative to the rate of carrier domain translocation. Nevertheless, 
the relative rates of re-equilibration clearly indicate that the carrier domain is subject to 
conformational selection and that ligands alter the equilibrium position of the carrier 
domain. 
 Substrates and ligands shift the carrier domain equilibrium as expected. BC domain 
ligands reduce the rate of intermolecular crosslinking (Figures 2 and 6, Tables 1, 2, and 3) 
and shift the carrier domain equilibrium away from the CT domain (Figures 4 and 7), 
consistent with proposals that BC domain ligands shift the carrier domain towards the BC 
domain (Easterbrook-Smith, et al., 1976; Goodall, et al., 1981; Attwood and Wallace, 
1986). These data are consistent with a ground state stabilization of the BC-BCCP domain 
interaction, resulting in a higher activation energy barrier and slower rate of re-
equilibration to the trapped intermolecular interaction with the CT domain. X-ray crystal 
structures show that the active site lid of the BC domain partially closes when Mg2+ and 
ATP are bound in the active site (Thoden, et al., 2000). When the BCCP domain interacts 
with the BC domain, the carrier domain is positioned directly against this tightly closed lid 
of the BC domain (Lietzan, et al., 2011). The lid closure that accompanies ligand binding 
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produces the binding interface for the carrier domain, stabilizing the BCCP-BC domain 
conformation, and shifting the BCCP positioning equilibrium toward the BC domain.  
 Pyruvate, the CT domain substrate, increased the kobs for intermolecular 
crosslinking (Figures 6 and 7; Tables 1 and 2). These results are consistent with 
observations that high concentrations of pyruvate inhibit the biotin-dependent ATPase 
reaction in PC (Zeczycki, et al., 2009). The conformational selection model allows that the 
carrier domain samples multiple positions and that the carrier domain positional 
equilibrium shifts to the CT domain as a consequence of biotin-dependent interactions with 
CT domain substrates (Lietzan, et al., 2013A). Similar interactions are thought to govern 
carrier protein positioning of SoxYZ with SoxB. In the substrate-unbound state, a mobile 
loop clashes with the SoxYZ binding site whereas, in the presence of substrate, the loop 
shifts to favor the SoxYZ interaction with SoxB (Grabarczyk, et al., 2015). These systems 
offer clear, simple examples of how substrates can locally shift carrier domain positioning 
through conformational selection, without the need to invoke long-range induced 
conformational changes to control carrier domain positioning. 
 Carrier domain positioning in the CT domain active site is proposed to be 
mediated by biotin (Lietzan, et al., 2013A). The carrier domain was trapped in an 
intermolecular crosslink, even in the absence of biotin (Figure S3), demonstrating that the 
carrier domain does not require biotin to adopt an intermolecular position. However, 
biotinylation strongly influences the carrier domain positioning equilibrium and the 
sensitivity of the enzyme to ligands. The positional equilibrium shifts dramatically, as 
observed by a greater than two-fold shift in the amount of uncrosslinked monomer at 
equilibrium (Figure S3). Furthermore, the unbiotinylated enzyme becomes insensitive to 
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the BC domain ligands, ADP and phosphonoacetate: in both their presence and absence, 
the kobs for the unbiotinylated enzyme is equivalent to the rate observed for the 
biotinylated enzyme in the absence of substrates.   Thus, biotin is necessary for the carrier 
domain to be sensitive to the presence of BC domain substrates and is critical to 
mediating the binding interactions with both the BC and CT domain active sites. 
 The allosteric activator, acetyl-CoA, increased the observed fluorescence signal 
intensity, indicating that acetyl-CoA shifts the carrier domain equilibrium towards the 
opposing CT domain (Figures 4A and 7). The presence of acetyl-CoA also increased the 
kobs for inactivation (Figure 6), even when ADP and phosphonoacetate were also present, 
further suggesting that acetyl-CoA favors an intermolecular positioning for the carrier 
domain. This agrees with our recent observation that acetyl-CoA uniquely activates an 
intermolecular catalytic pathway in which the carrier domain translocates to the CT 
domain on an opposing subunit (Liu, et al., 2018). The current findings suggest that 
acetyl-CoA activates that translocation pathway by favoring intermolecular carrier 
domain positioning at the CT domain. Contrary to the effect of acetyl-CoA on carrier 
domain positioning, L-aspartate had a negligible effect on carrier domain positioning, but 
it moderately reduced the observed rate of carrier domain intermolecular crosslinking 
(Figures S6A and S6B). This suggests that at least a portion of the inhibitory effect of L-
aspartate derives from reducing the rate of carrier domain translocation, as hypothesized 
by Sirithanakorn, et al (Sirithanakorn, et al., 2014).  
The current study leads to an updated model of conformational selection for 
carrier domain positioning in PC. The carrier domain exists in an ensemble of 
conformations, where ligand binding shifts the equilibrium to favor those conformations 
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that have a higher affinity for the ligand (Boehr, et al., 2009). Prior structural data suggest 
how these equilibrium shifts can occur. BC domain substrates promote the closing of the 
B-subdomain lid, generating a favorable binding site for the carrier domain. Similarly in 
the CT domain, the presence of a CT domain substrate or substrate analogue promotes 
the formation of a biotin-binding pocket that favors the positioning of biotin in the CT 
domain active site, shifting carrier domain positioning towards the CT domain (Lietzan, 
et al., 2013A). Common to both cases, biotin is chiefly responsible for interacting with 
residues in each active site, mediating the shift in equilibrium positioning of the carrier 
domain. However, independent of biotin, the carrier domain actively explores what is 
likely to be a wide variety of conformations. Both biotin and active site ligands promote 
interactions at the individual domains to shift the conformational equilibrium. Allosteric 
activation by acetyl-CoA facilitates the release of the carrier domain from the BC domain 
and promotes the intermolecular positioning of the carrier domain near the CT domain 
active site. Conformational selection offers a simple and updated model to explain the 
kinetic behavior of PC in response to substrates and allosteric effectors. Such a model is 
highly applicable to the positioning and long-range translocation of carrier domains and 
carrier proteins in a range of other complex multi-modular enzyme systems. 
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IV. THE CARRIER DOMAIN POSITIONAL EQUILIBRIUM OF S. AUREUS 
PYRUVATE CARBOXYLASE IS GOVERNED BY INTERACTIONS BETWEEN 
BIOTIN AND ACTIVE SITE RESIDUES 
1. Introduction  
In chapter III, I demonstrated that the carrier domain positioning of SaPC is 
governed by conformational selection. Substrates shift the carrier domain positional 
equilibrium while acetyl-CoA favors an intermolecular positioning of the carrier domain 
in the presence of substrates. While it is clear from chapter III that substrates, allosteric 
effectors and biotin alter the equilibrium positioning of the carrier domain, the molecular 
interactions underlying these positional shifts are not well described.  
Carrier domains are used in multi-domain enzymes to shuttle intermediate 
products between active sites. The molecular interactions that contribute to carrier 
domain positioning represent an area of intense study in many carrier-domain enzymes. 
For example, the interaction between the acyl carrier protein (ACP) and the microbial 
fatty acid synthase pathway enzyme FabA was observed to be regulated by electrostatic 
interactions between the ACP and the surface of FabA, gating residues at the opening to 
the active site, and the size of the active site pocket (Finzel, et al., 2015).  The 
conformational equilibrium of the nonribosomal peptide synthase gramicidin synthetase I 
from Aneurinibacillus migulanus has been found to be shifted by product inhibition, with 
a series of interactions between residues and substrates and intermediate products 
proposed to be responsible for this shift. (Alfermann, et al., 2017; Branchini, et al., 2011). 
In the Sox pathway, the interaction of the carrier protein SoxYZ with the enzyme SoxB 
has been found to be controlled, in part, by the positioning of a surface mobile loop that 
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exists in different conformations dependent upon the presence of substrate (Grabarczyk, 
et al., 2015). Studies investigating carrier protein-catalytic domain interactions have 
detailed numerous mechanisms governing the favorability of these interactions as the 
presence and identity of ligands change. While the field has begun to elucidate these 
mechanisms, the descriptions are currently limited to just a few discrete examples, 
precluding a general description of common mechanism(s) responsible for altering carrier 
domain positioning. Studies on the interactions between biotin and active-site residues 
and their contributions to shifting carrier domain positioning in PC will provide fresh 
examples of how carrier domain positioning is influenced by molecular level interactions.   
A number of kinetic and structural studies in PC have sought to unveil the 
molecular basis for carrier domain positioning. Two x-ray crystal structures of PC offer 
useful insights into how carrier domain equilibrium positioning may be shifted through 
interactions with the BC and CT domains. The structure of R. etli PC (RePC) co-
crystallized with ADP and phosphonoacetate, captured the interaction between the carrier 
domain and the BC domain (Lietzan, et al., 2011). In this structure, biotin was occluded 
from the BC domain active site by a salt bridge formed between Arg353 and Glu248. 
This conserved pair of residues was proposed to act as a molecular gatekeeper, 
preventing carboxybiotin from returning to the active site where it could undergo abortive 
decarboxylation (Lietzan, et al., 2011). Similarly, a structure of the isolated CT domain of 
RePC revealed that a flexible loop in the CT domain active site alters its conformation 
when pyruvate is bound, providing a stabilizing interaction between the sulfur in the 
thiophene ring of biotin and the aromatic ring of Tyr6285. Another CT domain active site 
residue, Thr882 in RePC, was shown to play a critical role in shuttling a proton between 
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the biotin enolate intermediate and pyruvate and was also proposed to play a role in 
stabilizing the positioning of biotin in the CT domain active site through a hydrogen-
bonding interaction with the N-1 of biotin6. Kinetic studies on a site-directed mutation of 
this residue (T882A) were interpreted to suggest that Thr882 is important in carrier 
domain positioning at the CT domain. Together, conserved residues in both the BC and 
CT domains are likely to make critical contributions to the positioning of the carrier 
domain through their interactions with biotin. However, the hypothesized roles of these 
residues are based on static structures and indirect kinetic studies that do not provide 
dynamic information on the interplay between ligand, residue, and carrier domain 
positioning.  
In this chapter, I seek to describe the role of three conserved residues that are 
predicted to interact with biotin to better understand the mechanism of ligand-associated 
carrier domain positioning changes in pyruvate carboxylase. Site-specific crosslinking is 
monitored by intrinsic tryptophan fluorescence (ITF) to more precisely determine the 
effects of ligands and the roles of the “gatekeeper” residues on carrier domain 
positioning. Tyr621 (equivalent to Tyr628 in RePC) in S. aureus PC (SaPC) was shown 
to have a crucial role in the positioning of the carrier domain, mutation of Glu243 
(equivalent to Glu248 in RePC) was observed to shift carrier domain positioning towards 
the BC domain, and mutation of Thr876 (equivalent to Thr882 in RePC) was also 
observed to shift carrier domain positioning towards the BC domain while decreasing the 
effect of pyruvate on carrier domain positioning. 
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2. Results 
2.1  Active Site Mutations Shift Carrier Domain Positioning 
As described in chapter III, I have designed and validated a system to trap the 
carrier domain in the exo-binding site through the introduction of site-specific Cys 
residues and the maleimide-based homobifunctional crosslinker, BMOE (Figure III-1B). 
This Q891C/N1102C (QN) mutant was used as a crosslinking-competent background 
into which additional mutations of active site residues were introduced.  
Three residues (Glu243, Thr876 and Tyr621) have been proposed to interact with 
biotin and contribute to translocation of the carrier domain. Consequently, three 
mutations were introduced into the Q891C/N1102C (QN) crosslinking-competent 
background. The proposed role of these residues (E243A, T876A, and Y621) in catalysis 
is summarized in Table IV-1. The catalytic activities of these mutants are reported in 
Table IV-2 and are similar to the activities reported in previous studies of these mutations 
(Lietzan, et al., 2011; Lietzan, et al., 2013).  
Table IV-1 Summary of active site residues selected for mutation in PC. 
Residue Location Proposed Function Citation 
Glu243 BC Domain One of two “gatekeeper” residues that control biotin access to active site 
Lietzan, et al., 2011; 
Zeczycki, et al., 2011 
Tyr621 CT Domain Stabilize biotin in active site Lietzan, et al., 2013 
Thr876 CT Domain Proton shuttle during CT domain reaction, H-bond to biotin Zeczycki, et al., 2011 
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Table IV-2 Kinetic characterization of Q891/N1102C SaPC and related mutants. 
SaPC Mutant Pyruvate carboxylation kcat, min-1 
Oxamate-induced 
oxaloacetate 
decarboxylation kcat, min-1 
ADP 
Phosphorylation 
kcat, min-1  
Wild-Type 1440 ± 100 3.9 ± 0.1 0.63 ± 0.01 
Q891C/N1102C 440 ± 10 19 ± 1 2.1 ± 0.1 
Q891C/N1102C/E243A 2.2 ± 0.1 20 ± 1 3.1 ± 0.1 
Q891C/N1102C/Y621A 14 ± 0.2 0.15 ± 0.02 0.47 ± 0.02 
Q891C/N1102C/T876A N/A N/A 0.62 ± 0.01 
 
The triple mutants were individually mixed with BMOE and were monitored for 
changes in ITF intensity, to determine the role these residues play in carrier domain 
positioning. The data were fit to Equation 2, which yields an observed rate constant (kobs) 
and an observed amplitude for ITF intensity change. In the interpretation of these data, 
the kobs is considered to be proportional to the kinetic barrier associated with the carrier 
domain adopting a new conformation. The observed amplitude represents the relative 
proportion of the carrier domain population that shifts from the initial equilibrium to the 
crosslinked conformation. As reported in Figure IV-1, both of the CT domain mutations 
(T876A or Y621A) resulted in an increase in kobs. It was not surprising to observe an 
increase in kobs considering that Thr876 and Tyr621 are proposed to interact with and 
stabilize biotin in the CT domain active site (Lietzan, et al., 2013). Perhaps, with these 
residues mutated, the carrier domain has more freedom to adopt a wider range of 
conformations and movements that increase the rate of crosslinking to the exo-binding 
site.  
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Figure IV-1 Observed rates and amplitudes of ITF change from QN SaPC mutants during 
crosslinking with BMOE 
Q891C/N1102C (QN) SaPC, Q891C/N1102C/E243A (QNE) SaPC, Q891C/N1102C/T876A (QNT) SaPC, 
and Q891C/N1102C/Y621A (QNY) SaPC were mixed with BMOE at 0 sec. in a stopped-flow instrument 
with tryptophan excitation at 295 nm and ITF emission measured at 350 nm. A single exponential decay 
equation was fit to the data. A. The relative change in kobs is the kobs obtained for each of the three active-
site residue mutants divided by the kobs obtained from the QN background. All measurements were made in 
triplicate. Error bars represent the standard deviation. B. The amplitudes of ITF signal change from the 
single exponential decay for each of the three active-site residue mutants obtained in A. were divided by 
the amplitude change obtained for the corresponding crosslinking background to yield a relative % change.  
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The Y621A mutation produced a drastically different behavior than the other 
mutations, with a large increase in the magnitude of the ITF signal change observed in 
the crosslinked Q891C/N1102C/Y621A (QNY) SaPC mutant compared to the QN 
crosslinking background. It is important to note that crosslinking still occurs in the QNY 
mutant, as confirmed by the formation of crosslinked dimers of QNY SaPC when 
analyzed by SDS-PAGE (Figure IV-2A). Interestingly, the ITF signal decreases for the 
QNY mutant in the presence of crosslinker, which is opposite to the behavior observed in 
all other cases (Figure IV-2B). This dramatic shift in initial equilibrium positioning of the 
carrier domain, observed by the large change in amplitude, may demonstrate that Tyr621 
has an important role in establishing the carrier domain positional equilibrium (Figure 
IV-1B). In contrast to the QNY mutant, the amplitude of the ITF signal change during 
crosslinking of the Q891C/N1102C/T876A (QNT) SaPC mutant remained similar to the 
QN crosslinking background, suggesting that the baseline equilibrium positioning of the 
carrier domain was not significantly shifted by this mutation.  
The observed rate of change in the ITF intensity increased in the Q891C/N1102C/ 
E243A (QNE) SaPC mutant. The overall signal evolution of the ITF signal appeared 
similar to that of the crosslinking background as shown in Figure IV-2. The amplitude of 
the ITF signal changes increased in the QNE mutant compared to background, indicating 
that the carrier domain equilibrium has shifted towards the BC domain in this mutant. 
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Figure IV-2 QN SaPC mutants crosslinked and ITF intensity changes. 
A. SaPC mutants as listed below at 1 mg/mL were reacted with 5% DMSO or 300 μM BMOE for 120 s, 
then quenched with 13 mM DTT for 15 minutes. 5 μg of SaPC was loaded in each lane. (1) 
Q891C/N1102C w/ DMSO (2) Q891C/N1102C w/ BMOE (AC); (3) Q891C/N1102C/E243A w/ DMSO; 
(4) Q891C/N1102C/E243A w/ BMOE; (5) Q891C/N1102C/Y621A w/ DMSO; (6) 
Q891C/N1102C/Y621A w/ BMOE; (7) Q891C/N1102C/T876A w/ DMSO; (8) Q891C/N1102C/T876A w/ 
BMOE. The molecular weights for the ladders are shown in kDa. B. Q891C/N1102C SaPC (red), 
Q891C/N1102C/E243A SaPC (gold), Q891C/N1102C/T876A SaPC (green), or Q891C/N1102C/Y621A 
SaPC (blue) was mixed with a final concentration of 200 μM BMOE at t = 0 and the ITF intensity was 
recorded for 120 seconds. Tryptophan was excited at 295 nm and ITF emission was recorded at 350 nm. 
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2.2 Mutation of Glu243 Shifts Carrier Domain Positioning Towards the BC Domain. 
Glu243 was proposed to serve as one of two residues that serve as “gatekeepers” 
to prevent the return of carboxybiotin to the BC domain active site where abortive 
decarboxylation could occur (Lietzan, et al., 2011). To further investigate the role of 
Glu243, the response of the QNE system to various substrates and effectors was 
evaluated in relation to the QN control.  
The observed rates of ITF intensity change were quite similar for the QNE mutant 
relative to the QN background and followed the same trends in the response to ligands 
(Figure IV-3A). However, the relative amplitude of ITF signal increased when the QNE 
enzyme was crosslinked in the presence of BC domain ligands compared to the QN 
background (Figure IV-3B). This is consistent with an overall shift in carrier domain 
equilibrium positioning towards the BC domain in the QNE mutant, particularly in the 
presence of BC domain ligands. The E243A mutation seems to have no appreciable effect 
on the shift in carrier domain positioning in the presence of pyruvate with similar kobs and 
observed amplitudes of ITF signal change compared to those observed in the crosslinking 
background (Figure IV-3). In QNE SaPC and in the presence of acetyl-CoA, kobs was 
~19% lower than kobs in the absence of acetyl-CoA (p < .001), suggesting that this 
mutation has raised a kinetic barrier to carrier domain repositioning in the presence of 
acetyl-CoA (Figure IV-3A). The amplitude of observed ITF signal change also increased 
in the QNE mutant in the presence of acetyl-CoA compared to the QN background, 
indicating that an equilibrium shift has occurred towards the BC domain in this mutant 
(Figure IV-3B).  
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Figure IV-3 Observed rates and amplitudes of ITF change from Q891C/N1102C/E243A SaPC during 
crosslinking with BMOE in the absence/presence of ligands. 
A. Q891C/N1102C SaPC (black) and Q891C/N1102C/E243A SaPC (pink) were incubated for a minimum 
of 10 minutes with 2.5 mM ATP, 0.25 mM acetyl-CoA, 12 mM sodium pyruvate, 5 mM ADP, or 5 mM 
phosphonoacetate (PPA) and then mixed with BMOE and an equal concentration of the substrate/effector 
at 0 sec. in a stopped-flow instrument with tryptophan excitation at 295 nm and ITF emission measured at 
350 nm. Equation II-2 was fit to the data and the kobs obtained for each of the three active-site residue 
mutants compared to the kobs obtained from the corresponding crosslinking background mutant. All 
measurements were taken in triplicate with the error bars representing the standard deviation in the rate. B. 
The amplitudes of ITF signal change from the single exponential equation for each of the three active-site 
residue mutants described in panel A were compared to the amplitude obtained for the corresponding 
crosslinking background. 
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2.3  Thr876 Mediates Carrier Domain Positioning in Response to Pyruvate 
To investigate the role of the CT domain active site threonine (Thr876) in carrier 
domain positioning, changes in the amplitude and rates of ITF signal changes were 
measured in the QNT enzyme and compared to the response of the QN background. In 
the presence of ATP or ADP, the observed rates of ITF intensity change for the QNT 
mutant were similar to the observed rates in the QN background (Figure IV-4A). 
However, the amplitude of ITF signal change was larger in the presence of ATP or ADP, 
suggesting a shift in carrier domain equilibrium towards the BC domain when these 
ligands are present (Figure IV-4B). The presence of ADP and phosphonoacetate had a 
major impact on the observed rate of ITF intensity change; the kobs for the QNT mutant 
was only 2% of kobs measured for the QN background in the presence of ADP and 
phosphonoacetate (Figure IV-4A). Furthermore, with ADP and phosphonoacetate 
present, the amplitude of the ITF intensity change was almost 4-fold higher for the QNT 
mutant relative to the QN background, highlighting a major shift in carrier domain 
positioning for the T876A SaPC mutant towards the BC domain (Figure IV-4B).  
In the presence of pyruvate or acetyl-CoA, the observed rates of ITF intensity 
change were lower in the QNT mutant compared to the QN background (Figure IV-4A). 
Pyruvate also had a reduced impact on the amplitude of ITF signal change in the QNT 
mutant compared to the QN background, suggesting that the effect of pyruvate on carrier 
domain positioning is diminished in the QNT mutant (Figure IV-4B). In the presence of 
acetyl-CoA, the amplitude of ITF signal change was similar in the QNT mutant compared 
to the QN background. Considering that acetyl-CoA decreased the kobs for the QNT 
mutant compared to the QN background but had a more minimal effect on the amplitude 
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compared to the QN background, this suggests that a kinetic barrier in the adoption of the 
crosslinking conformation in the presence of acetyl-CoA has been raised in this mutant 
(Figure IV-4B). 
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Figure IV-4 Observed rates and amplitudes of ITF change from Q891C/N1102C/T876A SaPC during 
crosslinking with BMOE in the absence/presence of ligands. 
A. Q891C/N1102C SaPC (black) and Q891C/N1102C/T876A SaPC (purple) were incubated for a 
minimum of 10 minutes with 2.5 mM ATP, 0.25 mM acetyl-CoA, 12 mM sodium pyruvate, 5 mM ADP, or 
5 mM phosphonoacetate (PPA) and then mixed with BMOE and an equal concentration of the 
substrate/effector at 0 sec. in a stopped-flow instrument with tryptophan excitation at 295 nm and ITF 
emission measured at 350 nm. A single exponential decay equation was fit to the data and the kobs was 
determined for each of the three active-site residue mutants compared to the kobs obtained from the QN 
crosslinking background mutant. All measurements were taken in triplicate with the standard deviation in 
the rate shown as the error bars. B. The amplitudes of ITF signal change from Equation II-2 for each of the 
three active-site residue mutants described in panel A were compared to the amplitude obtained for the 
corresponding QN crosslinking background. 
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2.4 CT Domain Tyr621 contributes to the kinetics and thermodynamics of carrier 
domain positioning. 
Tyr621 forms a stabilizing interaction with the thiophene ring of biotin in the CT 
domain (Lietzan, et al., 2013A). To investigate the contribution of this residue to carrier 
domain positioning, changes in the amplitude and rates of ITF intensity changes were 
measured in the QNY mutant relative to the QN background. The overall change in 
observed ITF signals were quite different than those observed in any other mutant, with 
the ITF signal decreasing upon introduction of the crosslinker (Figures IV-2). It must be 
acknowledged that the dramatic change in the observed ITF signal may be the result of a 
change in this protein that may render this data unable to be interpreted in the same 
manner used for the other mutations in this study. It is possible that as a result of this 
mutation, intrinsic fluorescence has changed in a way that is not related to carrier domain 
positioning. In this section, the QNY mutant data will be interpreted in the same manner 
under the assumption that carrier domain positioning was linked to changes in Trp 
fluorescence similar to the other mutants with the understanding that there is a large 
caveat to this until it can be shown that this assumption is valid. This is further discussed 
in Chapter VI.  
  In the presence of BC domain ligands or acetyl-CoA, the measured kobs 
values for the QNY mutant are relatively unchanged, in stark contrast to observations in 
the QN background (Figure IV-5A). The magnitude of the measured amplitudes 
decreased in the presence of BC domain ligands in the QNY mutant, indicating that the 
equilibrium position of the carrier domain had shifted away from the BC domain (Figure 
IV-5B). This result may support previous observations that alterations to one active site 
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can have an effect on a separate active site, suggesting communication between the BC 
and CT domains (Westerhold, et al., 2016; Lietzan, et al., 2014).  
However, in the presence of pyruvate, there was an increase in the measured kobs 
(Figure IV-5A), combined with a large increase in the magnitude of the amplitude change 
for the QNY SaPC, which is opposite to what was observed for the QN background 
(Figure IV-5B). The observation that the presence of pyruvate still has an effect on 
carrier domain positioning, despite this mutation, suggests that Y621A is not the sole 
residue responsible for mediating the effect of pyruvate on carrier domain positioning. 
The effect of acetyl-CoA on the measured ITF amplitude changes also diminished 
(Figure IV-5B), suggesting that Tyr621 mediates the effect of acetyl-CoA on carrier 
domain positioning. 
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Figure IV-5 Observed rates and amplitudes of ITF change from Q891C/N1102C/Y621A SaPC during 
crosslinking with BMOE in the absence/presence of ligands. 
A. Q891C/N1102C SaPC (black) and Q891C/N1102C/Y621A SaPC (green) were incubated for a 
minimum of 10 minutes with 2.5 mM ATP, 0.25 mM acetyl-CoA, 12 mM sodium pyruvate, 5 mM ADP, or 
5 mM phosphonoacetate (PPA) and then mixed with BMOE and an equal concentration of the 
substrate/effector at 0 sec. in a stopped-flow instrument with tryptophan excitation at 295 nm and ITF 
emission measured at 350 nm. Equation II-2 was fit to the data and the kobs obtained for each of the three 
active-site residue mutants compared to the kobs obtained from the corresponding crosslinking background 
mutant. All measurements were taken in triplicate with the error bars representing the standard deviation in 
the rate. B. The amplitudes of ITF signal change from the single exponential equation for each of the three 
active-site residue mutants described in panel A were compared to the amplitude obtained for the 
corresponding crosslinking background. 
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3. Discussion 
Regulation of carrier domain positioning is crucial for the coordination of multi-
step reactions in multi-domain enzymes and for the protection of reaction intermediates. 
However, the molecular mechanism linking the presence of ligand and an observed shift 
in carrier domain positioning or translocation pathway remains unclear (Lowry, et al., 
2016; Liu, et al., 2018) or unconfirmed (Alfermann, et al., 2017). The studies presented 
here sought to directly observe carrier domain positioning in order to provide insights 
into molecular level contributions from key active site residues to carrier domain 
positioning. 
Glu243 Acts to Shift Carrier Domain Positioning Away from BC Domain. In the 
absence of substrates, the E243A SaPC mutant shows an increase in the ITF signal 
amplitude when crosslinked with BMOE in the QN crosslinking background (QNE) 
(Figure IV-1B). This suggests that loss of the Glu243 “gatekeeper” residue shifts the 
carrier domain position towards the BC domain. This is consistent with observations by 
Lietzan, et al. that the salt bridge interaction between Glu243 and Arg346 (analogous to 
RePC Arg353) serves to control carboxybiotin access to the active site (Lietzan, et al., 
2011; Zeczycki, et al., 2011A). The loss of this gatekeeping residue resulted in a greater 
observed amplitude of ITF signal change, indicating that the carrier domain equilibrium 
had shifted towards the BC domain as a result of this mutation, as might be expected with 
greater biotin access to the active site.  
The relative increase in the ITF signal amplitude for QNE in the presence of BC 
domain ligands further supports the idea that Glu243 functions to regulate biotin access 
to the BC domain active site (Figure IV-3B). Thus, mutations of these gatekeeper 
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residues allow greater biotin access to the BC domain active site. It is, therefore, 
unsurprising that the current data with the QNE mutant is consistent with a shift in the 
carrier domain positioning towards the BC domain when the Glu243 gatekeeper residue 
is mutated to an alanine. With the gate-closing mechanism disrupted, biotin would have 
greater access to the BC domain active site in the presence of BC domain reaction 
products, such as ADP, further stabilizing the BCCP-BC domain interaction. However, 
there is likely more than one mechanism to regulate carrier domain interactions with the 
BC domain given observations that ADP or ADP/PPA shift carrier domain positioning 
towards the BC domain in the QN background. This is likely to include the formation of 
the BC domain / carrier domain interface by the B-subdomain lid closure in the presence 
of BC domain ligands (Menefee and Zeczycki, 2014). Thus, even if ADP is bound and 
the gatekeeper residue system is blocking biotin access to the active site, the carrier 
domain may still have a favorable interface to remain docked at the BC domain active 
site.    
Tyr621 has a critical role in carrier domain positioning. Tyr621 was proposed to 
stabilize the positioning of biotin in the CT domain active site (Lietzan, et al., 2013A). 
The Y621A SaPC mutant displayed a dramatically different ITF signal behavior than any 
other SaPC variant. This could be the result of either a large shift in initial carrier domain 
equilibrium positioning or a failure of the carrier domain to adopt the final crosslinking 
conformation. However, as shown in Figure IV-2A, this mutant still adopts the 
intermolecular crosslinking conformation, with crosslinked dimers formed when the 
QNY mutant was reacted with BMOE. This indicates that initial carrier domain 
positioning equilibrium was strongly shifted as a result of this mutation, which led to the 
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dramatic difference in ITF signal change behavior as the carrier domain was crosslinked 
to the final intermolecular conformation. In the absence of ligands, the observed rate 
constants for ITF signal change were also increased two-fold in the QNY mutant 
compared to the QN background (Figure IV-5A) suggesting that a kinetic barrier to the 
carrier domain repositioning has been reduced. This could result from the carrier domain 
being less anchored at the CT domain due to the disruption of the proposed biotin-
tyrosine interaction and, therefore, the carrier domain is freed to adopt a variety of 
conformations.  
The accompanying large change in amplitude upon crosslinking the QNY mutant 
compared to the QN background suggests a relatively large thermodynamic change in the 
BCCP-CT domain interaction, which resulted in a shift in carrier domain positioning 
(Figure IV-1B). This supports the hypothesis proposed by Lietzan, et al. that sulfur-pi 
interaction between the sulfur in the thiophene ring of biotin and the aromatic ring of 
Tyr621 contributes to the positioning of biotin in the CT domain active site5. In the 
Y621A mutation (QNY) this stabilizing interaction is lost, reestablishing a new initial 
equilibrium for the carrier domain position, as evidenced by the general reversal in 
behavior. An increase in the observed amplitude upon crosslinking is interpreted as a 
shift in the initial carrier domain positional equilibrium towards the BC domain. Thus, 
the decrease in amplitude observed in Figure IV-1B indicates an equilibrium shift away 
from the BC domain, perhaps towards the exo-binding site.  
As introduced in Section I.2.3, Tyr621 links pyruvate binding in the active site to 
biotin binding. Curiously, the response of the carrier domain to the presence of pyruvate 
was not abolished in this mutant. In fact, it was observed that the magnitude of the 
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amplitude during crosslinking decreased in the presence of pyruvate (Figure IV-5B), 
indicating that more than one residue may be responsible for interacting with both 
pyruvate and biotin. The Sox B and Sox YZ interaction behaves in a similar manner, with 
a substrate stabilizing a particular active-site conformation that itself favors interaction of 
the Sox B enzyme with the Sox YZ carrier domain (Grabarczyk, et al., 2015).  
The observed amplitude change in the presence of acetyl-CoA, however, was 
dramatically reduced in this mutant (Figure IV-5B). Acetyl-CoA favors the symmetrical 
conformation of PC which includes the carrier domain being positioned intermolecularly 
(Lasso, et al., 2014; Sirithanakorn, et al., 2016). These results suggest that while acetyl-
CoA may have an effect at the N-terminal portion of the carrier domain, where its 
binding site is located, the stabilization of biotin by Tyr621 in the CT domain active site 
is necessary for stable adoption of the carrier domain conformation favored by acetyl-
CoA. Without Tyr621, biotin and the flexible carrier domain have lost the anchoring site 
for biotin, destabilizing the intermolecular carrier conformation.  
Thr876 contributes to shifts in carrier domain positioning. Thr876 acts to shuttle 
a proton between the biotin enolate and pyruvate during pyruvate carboxylation and it is 
within hydrogen-bonding distance to the N-1 position of biotin (Zeczycki, et al., 2009). 
As such, it may play a role in shifting carrier domain positioning. The T876A mutant 
displayed the smallest ITF amplitude changes in the absence of ligands compared to the 
QN crosslinking background (Figure IV-1B). Unexpectedly, the presence of pyruvate 
also led to a smaller amplitude of ITF signal change in this mutant (Figure IV-4) 
compared to the QN background, suggesting that this mutation reduced the impact of 
pyruvate on carrier domain repositioning. This result could have two different 
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explanations. First, the biotin-stabilizing hydrogen bonding network that normally forms 
in the presence of pyruvate has been disrupted. Second, the alanine introduced at this 
position has an unfavorable interaction with pyruvate, leading to conformational changes 
that disfavor the positioning of biotin in the active site.  
The presence of BC domain ligands led to an increase in the observed ITF 
amplitude change for the QNT mutant, including a dramatic increase observed in the 
presence of ADP and phosphonoacetate (Figure IV-4B). This coincided with a dramatic 
reduction in the observed rate constant with ADP and phosphonoacetate (Figure IV-4A), 
further suggesting that the carrier domain favors an interaction with the BC domain in 
this mutant. This supports the observation by Zeczycki, et al. that mutation of Thr882 in 
RePC (equivalent to Thr876 in SaPC) led to an increased rate of ADP phosphorylation in 
the BC domain, which was further accelerated in the presence of free biotin (Zeczycki, et 
al., 2009). The authors of that study proposed that the Thr882 mutation shifted carrier 
domain positioning towards the BC domain, where the increased local concentration of 
biotin in the active site contributed to accelerating the rate of ADP phosphorylation. The 
data presented here also indicates that mutation of Thr876 shifts carrier domain 
positioning towards the BC domain.  
In summary, direct observations of carrier domain positioning in SaPC 
demonstrate that carrier domain positioning is shifted by interactions between biotin and 
specific conserved active-site residues. These residues control the access of biotin to the 
active site, which leads to shifts in carrier domain positioning. While multi-domain 
enzymes are diverse, the directionality of these reactions and the mechanism by which 
carrier domain translocation is controlled is becoming clearer as a result of studies like 
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these. In the related biotin-dependent enzyme, acetyl-CoA carboxylase from 
Saccharomyces cerevisiae, it has been shown that the conformational flexibility of the 
enzyme is controlled by the binding of a regulatory loop to an allosteric site that restricts 
conformational flexibility and disfavors a catalytically-relevant high-energy 
conformation (Hunkeler, et al., 2016). The binding of acetyl-CoA in pyruvate 
carboxylase may have a similar role, confining the flexible carrier domain to promote an 
intermolecular, catalytically-relevant conformation at the CT domain active site that is 
stabilized through the biotin-Tyr621 interaction in SaPC. The results described in this 
chapter clarify how carrier domain positioning, governed by conformational selection, 
can be shifted by ligand binding events in SaPC. These findings may be useful in 
explaining how carrier domain translocation can be controlled at the molecular level by 
similar interactions in many other complex multi-domain enzyme systems. 
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V. THE EFFECTS OF LIGANDS AND ACTIVE SITE MUTATIONS ON CARRIER 
DOMAIN TRANSLOCATION IN S. AUREUS PYRUVATE CARBOXYLASE 
1. Introduction 
Chapters III and IV summarized the effect of ligands on carrier domain 
positioning and clarified the relationship between active site residues and carrier domain 
positioning. The carrier domain is governed by conformational selection, where ligand 
binding serves to shift the carrier domain positioning equilibrium. The QN crosslinking 
system was based on a structure where biotin occupies the exo-binding site and not the 
CT domain active site. In an effort to discern between carrier domain interactions at the 
active site and carrier domain interactions at the exo-binding site, a new system was 
created: D907C/Q1118C (DQ) SaPC (Figure V-1A).  
Many studies were performed in the DQ system, which showed quite different 
behavior relative to the QN system described in the previous chapters. The studies in the 
DQ system described in this chapter were initially interpreted to inform on the 
differences between the exo-binding site-carrier domain conformation as compared to the 
CT domain active site-carrier domain conformation.  However, in a series of experiments 
run only weeks prior to the submission of this dissertation (as described in the Results 
section), it was revealed that the DQ mutant behaves identically to a single Q1118C 
SaPC mutant. Thus, all of the data collected in the DQ system, in fact, represents a 
BCCP-BCCP crosslink rather than a BCCP-CT crosslink. While the BCCP dimer is not 
expected to be a catalytically relevant conformation, it does represent a novel state in 
which the carrier domain is trapped in the process of translocating between active sites. 
Given the late breaking nature of this result, it was not possible to regenerate all of the 
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mutations, originally generated in the DQ background, in the single Q1118C background. 
This chapter will demonstrate that the DQ mutant and the Q1118C single mutant are 
indistinguishable in their behavior and will then investigate the impact of ligands and 
mutations in the DQ double mutant system. All results with the DQ system will be 
interpreted as being due exclusively to the Q1118C-Q1118C crosslink. 
2. Results 
2.1  Characterization of the D907C/Q1118C SaPC Crosslinking System 
A second conformation, observed in X-ray crystal structures of SaPC, was used to 
direct the design of a crosslink trap in which the carrier domain was bound in the 
catalytically competent conformation, with biotin extending into the CT domain active 
site (Figure V-1B). This was designed to facilitate the detection and comparison of two 
different conformational states for the BCCP domain. To trap this second conformation, 
Asp907 on the CT domain and Gln1118 on the BCCP domain were mutated to cysteines 
to generate the double mutant D907C/Q1118C SaPC (DQ) based on the X-ray crystal 
structure of SaPC (PDB ID: 3BG5) (Xiang and Tong, 2008). 
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Figure V-1 SaPC carrier domain motions and conformations. 
A.  A schematic of the PC tetrameric structure and intermolecular carrier domain translocation. BC 
domains are colored in blue, CT domains in yellow, and the BCCP carrier domain in red. A hypothetical 
intermolecular translocation pathway is traced for a single carrier domain from the BC domain of its own 
subunit to the active site in the CT domain of a neighboring subunit. B. The SaPC X-ray crystal structure 
(PDB ID: 3BG5) showing the BCCP domain of one subunit (red) interacting at the active site of the CT 
domain on the opposing subunit (yellow). The Mn2+ ion, colored as a grey sphere, and pyruvate are shown 
in the CT domain active site. Asp907 on the CT domain and Gln1118 on the BCCP domain were both 
mutated to cysteine to enable maleimide-based crosslinking to trap the BCCP domain in an intermolecular 
conformation. 
 
 
SDS-PAGE analysis of crosslinking in the DQ double-mutant compared with the 
Q1118C single-mutant, however, revealed that the crosslinking levels for both mutants 
were very similar (Figure V-2A). To confirm this, Q1118C SaPC was analyzed for ITF 
intensity changes during crosslinking and compared to D907C/Q1118C SaPC. The ITF 
signals obtained from crosslinking both of these mutants are virtually identical (Figure V-
2B). Thus, the D907C/Q1118C system is equivalent to Q1118C alone and represents a 
BCCP-BCCP dimerization and not the BCCP-CT interaction. This interaction could not 
have been predicted from the X-ray crystal structure of a BCCP dimer from E. coli 
acetyl-CoA carboxylase (PDB ID: 1BDO), which shows that the BCCP domain dimer 
that forms in the crystal lattice positions these residues on opposite sides of the dimer 
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(Figure V-2). While this system does not capture the desired BCCP-CT domain 
interaction, it is interesting that Q1118C can crosslink only when both of the BCCP 
domains are in motion, away from either active site. Consequently, this system can be 
used to report on how ligands and mutations impact the translocation of the BCCP 
domain, even if the final position captured in these crosslinks is not catalytically relevant. 
All of the DQ SaPC data was collected prior to making this observation. The late-
breaking nature of this result prevents the re-collection of this data in the Q1118C SaPC 
system alone.  For the remainder of this chapter, the data in the DQ system will be 
analyzed on the assumption that the carrier domain is being trapped in a BCCP-BCCP 
crosslink during translocation.  
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Figure V-2 D907C/Q1118C SaPC mutants crosslinked.  
A. SaPC mutants as listed below at 1 mg/mL were reacted with 5% DMSO or 300 μM BMOE for 120 s, 
then quenched with 13 mM DTT for 15 minutes. 5 μg was loaded in each lane. (1) D907C/Q1118C w/ 
DMSO; (2) D907C/Q1118C w/ BMOE; (3) Q1118C w/ DMSO; (4) Q1118C w/ BMOE. The molecular 
weights for the ladders on the left and right are shown in kDa. B. SaPC mutants mixed with 200 μM 
BMOE and ITF intensity changes measured.   D907C/Q1118C SaPC (grey/black) or Q1118C SaPC (red) 
were mixed with a final concentration of 200 μM BMOE at t = 0 and the ITF intensity was recorded for 
120 seconds. Tryptophan was excited at 295 nm and ITF emission was recorded at 350 nm. 
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Figure V-3 Acetyl-CoA Carboxylase BCCP Domain Dimer Comparison 
The BCCP dimer of acetyl-CoA carboxylase from E. coli (yellow; PDB ID: 1BDO) is shown overlayed 
with the S. aureus PC BCCP domain (green; PDB ID: 3BG5) The S. aureus PC BCCP domain is overlayed 
over each subunit of the acetyl-CoA carboxylase dimer. Shown in sticks are Gln1118 (Gln1150 in H. 
sapiens numbering). 
 
 
The DQ SaPC mutants were subjected to the same experimental setup as in 
Chapter III. Rates of ITF signal change were determined by fitting the data to a single 
exponential decay equation. As shown in Figure V-4 and summarized in Table V-1, the 
presence of acetyl-CoA increased kobs 2.5-fold compared to the rate observed in the 
absence of ligands, a remarkably more pronounced response to acetyl-CoA compared to 
the QN crosslinking background. The ITF signal observed when acetyl-CoA was mixed 
with DQ SaPC appears virtually identical to the ITF signal observed when DQ SaPC was 
mixed with BMOE (Figure V-4B), suggesting that acetyl-CoA on its own promotes a 
conformation very similar to the BCCP-BCCP crosslinked conformation trapped by 
BMOE. Similar to what was observed in QN SaPC, the rate of ITF signal change during 
crosslinking increased when acetyl CoA was combined with ATP, as compared to the 
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sample incubated with ATP alone (Figure V-4A). However, the addition of acetyl-CoA to 
ATP resulted in a much more pronounced increase in the rate for the DQ crosslinking 
system (2.5-fold faster; 150% increase over ATP alone) compared to the QN crosslinking 
system (~20% increase over ATP alone). These relative rates are summarized in Tables 
III-4 for the QN system and V-1 for the DQ system.  
 
 
Figure V-4 D907C/Q1118C SaPC crosslinked in the presence of ligands and monitored for change in 
ITF intensity. 
A final concentration of 0.175 mg/mL D907C/Q1118C (DQ) SaPC was mixed with either buffer or various 
substrates at final concentrations listed in the Methods section, with 200 μM BMOE present at 0 s in a 
stopped-flow instrument with tryptophan excitation at 295 nm and emission measured at 350 nm. A.  DQ 
SaPC was mixed with either buffer (black), buffer + BMOE (purple), ATP + BMOE (orange), acetyl-CoA 
and BMOE (green), or ATP + acetyl-CoA + BMOE (blue). B. DQ SaPC was mixed with either buffer (black), 
buffer+BMOE (purple), acetyl-CoA + BMOE (green), pyruvate + BMOE (orange), or acetyl-CoA + pyruvate 
+BMOE (blue), or acetyl-CoA only (gold). Dashed lines represent the fit of the data to Equation 2. 
 
  
  
 
 
124 
Table V-1 The effect of ligands on the observed rates of ITF intensity change.  
substrate 
(+ BMOE) 
 
D907C/Q1118C SaPC kobs (s-1) 
 
kobs / (kobs [No Substrate]) 
None [1.3 ± 0.3] x 10-1 - 
ATP [0.7 ± 0.3] x 10-1 0.54 
Acetyl-CoA + ATP [1.8 ± 0.3] x 10-1 1.4 
Acetyl-CoA [3.3 ± 0.7] x 10-1 2.5 
Pyruvate  [2.6 ± 0.3] x 10-1 2.0 
Pyruvate + Acetyl-
CoA [4.9 ± 0.1] x 10
-1 3.8 
None* [1.9 ± 0.2] x 10-1 - 
L-aspartate* [1.3 ± 0.3] x 10-1 0.70 
* Assay performed independently from above data. (n = 3; errors represent standard deviations) 
The addition of pyruvate, the CT domain substrate, had a similar impact on the 
observed rates of ITF intensity change for the DQ system as it did in the QN system 
(Figure V-4B, Table V-1). Again, however, the effect was magnified in the DQ system: 
while the observed rate increased only slightly with the addition of pyruvate in the QN 
background (Table III-4), the observed rate increased two-fold in the DQ background. 
Finally, in the DQ background, the combination of acetyl CoA and pyruvate resulted in a 
nearly four-fold increase in the kobs compared to the kobs recorded in the absence of 
ligands and a two-fold increase compared to pyruvate alone (Figure V-4B). This nearly 
four-fold increase in kobs in the presence of acetyl-CoA and pyruvate is similar to the 
observed increase in kobs in the QN system indicating that a kinetic barrier to 
translocation (DQ) and intermolecular positioning (QN) was reduced in the presence of 
these ligands.  
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2.2  Active Site Mutations Contribute to Carrier Domain Positioning 
This D907C/Q1118C (DQ) mutant was used as a crosslinking background in 
which to further introduce mutations of active site residues that are proposed to interact 
with biotin and influence the translocation of the carrier domain: Glu243, Thr876, and 
Tyr621 (Lietzan, et al., 2011; Lietzan, et al., 2013) were each mutated to alanine in the 
DQ crosslinking background. These mutations are the same as those introduced in the 
QN crosslinking background and described in Chapter IV. The catalytic activities of 
these mutants are shown in Table V-2 (Lietzan, et al., 2011; Lietzan, et al., 2013). All of 
the mutants also form similar degrees of intermolecular crosslinks, (Figure V-5), 
prompting the investigation of these mutants with the more sensitive ITF approach.  
 
 
Figure V-5 D907C/Q1118C SaPC mutants crosslinked.  
A..SaPC mutants as listed below at 1 mg/mL were reacted with 5% DMSO or 300 μM BMOE for 120 s, 
then quenched with 13 mM DTT for 15 minutes. 5 μg was loaded in each lane. (1) D907C/Q1118C w/ 
DMSO; (2) D907C/Q1118C w/ BMOE; (3) Q1118C w/ DMSO; (4) Q1118C w/ BMOE; (5) 
D907C/Q1118C/E243A w/ DMSO; (6) D907C/Q1118C/E243A w/ BMOE; (7) D907C/Q1118C/Y621A w/ 
DMSO; (8) D907C/Q1118C/Y621A w/ BMOE; (9) D907C/Q1118C/T876A w/ DMSO; (10) 
D907C/Q1118C/T876A w/ BMOE. The molecular weights for the ladders on the left and right are shown 
in kDa. 
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Table V-2 Kinetic characterization of D907C/Q1118C SaPC and related mutants 
SaPC Mutant Pyruvate carboxylation kcat, min-1 
Wild-Type 1440 ± 100 
D907C/Q1118C 740 ± 10 
D907C/Q1118C/E243A 3.3 ± 0.2 
D907C/Q1118C/Y621A 8.8 ± 0.2 
D907C/Q1118C/T876A N/A 
 
Each of the three mutants were individually mixed with 200 μM BMOE and the 
changes in ITF intensity were recorded to gain an initial determination of the role played 
by these residues in carrier domain translocation. Representative ITF signal changes upon 
introduction of the BMOE crosslinker are shown in Figure V-6.  
Overall, increases in kobs in the DQ crosslinking background with either the 
Y621A or T876A mutation suggest that these mutations reduce kinetic barriers to carrier 
domain translocation (Figure V-7A). The amplitude of the ITF signal change during 
crosslinking of the DQT mutant remained similar to the DQ crosslinking background, 
suggesting that baseline equilibrium positioning of the carrier domain wasn’t shifted by 
this mutation. The DQY mutant displayed a large shift in amplitude compared to the DQ 
crosslinking background (Figure V-7B), similar to what was observed in the QN 
crosslinking system.  
The amplitude of the ITF signal change increased slightly in the DQE mutant 
compared to the DQ crosslinking background, suggesting that carrier domain equilibrium 
has shifted towards the BC domain in this mutant (Figure V-7B), in agreement with the 
conclusions from the QN system in Chapter IV.  The rate of ITF signal change during 
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crosslinking decreased in DQE SaPC compared to the DQ crosslinking background, 
indicating that carrier domain translocation has become more kinetically unfavorable as a 
result of this mutation (Figure V-7A).  
 
 
Figure V-6 DQ SaPC Mutants ITF intensity changes during crosslinking. 
D907C/Q1118C SaPC (red), D907C/Q1118C/E243A SaPC (gold), D907C/Q1118C/T876A SaPC (green), 
or D907C/Q1118C/Y621A SaPC (blue) was mixed with a final concentration of 200 μM BMOE at t = 0 and 
the ITF intensity was recorded for 120 seconds. Tryptophan was excited at 295 nm and ITF emission was 
recorded at 350 nm. 
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Figure V-7 Observed rates and amplitudes of ITF change from DQ SaPC mutants during 
crosslinking with BMOE 
D907C/Q1118C (DQ) SaPC, D907C/Q1118C/E243A (DQE) SaPC, D907C/Q1118C/T876A (DQT) SaPC, 
and D907C/Q1118C/Y621A (DQY) SaPC were mixed with BMOE at 0 sec. in a stopped-flow instrument 
with tryptophan excitation at 295 nm and ITF emission measured at 350 nm. A single exponential decay 
equation was fit to the data. A. The relative change in kobs is the kobs obtained for each of the three active-
site residue mutants divided by the kobs obtained from the QN background. All measurements were made in 
triplicate. Error bars represent the standard deviation. B. The amplitudes of ITF signal change from 
Equation II-2 for each of the three active-site residue mutants obtained in panel A were divided by the 
amplitude change obtained for the corresponding crosslinking background to yield a relative % change. 
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2.3 Mutation of Glu243 Shifts Carrier Domain Positioning Towards BC Domain. 
The observed rates of crosslinking of the DQE mutant were attenuated in the 
presence of BC domain ligands compared to the DQ crosslinking background (Figure V-
8A). This is matched by a smaller increase in amplitude of ITF signal change for the 
DQE mutant compared to the DQ background (Figure V-8B). In this mutant, biotin has 
increased access to the active site. As a result of this, the carrier domain may have 
already adopted the positional equilibrium favored by these substrates, which would 
lessen the effect of the substrate on carrier domain positioning.  
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Figure V-8: Observed rates and amplitudes of ITF change from D907C/Q1118C/E243A SaPC during 
crosslinking with BMOE in the absence/presence of ligands.  
A. D907C/Q1118C SaPC (black) and D907C/Q1118C/E243A SaPC (pink) were incubated for a minimum 
of 10 minutes with 2.5 mM ATP, 0.25 mM acetyl-CoA, 12 mM sodium pyruvate, 5 mM ADP, or 5 mM 
phosphonoacetate (PPA) and then mixed with BMOE and an equal concentration of the substrate/effector 
at 0 sec. in a stopped-flow instrument with tryptophan excitation at 295 nm and ITF emission measured at 
350 nm. Equation II-2 was fit to the data and the kobs obtained for each of the three active-site residue 
mutants compared to the kobs obtained from the corresponding crosslinking background mutant. All 
measurements were taken in triplicate with the error bars representing the standard deviation in the rate. B. 
The amplitudes of ITF signal change from the single exponential equation for each of the three active-site 
residue mutants described in panel A were compared to the amplitude obtained for the corresponding 
crosslinking background. 
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2.4 Thr876 Mediates Translocation of the Carrier Domain in Response to Pyruvate 
The observed rates of ITF intensity change in DQT SaPC were similar to those in 
the DQ background in the presence of BC domain ligands (Figure V-9A). The amplitudes 
of ITF signal change (Figure V-9B) in the presence of these ligands were also similar to 
background, in stark contrast to the observations in QNT SaPC, especially in the presence 
of ADP and phosphonoacetate. While the large drop in kobs in DQT in the presence of 
ADP and phosphonoacetate is similar to that observed in QNT, the difference in how the 
amplitudes vary is astounding. The lack of difference in observed amplitudes in DQT 
compared to the DQ background indicates that the thermodynamics of translocating have 
not changed as a result of this mutation in the presence of ADP and phosphonoacetate. 
Rather, the large increase in amplitude observed in QNT compared to QN in the presence 
of these ligands indicates a large equilibrium positioning shift towards the BC domain.   
The observed amplitudes in DQT were similar to those of the DQ background in 
the presence of pyruvate (Figure V-9B). However, the observed rate dramatically 
decreased in the presence of pyruvate in the DQT SaPC mutant compared to the DQ 
background (Figure V-9A). Combined with a similar effect observed in the QNT SaPC 
mutant, these observations strongly suggest that Thr876 mediates the effect of pyruvate 
on carrier domain translocation (DQT) and positioning (QNT).  In the presence of 
pyruvate with this mutation, there is a larger kinetic barrier to overcome to translocate or 
adopt positioning in the exo-binding site. Finally, the observed rate of ITF intensity 
change in DQT SaPC in the presence of acetyl-CoA increased approximately 4-fold 
compared to in the absence of acetyl-CoA suggesting that a kinetic barrier to the 
translocation of the carrier domain has been reduced by the mutation of this active site 
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threonine (Figure V-9A). A larger change in the amplitude of ITF signal change in the 
presence of acetyl-CoA compared to the DQ crosslinking background in the presence of 
acetyl-CoA indicates that carrier domain translocation may be more thermodynamically 
favorable as a result of this mutation in the presence of acetyl-CoA.  
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Figure V-9: Observed rates and amplitudes of ITF change from D907C/Q1118C/T876A SaPC during 
crosslinking with BMOE in the absence/presence of ligands.  
A. D907C/Q1118C SaPC (black) and D907C/Q1118C/T876A SaPC (purple) were incubated for a 
minimum of 10 minutes with 2.5 mM ATP, 0.25 mM acetyl-CoA, 12 mM sodium pyruvate, 5 mM ADP, or 
5 mM phosphonoacetate (PPA) and then mixed with BMOE and an equal concentration of the 
substrate/effector at 0 sec. in a stopped-flow instrument with tryptophan excitation at 295 nm and ITF 
emission measured at 350 nm. Equation II-2 was fit to the data and the kobs obtained for each of the three 
active-site residue mutants compared to the kobs obtained from the corresponding crosslinking background 
mutant. All measurements were taken in triplicate with the error bars representing the standard deviation in 
the rate. B. The amplitudes of ITF signal change from the single exponential equation for each of the three 
active-site residue mutants described in panel A were compared to the amplitude obtained for the 
corresponding crosslinking background. 
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2.5  CT Domain Tyr621 Has A Crucial Role in Mediating Carrier Domain Positional 
Response to Pyruvate and Acetyl-CoA 
As described in Chapter IV and Chapter VI, this data may not be able to be 
interpreted in the same manner as the other mutants given the dramatic difference in ITF 
signals observed. The observed rate of ITF intensity change varied similarly in the DQY 
mutant as in the QNY mutant, with only small decreases in kobs in the presence of BC 
domain ligands (Figure V-10A), further evidence that alterations to one domain, such as 
the Y621A CT domain mutation, may affect the behavior of the other active site, as 
discussed in Chapter IV. While acetyl-CoA dramatically increased kobs in the DQ 
crosslinking background, it had virtually no effect in DQY SaPC (Figure V-10A). The 
effect of acetyl-CoA on the amplitude of the ITF signal changes is also diminished 
(Figure V-10B). Combined with the observations from QNY SaPC, this strongly suggests 
that Tyr621 is necessary for acetyl-CoA to affect carrier domain positioning (QNY) and 
translocation (DQY). The effect of pyruvate on observed rates of ITF intensity change 
was also reduced in this mutant, but not completely abolished (Figure V-10A). Similar to 
QNY SaPC, a large increase in the magnitude of the amplitude change was observed in 
DQY SaPC when crosslinked with pyruvate, as well, indicating that both carrier domain 
positioning (QNY) and translocation (DQY) in this mutant still responds to the presence 
of pyruvate (Figure V-10B).  
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Figure V-10: Observed rates and amplitudes of ITF change from D907C/Q1118C/Y621A SaPC 
during crosslinking with BMOE in the absence/presence of ligands.  
A. D907C/Q1118C SaPC (black) and D907C/Q1118C/Y621A SaPC (green) were incubated for a 
minimum of 10 minutes with 2.5 mM ATP, 0.25 mM acetyl-CoA, 12 mM sodium pyruvate, 5 mM ADP, or 
5 mM phosphonoacetate (PPA) and then mixed with BMOE and an equal concentration of the 
substrate/effector at 0 sec. in a stopped-flow instrument with tryptophan excitation at 295 nm and ITF 
emission measured at 350 nm. Equation II-2 was fit to the data and the kobs obtained for each of the three 
active-site residue mutants compared to the kobs obtained from the corresponding crosslinking background 
mutant. All measurements were taken in triplicate with the error bars representing the standard deviation in 
the rate. B. The amplitudes of ITF signal change from the single exponential equation for each of the three 
active-site residue mutants described in panel A were compared to the amplitude obtained for the 
corresponding crosslinking background.   
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3. Discussion 
In the current study, the crosslinking system, D907C/Q1118C SaPC, was 
designed to trap the carrier domain in a conformation with biotin projecting into the CT 
domain active site. An important control experiment was overlooked in the initial 
evaluation of this system and the Q1118C mutation was not assessed until after all the 
data had been collected on the DQ system. Due to the observation that the single Q1118C 
mutation readily crosslinked two BCCP domains through a Q1118C-Q1118C crosslink, 
the trapped conformation captured in the DQ system actually represents the carrier 
domain in a state of translocation, outside of either active site. However, due to the 
absence of single mutant controls for these experiments, the data is being interpreted as it 
is, but there is added uncertainty to the validity of these interpretations. For instance, 
some amount of D907C-Q1118C crosslinking may result in the presence of some or all 
of these mutations or in the presence of ligands, which would substantially weaken these 
interpretations.  
 The presence of acetyl-CoA resulted in a 2.5-fold increase in observed ITF 
signal change rates when crosslinking compared to the rate observed in the absence of 
ligands, in stark contrast to the negligible effect of acetyl-CoA on observed rates in the 
QN crosslinking background (Table V-1, Figure V-4). A moderate downward amplitude 
change was also observed in the presence of acetyl-CoA, which is interpreted to suggest a 
shift in carrier domain positioning away from the BC domain in favor of translocation. 
This data suggests that the presence of acetyl-CoA favors the release of the carrier 
domain from the BC domain for translocation. In order to crosslink the carrier domain in 
this system, the carrier domain must be in motion. Since acetyl-CoA increases the kobs 
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2.5-fold compared to its absence, translocation of the carrier domain between sites is 
increasing. The presence of pyruvate led to a two-fold increase of kobs while the 
combination of pyruvate and acetyl-CoA during crosslinking in DQ SaPC produced a 
nearly four-fold increase in kobs compared to kobs  in the absence of ligands or a two-fold 
increase compared to kobs in just the presence of pyruvate (Table V-1, Figure V-4), 
suggesting a large drop in the kinetic barrier for translocation between sites. This result is 
consistent with observations of a 2-fold activation of SaPC catalytic activity by acetyl-
CoA (Yu, et al., 2009).  
The amplitude of ITF signal changes during crosslinking in the presence of BC 
domain ligands was observed to be smaller in DQE SaPC than in the DQ SaPC 
crosslinking background (Figure V-8B), suggesting that the mutation shifts the carrier 
domain positioning equilibrium towards the BC domain. Combined with the reduced 
observed rate of crosslinking in the absence of substrates and the reduced effect of BC 
domain substrates on kobs, these results are consistent with the proposal that Glu243 is 
part of a gatekeeper system to control the access of biotin to the BC domain active site. 
The E243A mutation in SaPC resulted in a larger kinetic barrier for carrier domain 
translocation. This greater kinetic barrier is a consequence of stabilizing the BCCP-BC 
domain interaction in the ground state. This is illustrated in Figure V-11.  
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Figure V-11: Free energy diagram for DQE SaPC 
A potential energy landscape is shown for the DQE SaPC mutant. The Gibbs free energy (G) is plotted 
against the translocation progress of BCCP between the BC and CT domains. The kinetic barrier is 
represented by a dashed black line. The wild-type reaction is represented in black while the mutation is 
represented in red.  
 
 
Observed ITF signal change rates during crosslinking were increased in the DQY 
SaPC mutant by 50% compared to the observed rates in the DQ background (Figure V-
8A), suggesting that the carrier domain was less anchored in the CT domain and freer to 
translocate and adopt a variety of conformations. Just as in the QNY system, a large 
increase in amplitude was observed in DQY SaPC, indicating a shift in carrier domain 
positioning towards the BC domain (Figure V-10B) as illustrated in Figure V-12. This is 
consistent with the proposal that Tyr621 stabilizes carrier domain positioning in the CT 
domain in the presence of pyruvate (Lietzan, et al., 2013). The loss of this stabilizing 
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interaction in the CT domain of this mutant, results in a shift in carrier domain 
positioning towards the BC domain.  
The effect of acetyl-CoA in the DQY SaPC mutant was nearly abolished with no 
significant difference in the kobs between the DQY SaPC and the DQ crosslinking 
background (Figure V-10A). Similarly, the observed amplitude in the presence of acetyl-
CoA was also reduced in this mutant (Figure V-10B). These results indicate that the 
biotin-binding pocket in the CT domain active site plays an important role in mediating 
the effect of acetyl-CoA on carrier domain translocation. While acetyl-CoA binds near 
the flexible linker to the carrier domain, the flexible carrier arm is ultimately stabilized by 
interactions with biotin, such as those at the cleft of the exo-binding site. For example, 
the interaction between Tyr621 and biotin stabilizes the carrier domain in an 
intermolecular position. Acetyl-CoA has been shown to favor that conformation. In the 
absence of this Tyr621-biotin interaction, the carrier domain is granted greater 
translocational freedom.   
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Figure V-12: Free energy diagram for DQY SaPC 
A potential energy landscape is shown for the DQY SaPC mutant. The Gibbs free energy (G) is plotted 
against the translocation progress of BCCP between the BC and CT domains. The kinetic barrier is 
represented by a dashed black line. The wild-type reaction is represented in black while the mutation is 
represented in red. 
 
 
The T876A mutant displayed the smallest amplitude changes in the absence of 
ligands compared to DQ crosslinking background (Figure V-7B). A remarkably 
decreased kobs in the presence of pyruvate was observed in DQT SaPC with a rate ~20% 
of that observed in the DQ background (Figure V-9A). The decreased observed rates of 
ITF intensity change in the presence of pyruvate for this mutant support the hypothesis 
by Zeczycki, et al. that biotin positioning is stabilized in the CT domain active site by the 
T876A mutant in the presence of pyruvate (Zeczycki, et al., 2009). With the DQ SaPC 
system capturing the translocation of the carrier domain, a decreased kobs indicates that 
the combination of this active site mutation and the presence of pyruvate has increased a 
kinetic barrier to carrier domain translocation.  
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The observed amplitude in the DQT mutant did not significantly change 
compared to the DQ crosslinking background in the presence of BC domain ligands, 
suggesting that mutation to the CT domain Thr876 did not alter the ground state free 
energies in the presence of ATP or ADP (Figure V-9B). However, there was a dramatic 
reduction in kobs for the DQT SaPC in the presence of ADP and phosphonoacetate, 
compared to the DQ crosslinking background (Figure V-9A), indicating that the carrier 
domain is favored to remain interacting with the BC domain in these mutants as a 
consequence of a larger kinetic barrier. These observations are consistent with the 
observation by Zeczycki, et al. that mutation of Thr882 in RePC (the analogous residue to 
Thr876 in SaPC) increased the rate of ADP phosphorylation in the BC domain (Zeczycki, 
et al., 2009). The authors proposed that carrier domain positioning was shifted towards 
the BC domain as a result of this mutation, increasing the presence of biotin in the active 
site and accelerating the rate of ADP phosphorylation. The DQT data presented in this 
chapter suggest that the thermodynamics of translocation largely weren’t affected by this 
mutation, with the exception of pyruvate, as discussed. Rather, carrier domain 
translocation has become more unfavorable due to an increase in the energy barrier for 
translocation in the presence of ADP and phosphonoacetate, hinting at a complex change 
in the energy landscape in this mutation. This special case is illustrated in Figure V-13 
where both the lowering of a kinetic barrier by the mutation and the thermodynamic 
change proposed by the addition of ADP and phosphonoacetate is shown. The reduced 
Gibbs free energy of the BCCP-BC domain interaction in the presence of ADP and 
phosphonoacetate results in both a shift in equilibrium positioning and a larger kinetic 
barrier to translocation relative to the absence of ligands.  
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In this chapter, I have presented data from a novel study investigating the kinetic 
and thermodynamic effects of active site mutations in PC on carrier domain translocation 
by directly observing the capture of the carrier domain “in flight”. These results have 
further illustrated the important role each active site residue plays in shifting carrier 
domain positioning and how carrier domain positioning can be controlled within the 
conformational selection model.   
 
Figure V-13: Energy landscape diagram for DQT SaPC 
A potential energy landscape is shown for the DQE SaPC mutant. The Gibbs free energy (G) is plotted 
against the translocation progress of BCCP between the BC and CT domains. The kinetic barrier is 
represented by a dashed black line. The wild-type reaction is represented in black while the mutation is 
represented in blue. The effect of the presence of ADP and phosphonoacetate (PPA) in the mutant on this 
landscape is shown in red while in the DQT mutant it is shown in blue.  
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VI.  CONCLUSIONS  
1. Mechanism Governing Carrier Domain Translocation in S. aureus Pyruvate 
Carboxylase  
In this section, the conformational selection model will be utilized to explain the 
translocation of carrier domain in S. aureus pyruvate carboxylase. The application of this 
model will attempt to integrate all of the results from the current study to generate a 
comprehensive view of how carrier domain translocation is controlled. The contribution 
of each domain to the regulation of carrier domain positioning will be discussed. A model 
will be proposed for how acetyl-CoA may influence carrier domain positioning that 
attempts to account for a wide-range of observations. Finally, the findings discussed here 
will be compared to several multi-domain enzymes.  
Conformational selection governs carrier domain positioning. As introduced in 
Chapter I, the induced conformational change model would predict that the carrier 
domain in PC remains in one conformation in the absence of a ligand (Easterbrook-
Smith, et al., 1976; Goodall, et al., 1981; Attwood and Wallace, 1986). Alternatively, the 
conformational selection model predicts that the carrier domain exists in an ensemble of 
conformations regardless of ligand present. The results presented in Chapter III all 
support the conformational selection model as the mechanism governing carrier domain 
positioning. The carrier domain was observed to position itself intermolecularly or get 
trapped in the state of translocation between sites irrespective of the presence or identity 
of ligands. Under no circumstances was the carrier domain unable to be trapped in either 
“state”, consistent with the conformational selection model. It is important to note that an 
assumption has been made that the QN crosslinking system can distinguish between the 
  
 
 
144 
BCCP-exo binding site and BCCP-CT domain conformations. An X-ray crystal structure 
of crosslinked PC or a comparison between the QN system and a system that traps the 
carrier domain while interacting with the CT domain active site would provide evidence 
for this, as no evidence currently exists. However, the distance between the Q891C and 
N1102, which crosslink in the exo-binding site conformation, are ~22 Å apart when the 
carrier domain is positioned with biotin in the CT domain active site (PDB ID: 3BG5). 
This is a much greater distance than the 8 Å BMOE crosslinker used throughout these 
experiments, which supports the ability of this system to distinguish the two 
conformations.  
BC domain ligands shift carrier domain positioning towards the BC domain as 
observed by the increased observed amplitudes of ITF signal change when crosslinking 
the carrier domain during translocation or in the exo-binding site conformation in the 
presence of BC domain ligands compared to in the absence of ligands. Observed rates of 
ITF signal change (kobs) decreased when the carrier domain was crosslinked in either 
system in the presence of BC domain ligands, indicating that a kinetic barrier increased 
for the translocation of the carrier domain and for the positioning of the carrier domain 
away from the BC domain in the exo-binding site (Tables V-1, III-4). The observed 
amplitudes also increased during crosslinking in the QN or DQ system in the presence of 
BC domain ligands, indicating a shift in carrier domain positioning towards the BC 
domain (Figures V-7B, IV-3B). The results presented here are also consistent with 
observations in 1965 when Scrutton and Utter observed that BC domain substrates 
protected PC from avidin deactivation (Scrutton and Utter, 1965). Avidin binds to the 
carrier domain-tethered biotin, preventing it from contributing to catalysis. When biotin 
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is positioned in the BC domain active site, such as when BC domain ligands are present, 
biotin would be unavailable to react with avidin, leading to a reduction in deactivation by 
avidin binding. 
Pyruvate, the CT domain substrate, has the opposite effect, as expected, shifting 
carrier domain positioning towards an intermolecular position. However, there is some 
subtlety to this behavior. The creation of the two different crosslinking constructs has 
allowed a finer determination to be made of what carrier domain state is favored in the 
presence of pyruvate. The conformation in which the carrier domain is translocating 
between active sites, trapped by D907C/Q1118C SaPC, is kinetically favored, with a 2-
fold increase in kobs when crosslinking in the presence of pyruvate. In contrast, the 
presence of pyruvate only yields a 1.1-fold increase in kobs when crosslinking the carrier 
domain in the exo-binding site conformation (Tables III-4, V-1). However, the observed 
amplitudes do not differ much between crosslinking the carrier domain with biotin 
positioned in the exo-binding site or in the translocation state. Pyruvate has been shown 
to bind/unbind approximately twice per catalytic cycle, diffusing relatively easily into 
and out of the active site (Warren G.B. and Tipton K.F., 1974, Cheung Y.F. and Walsh 
C., 1976, Zeczycki, T.N., et al., 2011). When pyruvate dissociates, the biotin-binding 
pocket that Lietzan, et al. observed would no longer be stabilized, making the BCCP-CT 
interaction less favorable (Lietzan, et al., 2013). Therefore, the carrier domain would be 
more likely to leave the CT domain after which BCCP-biotin would be free to translocate 
and could become temporarily stabilized in the nearby exo-binding site, providing an 
explanation for the similar amplitude changes observed in ITF signal changes when 
crosslinking to either conformation. These observations also suggest that the role of the 
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exo-binding site may be to stabilize the carrier domain close to the CT domain, 
effectively increasing the local concentration of carboxybiotin.  
My findings in favor of the conformational selection model are not inconsistent 
with early kinetic observations in PC (Easterbrook-Smith, et al., 1976, Goodall, et al., 
1981, Attwood and Wallace, 1986) in which the authors followed the decarboxylation of 
biotin and observed that the rate of biotin decarboxylation increased in the presence of 
CT domain ligands. These results were interpreted to suggest that CT domain ligands 
induce carrier domain translocation towards the CT domain. Rather, the carrier domain 
positioning, which exists in an equilibrium, was shifted to favor the CT domain in the 
presence of CT domain ligands. The CT domain promotes the decarboxylation of biotin, 
so an increased presence of carboxybiotin in the CT domain naturally leads to an 
increased rate of decarboxylation. Conversely, without a CT domain ligand present, the 
carrier domain may still attain this conformation, but biotin would not be stabilized as the 
active site tyrosine would not be properly positioned to stabilize biotin in the active site. 
Thus, rates of carboxybiotin decarboxylation in the absence of a CT domain ligand would 
be low.  
Physiological Relevance. The induced conformational change model might seem 
to be the more efficient model for governing carrier domain positioning in PC or other 
enzymes since the carrier domain would only translocate to the next active site when the 
relevant substrate is bound and the active site ready to accept the intermediate product 
from the first active site. However, the KM value for many enzymes, the ligand 
concentration at which half of the binding sites have ligand bound, is often close to the 
physiological concentration of the respective substrate (Waelbroeck, 2007; Berg, et al., 
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2002). If the assumption that all active sites must have substrate bound for an induced 
conformational change to take place is valid, this model would lead to a less productive 
enzyme when substrate concentrations are near or below KM. In this situation, substrate 
could be bound without carrier domain translocation or reaction completion. However, 
the conformational selection model would allow for comparatively more productivity in 
these conditions. In a case where substrate concentrations are around the KM value, 
approximately half of the active sites would have substrate bound. Thus, those active 
sites would favor interactions with the carrier domain, leading to the formation of 
product. Comparatively, if the same enzyme were governed by the induced 
conformational change model, very little product would be formed since it would be rarer 
to have all active sites bound with substrate to induce carrier domain translocation. 
Overall, when substrate values are near or below KM, I believe that the conformational 
selection would be favored for organismal fitness.  
Conversely, if the assumption that all active sites must have substrate bound for 
an induced conformational change to take place is not valid, there would not be such a 
clear distinction between these models and organismal fitness. For example, if half of the 
active sites were required to be bound with substrate for an induced conformational 
change to take place, this model would perform similarly to the conformational selection 
model when substrate concentrations are at KM, since by the definition of KM, 
approximately half of the active sites would have substrate bound. The complexity of this 
topic is highlighted by studies that have investigated proteins that can utilize both 
models, dependent upon ligand concentration. Dihydrofolate reductase (DHFR) was 
observed to operate via conformational selection at low ligand concentrations and via an 
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induced fit mechanism at high ligand concentrations. At intermediate concentrations, 
both mechanisms were observed to be in use (Hammes, et al., 2009; Grieves and Zhou, 
2014). Thus, enzymes may have evolved more than one mechanism to ensure the 
efficient coupling of reactions over a range of substrate concentrations.  
BC domain interactions with the carrier domain. The interface between the carrier 
domain and BC domain is composed of the B-subdomain lid, a solvent-exposed loop 
belonging to the C-subdomain, and the carrier domain (Lietzan, et al., 2011). Only two 
pairs of residues directly interact while the majority of contact between these domains are 
non-specific, burying ~1200 Å2. Given the lack of direct or conserved interactions, it’s 
reasonable to expect that changes in the positioning of the B-subdomain lid would alter 
the docking favorability of the carrier domain to the BC domain. B-subdomain lid 
conformations have been observed to shift to more closed conformations in the presence 
of BC domain ligands in several crystal structures (Kondo S., et al., 2004, Thoden JB, et 
al., 2000, Chou CL, et al., 2009, Chou CY and Tong L., 2011, Lietzan, et al., 2011). The 
presence of tethered biotin was observed to lead to tighter lid closure than the presence of 
free biotin (Lietzan, et al., 2011). This relationship between the presence of BC domain 
ligands and the composition of the BCCP-BC domain interface may be the primary 
mechanism in the BC domain to govern carrier domain positioning.  
The second BC domain mechanism that may play a role in shifting carrier domain 
positioning was observed by Lietzan, et al. in 2011 in an X-ray crystal structure of 
T882A RePC that was co-crystallized with MgADP and phosphonoacetate (Lietzan, et al. 
2011). In this structure, the carrier domain was docked at the BC domain, which was the 
first high-resolution structure to capture this, but carboxybiotin was positioned outside of 
  
 
 
149 
the active site. A pair of residues that were located between the active site and the entry 
site for carboxybiotin, Arg353 and Glu248, were oriented such that a salt bridge formed 
between them, stabilizing the positioning of Arg353 which was proposed to preclude 
carboxybiotin access. The authors proposed that this interaction may prevent abortive 
decarboxylation, serving as a mechanism to control carboxybiotin positioning. This 
interaction between these residues and biotin had not since been studied to determine the 
effect on carrier domain positioning.  
As discussed in chapter IV and V, mutation of Glu243 in SaPC, the homolog of 
Glu248 in RePC, resulted in a shift in carrier domain positioning towards the BC domain, 
consistent with proposals that this residue may preclude carboxybiotin access to the BC 
domain active site. Presumably, a more favorable interaction between the BC and BCCP 
domains occurs with increased carboxybiotin access to the BC domain active site. When 
crosslinking to the exo-binding site conformation, the presence of BC domain substrates 
led to an increase in the observed amplitudes of ITF signal change in the E243A SaPC 
mutant, indicating a greater shift in carrier domain positioning towards the BC domain as 
a result of this mutation (Figure IV-3B). However, when capturing the translocating 
carrier domain, the opposite results were observed, potentially indicating an increased 
amount of carrier domain translocation (Figure V-8B). Rates of ITF signal change 
remained unchanged in this mutant when crosslinking to the exo-binding site in the 
presence of BC domain ligands (Figure IV-3A). However, the decrease in kobs was 
attenuated when crosslinking in the DQE mutant with BC domain ligands present 
compared to the decrease in kobs in the DQ background (Figure V-8A). While it might 
seem that this indicates that this mutation has lowered a kinetic barrier to the 
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translocation of the carrier domain in the presence of BC domain ligands, recall that in 
the absence of any ligands, the kobs for this mutant was decreased compared to the DQ 
background (Figure V-6). This indicates that the BC domain substrates have less of an 
effect in this mutant because a kinetic barrier to carrier domain translocation has 
increased as a consequence of the mutation itself. Conversely, the rate of crosslinking 
translocating carrier domains in DQE was attenuated and indistinguishable from the 
crosslinking background in the presence of pyruvate. This indicates that a kinetic barrier 
has increased for the translocation of the carrier domain in the presence of pyruvate, 
consistent with the effect observed in the presence of BC domain ligands.  
CT domain interactions with the carrier domain. When the carrier domain is 
positioned at the CT domain, there are several pairs of residues that engage in hydrogen-
bonding and many hydrophobic interactions occur, as well (Xiang S. and Tong L., 2008). 
However, no alterations to the binding interface have been reported in the 
presence/absence of ligands. Rather, small conformational changes occur in the active 
site in the presence of a CT domain ligand, such as pyruvate (Lietzan, et al., 2013). The 
carboxyl moiety of pyruvate was shown to form a salt bridge with the guanidinium group 
of Arg621 (RePC numbering), which promoted the movement of an active site loop. This 
loop movement ultimately resulted in a reorientation of Tyr628 (Tyr621 in SaPC) to 
rotate towards the CT domain active site. Based on an overlay with H. sapiens PC, biotin 
was proposed to position itself over this tyrosine in a stable interaction between the sulfur 
of the thiophene ring of biotin and the aromatic ring of tyrosine. The rotation of tyrosine 
towards the active site in the presence of pyruvate has been proposed to stabilize biotin in 
the CT domain active site.  
  
 
 
151 
The findings that I presented in chapters IV and V have shown the important role 
of this residue in the positioning of the carrier domain with the CT domain. The BCCP-
CT domain interaction likely became less thermodynamically favorable in the presence 
of pyruvate in the DQY mutant. This was observed as a large increase in kobs when 
trapping the translocating carrier domain in the DQY mutant without any ligands present, 
indicating that a kinetic barrier has decreased for the translocation of the carrier domain 
(Figure V-7A). Similarly, a large change in the observed amplitude when trapping the 
translocating carrier domain was observed in this mutant, indicating a large shift in 
carrier domain equilibrium away from the BC domain, potentially towards the 
translocation state and/or an intermolecular interaction (Figure V-7B). A large shift in 
amplitude was also observed in the QNY mutant when crosslinking in the absence of 
ligands, supporting the proposal that the carrier domain equilibrium has shifted towards 
the exo-binding site (Figure IV-5B). It is clear that the kinetic and thermodynamic 
landscape for carrier domain interaction with the CT domain has been dramatically 
altered, presumably with the CT domain active site becoming more unfavorable for the 
positioning of biotin and the carrier domain in this mutant.  
Only minimal decreases in kobs were observed when crosslinking in the QNY or 
DQY mutants in the presence of BC domain ligands (Figures IV-5A, V-10A). This was a 
strange result in that a CT domain mutation altered the effect of BC domain ligands on 
carrier domain positioning at the exo-binding site. This result may support previous 
observations that mutations or ligand binding in one active site can have an effect on a 
distant active site. This effect was recently observed in SaPC and RePC, respectively, 
with results interpreted to suggest communication between the BC and CT domains 
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(Westerhold, et al., 2016; Lietzan, et al., 2014). However, no specific mechanism for this 
has been proposed or observed to date. Given that the symmetric/asymmetric 
conformation of PC is linked to carrier domain positioning (St. Maurice, et al., 2007; Yu, 
et al., 2009; Lasso, et al., 2014), this communication could be the result of shifts in the 
carrier domain positional equilibrium caused by ligand binding or mutations that 
influence the overall symmetric state of PC. If this were true, for example, the mutation 
of Tyr621 would be predicted to disrupt acetyl-CoA binding. Since Tyr621 presumably 
shifts the carrier domain equilibrium away from the CT domain, the asymmetric form of 
PC would be more favorable. This form of PC has two binding sites for acetyl-CoA, 
while the disfavored symmetric form has four binding sites (Lasso, et al., 2014). Thus, 
this mutation may ultimately have an effect on the cooperativity and observed Hill 
coefficients of acetyl-CoA binding.  
Pyruvate was observed to still have an effect on kobs and amplitudes in the Y621A 
mutants. The effect of pyruvate on carrier domain positioning may be reduced when 
crosslinking in the DQY mutant compared to the QNY mutant, but there is still a 
relatively large change in the amplitude of observed ITF signal change compared to in the 
absence of pyruvate, indicating there is likely another interaction that occurs between 
pyruvate binding and biotin (Figures IV-5B, V-10B). Interestingly, a difference exists in 
the response to pyruvate between the QNY and DQY mutants. In the QNY mutant, 
pyruvate increases the kobs compared to the QN background in the presence of pyruvate 
(Figure IV-5A). Conversely, in the DQY mutant, this increase in kobs is attenuated (Figure 
V-10A). Taken together, this suggests a reduced kinetic barrier for the positioning of the 
carrier domain in the exo-binding site in the presence of pyruvate while pyruvate has a 
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reduced effect on lowering the kinetic barrier for carrier domain translocation. In the 
QNY system, the destabilization of the carrier domain in the CT domain by the loss of 
the biotin-Tyr621 interaction can explain this observation. A reduced interaction energy 
increases the off rate for the BCCP domain in the CT domain, thereby increasing the 
likelihood of positioning at the exo-binding site. Similarly, without the Tyr621 residue to 
“communicate” the presence of pyruvate to biotin and stabilize biotin in the CT domain, 
the effect of pyruvate on translocation will be weakened, as observed, with the carrier 
domain likely remaining stabilized in other low energy wells, such as the exo-binding site 
or BC domain.  
The second residue CT domain active site residue that biotin was proposed to 
interact with is Thr876 in SaPC numbering (Thr882 in RePC). The N-1 position of biotin 
is proposed to hydrogen-bond with this residue when biotin is positioned in the active site 
(Zeczycki, et al, 2009). In the presence of ADP and phosphonoacetate, I observed that a 
kinetic barrier has dramatically increased for the translocation of the carrier domain and 
for the positioning of the carrier domain in the exo-binding site (Figures IV-4A, V-9A). 
The carrier domain positioning was also observed to shift towards the BC domain with a 
much larger amplitude in the presence of ADP and phosphonoacetate in QNT SaPC 
compared to the QN background, whereas the amplitude is virtually unchanged when 
crosslinking the translocating carrier domains (Figure V-9B). This large equilibrium shift 
suggests Thr876 may have a role stabilizing biotin in the CT domain active site, where 
this residue is located.   
The observed behavior of the T876A mutants is also dramatically altered in the 
presence of pyruvate. Whether crosslinking the carrier domain to the exo-binding site or 
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crosslinking translocating carrier domains in the presence of pyruvate, a kinetic barrier 
has increased, with slower rates of ITF signal change observed compared to the 
crosslinking backgrounds (Figures IV-4A, V-9A). This observation strongly supports the 
proposal by Zeczycki, et al. that because the T876A mutant cannot complete the proton-
transfer step, the reaction cannot be completed and biotin would remain in the CT domain 
active site (Zeczycki, et al., 2009).  If the carrier domain were “trapped” in the CT 
domain, translocation would become more unfavorable, as well as positioning in the exo-
binding site.  
A comparable observation to the QNY/DQY systems was made in the presence of 
pyruvate in the QNT/DQT systems in that the effect of pyruvate was attenuated but not 
abolished. This residue may be the other residue predicted above to mediate the effect of 
pyruvate on carrier domain positioning and translocation. The CT domain active site has 
a network of hydrogen bonds between pyruvate and biotin. Disruption of that by 
mutation of this residue may explain these observations. An experiment observing the 
effects of pyruvate on kobs and amplitudes in double mutant crosslinking systems in 
which both Tyr621 and Thr876 are mutated would allow further clarification of the roles 
of these residues in mediating the effect of pyruvate on carrier domain positioning.  
Role of acetyl-CoA in carrier domain positioning. A multitude of kinetic and 
structural studies have been performed to determine how acetyl-CoA activates PC. 
Kinetic studies have determined that acetyl-CoA stimulates the BC domain reaction 
(Attwood and Graneri, 1992; Branson, et al., 2002; Legge, Branson, and Attwood, 1996; 
Phillips, et al., 1992; Jitrapakdee, et al., 2010) and not the CT domain reaction (Attwood 
and Wallace, 1986). However, the exact mechanism by which this acceleration occurs is 
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not known. It has been proposed that acetyl-CoA may promote Mg2+ binding (Attwood 
and Graneri, 1992) or substrate binding in the BC domain (Legge, Branson and Attwood, 
1996). The structure of RePC with acetyl-CoA bound did not show any significant 
conformational change in the BC domain ligand binding sites, suggesting that the 
activation effects of acetyl-CoA extend beyond the BC domain active site (St. Maurice, et 
al., 2007) (Lietzan, et al., 2011).  
Acetyl-CoA has also been shown to have a role in coupling the two half-reactions, 
with the coupling efficiency being increased in the presence of acetyl-CoA. Because the 
translocation of the carrier domain is what physically couples these reactions, it was 
proposed that the translocation of the carrier domain was regulated by acetyl-CoA 
(Zeczycki, et al., 2011B). Pyruvate and MgATP were also shown to be 
thermodynamically linked in the presence of acetyl-CoA (Westerhold, et al., 2017). In the 
same study, ATP cleavage was observed to be promoted by pyruvate binding in the CT 
domain, which was suggested to show communication between the two active sites, 
possibly connected by carrier domain translocation. Westerhold, et al. also showed that 
activation entropy decreased in SaPC in the presence of acetyl-CoA, which the authors 
suggested meant that carrier domain movement was restricted in the presence of acetyl-
CoA (Westerhold, et al., 2017). While investigating carrier domain translocation 
pathways, Liu, et al. (Liu, et al., 2018) showed that acetyl-CoA stimulates catalytic 
activity for the translocation pathway between the intramolecular BC domain and 
intermolecular CT domain, which is consistent with the observation by Westerhold, et al. 
that activation entropy is decreased by acetyl-CoA. Finally, in studies investigating the 
roles of allosteric binding site residues in RePC, it was proposed that acetyl-CoA favored 
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the symmetric conformation of PC which is associated with the carrier domain positioned 
across the face of the tetramer (Choosangtong, et al., 2015; Sirithanakorn, et al., 2016). 
I have observed that acetyl-CoA, when mixed with SaPC, promotes a carrier 
domain conformation very similar, if not identical, to that captured by crosslinking 
translocating carrier domains (Figure V-4). A kinetic barrier for the translocation of the 
carrier domain and for the intermolecular positioning of the carrier domain was lowered 
when acetyl-CoA is added to either ATP or pyruvate (Figures IV-1, V-4). Further, a 
decrease in the amplitude of the ITF signal when crosslinking to the exo-binding site 
conformation was observed in the presence of acetyl-CoA, indicating an equilibrium 
positioning shift of the carrier domain towards an intermolecular interaction (Figure IV-
3). A similar decrease in amplitude was observed when crosslinking translocating carrier 
domains, suggesting that it has become more thermodynamically favorable to translocate 
between active sites (Figure V-8). Further, I have observed that mutation of Tyr621 
virtually abolished the effect of acetyl-CoA on carrier domain positioning and 
translocation (Figures IV-5, V-10. While acetyl-CoA may promote positioning of the 
carrier domain at or near the CT domain, without a way to stabilize the C-terminal side of 
the flexible carrier domain in a specific conformation, such as when Tyr621 is mutated, 
the effect of acetyl-CoA on carrier domain positioning was lost (Figures IV-5, V-10).  
Based on these observations, I conclude that acetyl-CoA favors the release of the 
carrier domain from the BC domain and stabilizes its positioning at or near the opposing 
CT domain. The release of the carrier domain from the BC domain would allow the 
opening of the B-subdomain lid, aiding the release of products and binding of Mg2+ and 
nucleotides (Menefee and Zeczycki, 2014). Acetyl-CoA has been observed to decrease 
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the affinity of chicken liver PC for nucleotides (Geeves, et al., 1995). This is consistent 
with the B-subdomain lid attaining a more open conformation due to a shift in carrier 
domain positioning away from the BC domain, allowing easier diffusion of ligands in 
and out of the active site. Further, as introduced in Section I.2.2.2, the B-subdomain lid 
must close for proper positioning of the P-loop, which aids in substrate binding. If the B-
subdomain lid is in a more open conformation, the P-loop would most likely be poorly 
positioned to aid substrate binding, which could increase the dissociation constant. 
However, the overall effect of acetyl-CoA on BC domain reaction steps is complex. For 
instance, ATP-cleavage was determined to be the rate-limiting step in the acetyl-CoA 
sensitive sheep and chicken liver PC enzymes (Goodall, et al., 1981; Attwood and 
Wallace, 1986). Acetyl-CoA was also shown to increase the productive cleavage of ATP 
in chicken liver PC (Legge, et al., 1996). Overall, differences exist between PCs from 
different species in which step is rate-limiting, which could be a result of changes in the 
locus of activation by acetyl-CoA (Adina-Zada, et al., 2012).  
Overall, while it may seem contradictory to have evidence that acetyl-CoA 
enhances BC domain catalysis and evidence that acetyl-CoA favors the release of the 
carrier domain and translocation away from the BC domain, findings from a recent cryo-
EM study of SaPC help to unite these observations (Lasso, et al., 2014). In this study, 
distinct populations of SaPC were observed in either the asymmetric conformation or the 
symmetric conformation. In the asymmetric conformation, with the carrier domain 
interacting with the BC domain, two binding sites for acetyl-CoA exist. Conversely, in 
the symmetric conformation, four acetyl-CoA binding sites exist. Thus, irrespective of 
the positioning of the carrier domain, acetyl-CoA could be present and enhancing BC 
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domain catalysis. As acetyl-CoA concentrations increase, the symmetric conformation 
would be favored, shifting carrier domain positioning towards an intermolecular 
interaction. By promoting a specific or more limited set of conformations near the CT 
domain, acetyl-CoA would be favoring the translocation pathway between the 
intramolecular BC domain and intermolecular CT domain, as Liu, et al. observed (Liu, et 
al., 2018). The constraint of favorable carrier domain conformations by acetyl-CoA 
would also have the effect of reducing activation entropy, as the carrier domain’s 
conformational flexibility would be reduced, as Westerhold, et al. observed (Westerhold, 
et al., 2017).  
Role of biotin in carrier domain positioning. While many studies suggest that 
biotin plays a key role in the positioning of the carrier domain and coupling of the half-
reactions, it has been difficult to study the role of biotin in carrier domain positioning 
since the loss of biotin abolishes much of the catalytic activity of PC (Zeczycki, et al. 
2009; Lietzan, et al., 2014; Menefee and Zeczycki, 2014). As my studies are independent 
of catalytic activity and I can directly observe carrier domain positioning, the systems 
presented here enable me to study the role of biotin in carrier domain positioning. The 
loss of biotin was observed to greatly diminish carrier domain sensitivity to BC domain 
substrates (Figure III-8). Unfortunately, ITF signals are dependent on the presence of 
biotin, making more detailed observations impossible at the current time (Figure III-6C). 
However, given the importance of the previously discussed residues that interact with 
biotin to affect carrier domain positioning, I propose that biotin leads the interaction 
between the carrier domain and the active sites/exo-binding site when establishing an 
equilibrium or when an equilibrium shift occurs due to the presence of a ligand. An 
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inability to stabilize a conformation due to a mutation of one of these residues, such as 
Tyr621, results in dramatically altered carrier domain behavior.  
However, biotin and the interactions with active site residues are not the sole 
participant in shifting carrier domain positioning. In the unbiotinylated SaPC mutant, the 
presence of ADP and phosphonoacetate still had some effect on carrier domain behavior 
with the observed rate of crosslinking decreasing in the presence of the ligands (Figure 
III-8). I believe that this result can be explained by the interface that is formed between 
the carrier domain and the BC domain. With ligands bound, the B-subdomain lid of the 
BC domain should be in a closed conformation, forming the final binding interface for 
carrier domain docking (Menefee and Zeczycki, 2014). While biotin may not be present 
to interact with the “gatekeeper” residue or enter the active site, the carrier domain would 
encounter a favorable binding interface that would stabilize carrier domain positioning 
and lead to a shift in equilibrium positioning.  
Shifting energy landscapes in Q891C/N1102C/E243A SaPC mutant. The QNE 
mutants was observed to have a higher kobs and an increased amplitude compared to the 
QN SaPC background (Figure IV-1). The presence of ADP and phosphonoacetate during 
crosslinking resulted in little change in kobs in the QNE mutant but an increase in 
observed amplitude compared to in the absence of ligands in QNE SaPC (Figure IV-3). 
This can be visualized in the energy landscape diagram shown in Figure VI-1. The 
traditional interpretation is shown in Figure VI-1A with the E243A mutation lowering the 
free energy of interaction in the BC domain, presumably due to greater biotin access of 
the BC domain active site. This lower free energy would result in the observed increase 
in amplitude during crosslinking in this mutant due to a shift in carrier domain 
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positioning towards the BC domain (Figure IV-1B). A reduction in the kinetic barrier to 
adoption of the BCCP-CT interaction is also shown to take the increased kobs into 
account. The presence of ADP and phosphonoacetate is also shown to further reduce the 
free energy of the BCCP-BC interaction as well, matching the increased amplitudes 
observed (Figure IV-3B).  
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Figure VI-1: Energy landscape diagram for QNE SaPC 
A potential energy landscape is shown for the QNE SaPC mutant. The Gibbs free energy (G) is plotted 
against the translocation progress of BCCP between the BC and CT domains. The kinetic barrier is 
represented by a dashed black line. The wild-type reaction is represented in black while the mutation is 
represented in blue. The effect of the presence of ADP and phosphonoacetate (PPA) in the QN mutant on 
this landscape is shown in red while in the QNE mutant it is shown in blue. A. The traditional interpretation 
is shown with the BC domain mutation affecting the BCCP-BC interaction. B. An alternate interpretation is 
shown. 
  
  
 
 
162 
However, an alternate interpretation is possible with the E243A mutation 
resulting in an increase in the free energy of the BCCP-CT interaction (Figure VI-1B). 
This increase in the free energy would result in a destabilization of the BCCP-CT 
interaction, shifting carrier domain positioning towards the BC domain. This would also 
have the effect of increasing the observed amplitude during crosslinking in this mutant 
(Figure IV-1B). A reduction in the kinetic barrier to adoption of the BCCP-CT 
interaction, similar to that in the traditional interpretation, is also shown to take the 
increased kobs into account (Figure IV-1A). In this alternate interpretation, the presence of 
ADP and phosphonoacetate have a similar reduction in the free energy of interaction for 
the BCCP-BC, resulting in the increased amplitudes observed. Due to the increased shift 
in carrier domain positioning due to the QNE mutation, the observed amplitude in the 
presence of ADP and phosphonoacetate would be larger.  
Shifting energy landscapes in Q891C/N1102C/T876A SaPC mutant. The QNT 
mutant was observed to have a higher kobs but a negligible amplitude change compared to 
the QN SaPC background (Figure IV-1). The presence of ADP and phosphonoacetate 
during crosslinking resulted in a large decrease in kobs in the QNT mutant compared to in 
the QN mutant. A large increase in observed amplitude compared to the observed 
amplitude in the absence of ligands in QNT SaPC or compared to the QN mutant in the 
presence of ADP and phosphonoacetate  (Figure IV-4). This can be visualized in the 
energy landscape diagram shown in Figure VI-2. The traditional interpretation is shown 
in Figure VI-2A with the T876A mutation having little effect on the free energy of 
interaction in the BC domain, resulting in negligible change in amplitude during 
crosslinking in this mutant due to little or no shift in carrier domain positioning towards 
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the BC domain (Figure IV-4B). A reduction in the kinetic barrier to adoption of the 
BCCP-CT interaction, the primary observed effect of this mutation in the absence of 
ligands, is also shown to account for the increased kobs in QNT SaPC (Figure IV-1A). The 
presence of ADP and phosphonoacetate is also shown to dramatically reduce the free 
energy of the BCCP-BC interaction as well, matching the large increase of amplitude 
change observed (Figure IV-4B). This drop in the free energy of interaction also results 
in a much larger kinetic barrier to the adoption of the BCCP-CT interaction, matching the 
observed drop in kobs in QNT SaPC in the presence of ADP and phosphonoacetate 
(Figure IV-4A) 
An alternate interpretation is possible with the T876A mutation resulting in an 
increase in the free energy of the BCCP-CT interaction in the presence of ADP and 
phosphonoacetate (Figure VI-2B). This would have the similar effect of shifting carrier 
domain positioning towards the BC domain in the presence of these ligands, resulting in a 
larger observed amplitude change during crosslinking. An increase in the kinetic barrier 
to adoption of the BCCP-CT interaction in the presence of ADP and phosphonoacetate is 
also shown. This would result in the decreased kobs observed in QNT SaPC in the 
presence of ADP and phosphonoacetate (Figure IV-4A). A reduction in the kinetic barrier 
to adoption of the BCCP-CT interaction is still necessary, as shown in Figure VI-2B, in 
the absence of ligands to account for the increased kobs in QNT SaPC (Figure IV-1).  
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Figure VI-2: Energy landscape diagram for QNT SaPC 
A potential energy landscape is shown for the QNT SaPC mutant. The Gibbs free energy (G) is plotted 
against the translocation progress of BCCP between the BC and CT domains. The kinetic barrier is 
represented by a dashed black line. The wild-type reaction is represented in black while the QNT mutation 
is represented in blue. The effect of the presence of ADP and phosphonoacetate (PPA) in the QN mutant on 
this landscape is shown in red while in the QNT mutant it is shown in blue. A. The traditional interpretation 
is shown with the mutation affecting the kinetic barrier in the absence of ligand. B. An alternate 
interpretation is shown.  
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Shifting energy landscapes in Q891C/N1102C/Y621A SaPC mutant. An 
acknowledgement of the complexity of this system needs to be made in light of the odd 
ITF signal behavior in this mutant. The data may be unable to be interpreted in the same 
manner as the other mutants, given the starkly different ITF signal observed. The 
alteration in ITF signal could be due to a different set of interactions between biotin and 
tryptophans in QNY SaPC due to the Y621A mutation. The mutation may have caused a 
change in observed fluorescence that was not due to an alteration in carrier domain 
positional equilibrium. Another possibility for the difference in observed signal could be 
due to an alteration in the orientation of biotin in this mutant. This could occur if we 
consider that Y621 not only positions biotin in a specific location in the CT domain 
active site, but most likely orients it in a specific plane for optimal interaction between 
the aromatic ring of Y621 and the thiophene ring of biotin. This orientation of biotin may 
influence interactions with tryptophans either inside the CT domain active site or Trp808, 
located near the exo-binding site. However, if the interactions between biotin and 
tryptophans in QNY SaPC remain similar and changes in the observed fluorescence 
signal were due to changes in carrier domain positioning, the data will be interpreted in 
the following paragraphs in a similar manner to the other SaPC mutations.  
To interpret this data in a similar manner as the other mutations, a subtle 
distinction needs to be made between the CT domain active site and exo-binding site. 
Whereas the T876A mutation did not have a significant impact on carrier domain 
positioning in the absence of ligands, the Y621A mutation was observed to, with a large 
decrease in amplitude change compared to the QN SaPC background (Figure IV-1). 
Generally, an increase in amplitude has been interpreted as a shift towards the BC 
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domain while a decrease in amplitude has been interpreted as a shift towards an 
intermolecular interaction for crosslinking. More precisely, the conformation trapped due 
to crosslinking was chosen to be the conformation in which biotin is positioned in the 
exo-binding site. Thus, I propose that the mutation of Y621A resulted in a large shift in 
carrier domain positioning away from the CT domain active site. This shift would lead to 
a higher population of carrier domains occupying to exo-binding site conformation, 
among potential other conformations, including BCCP-BC interactions. The increased 
population of the exo-binding site would lead to a higher initial ITF signal intensity. 
When the crosslinker was introduced, a much smaller magnitude of the amplitude was 
observed, consistent with a smaller shift in carrier domain equilibrium due to the large 
initial re-equilibration due to the mutation (Figure IV-2B). The equilibrium may be such 
that ITF is at or close to a maximum possible value and the introduction of the 
crosslinker pulls the carrier domain equilibrium away from that maximum, resulting in a 
decrease in ITF signal intensity during crosslinking (Figure IV-2B).  
The QNY mutant was observed to have a higher kobs and a decreased amplitude 
compared to the QN SaPC background (Figure IV-1).The presence of ADP and 
phosphonoacetate during crosslinking resulted in a small decrease in kobs in the QNY 
mutant and a decrease in observed amplitude compared to the QNY mutant in the 
absence of ligands (Figure IV-3). However, it should be noted that this decrease in 
observed amplitude actually results in a larger ITF signal intensity, due to the fact that the 
signal is starting out with a negative amplitude. These concepts can be visualized in the 
energy landscape diagram shown in Figures VI-5A,B. Figure VI-5A depicts the increase 
in the free energy of the BCCP-CT interaction as a result of the Y621 mutation, which 
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results in a carrier domain positioning shift towards the exo-binding site and a reduction 
in the kinetic barrier for this equilibrium shift.  
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Figure VI-3: Energy landscape diagram for QNY SaPC 
A potential energy landscape is shown for the QNY SaPC mutant. The Gibbs free energy (G) is plotted 
against the translocation progress of BCCP between the BC and CT domains. The kinetic barrier is 
represented by a dashed black line. The wild-type reaction is represented in black while the mutation is 
represented in red. A. The BCCP-Exo and BCCP-CT interactions are shown. B. The BCCP-BC and BCCP-
Exo interactions are shown. The effect of the presence of ADP and phosphonoacetate (PPA) in the QN 
mutant on this landscape is shown in red.  
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Figure VI-3B illustrates the energy landscape between the BCCP-BC and BCCP-
Exo interactions. The addition of ADP and phosphonoacetate results in a reduction in the 
free energy of the BCCP-BC interaction. This would result in a shift in carrier domain 
positioning towards the BC domain, increasing the fluorescence intensity observed in 
QNY SaPC compared to that in the absence of ligands in the QNY SaPC mutant. A 
smaller change in kobs in the presence of these ligands compared to QN background could 
result from a simpler translocation pathway. The kinetic barrier to crosslinking in the 
exo-binding site may be decreased due to the proposed instability of positioning at the 
CT domain active site. If the carrier domain does not interact with the CT domain active 
site while translocating from the BC domain to the exo-binding site, there is one less 
kinetic barrier to overcome to adopt the final crosslinking conformation.  
An alternate interpretation of the energy landscape is possible with the Y621A 
mutation resulting in an increase in the BCCP-BC interaction free energy. As observed, 
this would lower the kinetic barrier for the adoption of an intermolecular conformation, 
resulting in a higher kobs in the Y621A mutant (Figure IV-1A). This would also shift 
carrier domain positioning towards the CT domain and/or exo-binding site, resulting in a 
decrease in observed amplitude when crosslinking in the absence of ligands (Figure IV-
1B). The presence of ADP and phosphonoacetate results in a small decrease in the free 
energy of the BCCP-BC interaction as illustrated in Figure VI-4 and observed by an 
increase in absolute ITF signal in Figure IV-5B.  
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Figure VI-4: Alternate energy landscape diagram for QNY SaPC 
A potential alternate energy landscape is shown for the QNY SaPC mutant. The Gibbs free energy (G) is 
plotted against the translocation progress of BCCP between the BC and CT domains. The kinetic barrier is 
represented by a dashed black line. The wild-type reaction is represented in black while the mutation is 
represented in blue. The effect of the presence of ADP and phosphonoacetate (PPA) in the QN mutant on 
this landscape is shown in red while in the QNY mutant it is shown in blue.  
Experimentally testing these energy landscape models. The experiments 
conducted in this study inform on the relative difference in free energies between the 
interactions. Thus, the limitation in this approach is that absolute energies of the 
interactions are unable to be measured. Further, the relative height of the kinetic barrier 
moving from the BC domain to the CT domain is measured but the height of the kinetic 
barrier moving towards the BC domain isn’t measured by this system. These limitations 
are due to the conformation crosslinked, with the carrier domain positioned in the vicinity 
of the CT domain. Carrier domains traveling from a position away from the CT domain, 
such as those interacting with the BC domain must overcome the kinetic barrier to 
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interact with the CT domain. In order to measure the relative height of the kinetic barrier 
on the right side of these depictions, a system must be designed that crosslinks the carrier 
domain when interacting with the BC domain. ITF experiments and analysis similar to 
that presented in Chapters IV and V would be performed to obtain a thermodynamic and 
kinetic analysis of the effect of mutations and the presence of ligands on the carrier 
domain energy landscape. I predict that the ITF signal intensity would decrease in many 
cases when crosslinking to the BC domain, since carrier domain positioning would be 
drawn away from the tryptophans in the vicinity of the CT domain.  
To further explore the relationship between the observed tryptophan fluorescence 
signal as it relates to carrier domain positioning in Y621A SaPC, solution FRET could be 
utilized as a way to sidestep any change in interactions between biotin and the CT 
domain tryptophans compared to the QN background that may cause the signal to be 
untrustworthy. With a FRET-compatible fluorophore introduced onto the carrier domain 
and a matching FRET-compatible fluorophore placed in the CT domain, whether through 
maleimide-based reactions or using non-natural amino acids and click chemistry, an 
analysis of carrier domain positioning should be possible. Instead of receiving a high 
tryptophan fluorescence signal upon crosslinking of the carrier domain or a shift in 
positioning towards the CT domain, a higher FRET signal should be observed. A similar 
analysis to that presented in these studies should be possible to reveal the effect of this 
mutation on carrier domain positioning.  
To distinguish whether a change in the free energy of interaction is occurring in 
the BC or CT domain, dynamic light scattering could be used to measure thermodynamic 
parameters of interacting proteins (Hanlon, et al., 2010). This technique has been used in 
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other systems to study protein-protein interactions. However, given that the PC tetramer 
stays intact during the translocation process and that this technique is generally used 
more to study entire proteins during association and dissociation, a different technique 
may be better suited to study this phenomenon. A technique that may be able to more 
directly investigate these free energies of domain interactions is isothermal calorimetry. 
This technique can measure the entropic and enthalpic contributions to the affinity 
between two proteins and is likely the most applicable technique for directly investigating 
alterations in the affinity between the carrier domain and BC or CT domains (Valazquez-
Campoy, et al., 2015). A number of controls must be investigated given the multitude of 
interactions that exist in PC. For example, the protein with the carrier domain truncated 
would serve as an important control to be able to account for any measured energy 
changes due to ligand binding and small active-site conformational changes from the free 
energy change of a carrier domain associating and dissociating with another domain. 
Finally, microscale thermophoresis may offer an alternative technique to measure these 
thermodynamic parameters. This technique follows changes in either intrinsic 
fluorescence or signal changes due to the interaction of fluorophores across a range of 
temperatures to allow the deduction of a number of thermodynamic quantities that would 
ultimately allow the measurement of changes in Gibbs free energies of interacting 
proteins (Jerabek-Willemsen, et al., 2014).  
2. Extending the Model to Other Multi-Domain Enzymes 
The carrier domain of S. aureus PC was observed here to be governed by 
conformational selection with the equilibrium positioning shifted by the presence/absence 
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of ligands that alter interactions between BCCP-biotin and active-site residues.  These 
findings are consistent with the conformational flexibility observed in S. cerevisiae 
acetyl-CoA carboxylase (Hunkeler, et al., 2016). While carrier domain conformational 
changes haven’t been investigated in acetyl-CoA carboxylase to date, a large, non-
catalytic central domain (CD) has been shown to exhibit great conformational flexibility 
that allows two distant BC domains to come together and dimerize, forming a 
catalytically-active conformation. A regulatory loop controls these conformational 
dynamics, when phosphorylated, restricting the conformational flexibility in the CD and 
preventing the BC domain dimerization necessary for catalysis. This is similar to the role 
of acetyl-CoA in PC, where it has been observed to limit conformational flexibility of the 
carrier domain (Westerhold, et al., 2017; Liu, et al., 2018). In the case of acetyl-CoA, 
however, this confinement of conformational dynamics results in more efficient catalysis, 
not the inability to form a catalytically-relevant conformation as is the case with 
phosphorylation of the regulatory loop in acetyl-CoA carboxylase. Given the lack of 
studies on carrier domain positioning in acetyl-CoA carboxylase, it seems reasonable to 
expect its positioning to be governed by conformational selection, similar to PC. One 
potential mechanism to favor/disfavor carrier domain positioning was recently 
discovered. As introduced in Section I.3.1, a loop that sterically blocks carrier domain 
binding is shifted out of the way when the BC domain dimerizes (Wei and Tong, 2015). 
Future crystal structures with the carrier domain interacting with either active site would 
aid in further determining how the positioning of the carrier domain of acetyl-CoA 
carboxylase is regulated.  
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The assembly line polyketide synthase, 6-deoxyerythronolide B synthase (DEBS), 
is a composition of three polypeptides that in total contain six homologous, homodimeric 
modules that catalyze the production of the macrocyclic core of erythromycin. As 
described in the Introduction, this multi-domain enzyme uses an acyl-carrier protein to 
shuttle the growing polyketide chain from the intramodular ketosynthase (KS) domain to 
the downstream KS domain. A recent study has investigated how vectorial synthesis may 
be coordinated to maintain proper reaction directionality during chain elongation (Lowry, 
et al., 2016). A novel turnstile mechanism was discovered that prevents the KS domain 
from premature acylation until the previous elongation and modification reactions 
product have been removed from the intramolecular ACP domain. This model appears 
consistent with conformational selection as well, with catalytic steps energetically 
coupled without relying on a complex induced conformational change mechanism. This 
energetic coupling of reaction steps is also similar to an observation made in SaPC in 
which the two half-reactions are thermodynamically coupled in the presence of the 
allosteric activator, acetyl-CoA (Westerhold, et al., 2017). Both of these mechanisms rely 
on regulation of translocation of the carrier domain to efficiently couple the multi-step 
reactions. In the case of PC, acetyl-CoA was observed to favor translocation of the carrier 
domain (Figure V-8) with the effects of mutation to several active-site residues on carrier 
domain translocation discussed above.  
The bacterial sulfur oxidation pathway enzyme SoxB interacts with the carrier 
protein SoxYZ, which carries Sox pathway intermediates. A recent study investigated the 
interaction between these two proteins to better understand how carrier proteins transport 
intermediates between enzymes in the Sox pathway (Grabarczyk, et al., 2015). It was 
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observed that the carrier protein has 2 major points of interaction with the SoxB enzyme. 
One point of contact is in the active site tunnel with multiple points of hydrogen bonding 
between the carrier protein and SoxB. More tangential to my research is the formation of 
a second point of contact outside of the active size. A mobile loop on the surface of SoxB 
was observed to be stabilized when substrate-bound SoxYZ bound with SoxB. In the 
substrate-free form, this mobile loop occupies a different conformation that clashes with 
SoxYZ binding, favoring the release of SoxYZ after the reaction has completed. This 
mechanism is similar to the CT domain mechanism of stabilizing biotin in the active-site 
of PC in that when substrate is bound in the CT domain, Tyr621 adopts a conformation 
favorable for carrier domain positioning at the CT domain active site.  
Finally, gramicidin synthase I, a non-ribosomal peptide synthase, was recently 
investigated to study the control of interactions between the catalytic and carrier domains 
(Alfermann, et al., 2017). It was observed that this flexible enzyme exists in an 
equilibrium of at least two conformations, with product inhibition, and in general the 
presence of ligands, shifting the conformational equilibrium. A series of interactions 
between active site residues, carrier domain residues and prosthetic groups, and ligands 
were proposed to be responsible for these equilibrium shifts. These findings are 
consistent with the work presented here regarding how the positioning of the carrier 
domain of pyruvate carboxylase is governed.  The authors have come to a very similar 
conclusion in that the enzyme exists in a conformational equilibrium that is shifted by the 
presence of ligands.  
In summary, our understanding of how carrier domain positioning is regulated has 
progressed dramatically in recent years. Mechanisms have been discovered in several 
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enzyme systems that have revealed various types of interactions between carrier domains 
and catalytic domains, pushing forward our understanding of the underlying biophysical 
nature of how carrier domain translocation is governed for efficient catalysis. The studies 
that I have performed in PC offer further evidence of conformational selection governing 
carrier domain positioning and translocation while offering to further extend our 
understanding of how interactions between active site residues and the prosthetic group 
of carrier domains can shift equilibrium positioning. 
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VII.  FUTURE DIRECTIONS 
To explore trapping the carrier domain during translocation in a cleaner system, 
the single mutant Q1118C needs to be investigated in the same manner as presented here. 
A double mutant that would trap the carrier domain in the conformation in which biotin 
extends into the active site, which was the goal of the D907C/Q1118C SaPC mutant, 
should also be generated and investigated. These two systems would allow a higher 
confidence of interpretation of not only the data regarding carrier domain translocation in 
Chapter V, but also offer a comparison to the data presented in Chapter III and IV. For 
instance, if carrier domain positioning if observed to have shifted towards the BC 
domain, is it shifting away from every other state/conformation equally? Trapping the 
carrier domain in more states would allow this more thorough explanation of carrier 
domain dynamics. Throughout this current work, the positioning of the carrier domain at 
the BC domain has been presumed when carrier domain positioning is shifted away from 
the intermolecular CT domain in the presence of BC domain ligands. While this is a 
reasonable assumption, this study would be further supported by the ability to trap the 
carrier domain at the BC domain to more completely assess shifts in carrier domain 
positioning. Similar to the crosslinking system introduced in this study, a pair of 
cysteines would need to be introduced that would come within crosslinking range (<8 Å) 
when the carrier domain is docked at the BC domain for the generation of this new 
crosslinking system.  
As Liu, et al. demonstrated, the carrier domain can interact with both the 
intramolecular and intermolecular BC domains (Liu, et al., 2018). This presents a 
problem in that assaying crosslinking by SDS-PAGE would only report on intermolecular 
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crosslinking and be blind to intramolecular crosslinking. Thus, inactivation kinetics, 
which measures the inactivation of the enzyme due to carrier domain crosslinking in 
either form, would be more appropriate to use when assessing the total amount of 
crosslinking. Alternatively, a co-expression of two different mutants would allow a fuller 
assessment of only intermolecular crosslinking. One mutant would have a cysteine 
introduced onto the BC domain while the other mutant would have a cysteine introduced 
onto the carrier domain. This population would form a hybrid tetramer in vivo during co-
expression (Liu, et al., 2018). Thus, the carrier domain on one polypeptide chain would 
only be able to form crosslinks with the BC domain cysteine on a separate polypeptide 
chain, trapping the intermolecular interaction. For either the system assessing both 
intramolecular and intermolecular crosslinking or just intermolecular crosslinking, the 
techniques described in this study would be applied to assess kinetic and thermodynamic 
changes to carrier domain positioning as a result of mutations or the presence of ligands.  
The use of solution FRET, as used to investigate conformational shifts in an 
NRPS as described in the introduction, could be implemented in SaPC to study shifts in 
carrier domain positioning due to mutations or the presence of ligands without the need 
for crosslinking (Alfermann, et al., 2017). FRET-compatible fluorophores could be 
covalently attached to the carrier domain and either the BC domain or CT domain for an 
introductory set of studies. These fluorophores could be bound through the introduction 
of cysteines in the desired locations for maleimide-based linking or through the use of 
non-natural amino acids in the desired location and click chemistry-based fluorophore 
linking. Given that 5 cysteines exist naturally in SaPC, the use of non-natural amino acids 
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for fluorophore labeling would most likely yield the greatest chance of success as 
undesired background labeling of the enzyme should be limited.  
A crystal structure of Q891C/N1102C SaPC with the carrier domain crosslinked 
would allow an analysis of the positioning of biotin in relation to the tryptophans located 
in the CT domain. The attainment of such a crystal structure would be a possible next 
step in determining the origin of changes in the observed tryptophan fluorescence signals 
with the goal of better understanding the exact positioning of the carrier domain in 
relation to the observed signal. Alternatively, these tryptophans could be individually 
conservatively mutated to phenylalanines or histidines to determine their contributions to 
the observed fluorescence signal. However, 2 of the 4 remaining tryptophans to be 
studied are strictly conserved, which suggests that their mutation could result in an 
unstable protein. The tryptophan mutated as part of the studies described in Chapter III is 
also strictly conserved with mutation of that tryptophan resulted in an unstable protein. In 
summary, I believe the obtainment of a crystal structure of crosslinked SaPC would be 
the logical next step for the determination of the origin of the tryptophan fluorescence 
signal.  
Finally, carrier domain movement could be investigated to determine the effects 
of ligands, including acetyl-CoA and L-aspartate, on carrier domain movement rates. For 
example, in chapter III, L-aspartate wasn’t observed to alter carrier domain positioning 
but exhibited an effect on the kinetic barrier to translocation. Perhaps the movement rate 
of the carrier domain is slowed by L-aspartate, resulting in a reduction in catalytic rate. 
Carrier domain movement could be determined either through single-molecule FRET 
studies, fluorescence anisotropy, or RFQ-DEER (rapid freeze quench-double electron-
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electron resonance). While our lab does not currently have direct experience with these 
techniques, they would represent a new frontier of research for not only the lab, but 
studies of carrier domain motion in carrier domain enzyme systems. Initial studies of 
carrier domain movement have been investigated with fluorescence anisotropy in 
collaboration with Dr. Evgueni Kovriguine. However, it was determined that either a 
much higher percentage of fluorophore labeling of SaPC was required or a much higher 
concentration of protein was necessary, as the obtained fluorescence signals were 
inconclusive. Thus, for many of the research pathways described here, an optimization of 
the specific labeling of PC with various fluorophores is necessary to expand our 
investigations of carrier domain positioning and movement.  
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VIII.  APPENDIX A: PRIMERS FOR MUTAGENESIS OF SaPC 
Table VIII-1 Forward Primers for SaPC Mutagenesis 
Mutation Sequence 
Q891C 5’-GGCACTTTATATGGTATGCAATGATCTTGATGAACAATC-3’ 
(forward) 
5’-GATTGTTCATCAAGATCATTGCATACCATATAAAGTGCC-3’ 
(reverse) 
N1102C 5’-GTGAAACTGTGAAAGCTTGTCAGCCGTTGCTAATTAC-3’ 
(forward) 
5’-GTAATTAGCAACGGCTGACAAGCTTTCACAGTTTCAC-3’ 
(reverse) 
D907C 5’-GGCTATAAATTATGTTTCCCAGAATCAG-3’ (forward) 
5’-CTGATTCTGGGAAACATAATTTATAGCC-3’ (reverse) 
Q1118C 5’-GAAACAACAATTTGCGCACCATTTG-3’ (forward) 
5’-CAAATGGTGCGCAAATTGTTGTTTC-3’ (reverse) 
K1112Q 5’-CTGAAGCTATGCAAATGGAAACAAC-3’ (forward) 
5’-GTTGTTTCCATTTGCATAGCTTCAG-3’ (reverse) 
Y621A 5’-GCTTCAAACGCAGTTGGTGCTAAAAACTATCCTGATAATG-3’  
(forward) 
5’-CATTATCAGGATAGTTTTTAGCACCAACTGCGTTTGAAGC-3’ 
(reverse) 
T876A 5’-GGTGATATCGTAAAAGTAGCACCATCGTCTAAAGTAG-3’ 
(forward) 
5’-CTACTTTAGACGATGGTGCTACTTTTACGATATCACC-3’ 
(reverse) 
E243A 5’-CAAAAAGTTGTAGCAGTTGCACCATC-3’ (forward) 
GATGGTGCAACTGCTACAACTTTTTG-3’ (reverse) 
V1062* 5’-GATGAAAATTAGCATACAAATGCG-3’ (forward) 
5’-CGCATTTGTATGCTAATTTTCATC-3’ (reverse) 
W808F 5’-GGAGTCACTTAGTCATTATTTCTCAACTGTACGTAC-3’ 
(forward) 
5’-GTACGTACAGTTGAGAAATAATGACTAAGTGACTCC-3’ 
(reverse) 
 
 
